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Breast cancer is the most common cause of death amongst women, with the incidence of 
the disease varying between cQuntries. Like all other cancers, breast cancer is a 
multigenic disorder with mutations in oncogenes and tumour suppressor genes playing an 
important role in cellular transformation and ultimately in tumour formation. In this 
study, 40 breast cancer patients from the Western Cape province in South Africa and 4 
breast cancer cell lines were screened for mutations in the human Ha-ras oncogene and 
the p53 tumour suppressor gene. The majority of the patients were of mixed ancestry 
comprising 39 females and one male. DNA was isolated from both fresh tissue biopsies 
and formalin fixed paraffin sections and screened for mutations by PCR-SSCP and DNA· 
sequence analysis. Since mutations in codons 12, 13 and 61 of the Ha-ras gene 
constitutively activate RAS, exons 1 and 2 (encompassing codons 12, 13 and 61) were 
sequenced and shown to harbour no mutations at these sites. A polymorphism at codon 
27 was detected, however, this was not associated with the disease condition as the allele 
frequency was the same as in control samples. These results agree with published data 
and imply that mutations in the Ha-ras gene do not playa critical role in the aetiology of 
breast cancer. 
The p53 tumour suppressor gene is the most frequently mutated gene in human tumours, 
and in breast cancer the reported frequency of mutation is approximately 50%. Mutations 
occur over a wide region of the gene, however, hotspots have been identified in exons 5­
9. Screening of exons 5-9 and 11 of this gene revealed the presence of mutations in only 
10% of breast cancer patients, 2 in exon 7 and 2 in exon 8, and 2 mutations in the breast 
cancer cell lines. Three of the mutations in the cancer patients were novel and have not 
been previously documented. These novel mutations were a deletion of a single adenine 
residue at codon 239 (p53-6.A), resulting in a frameshift and the introduction of a 
termination codon at position 263, a C ~ A base substitution at codon 269 (p53-S269R) 
resulting in the substitution of an arginine for a serine in the protein, and a ISbp 











Wild-type p53 has a short half-life and mutations stabilise the protein, allowing it to be 
detected using immunohistochemistry, which is an indirect method for detection of 
mutant p53. Tissue sections from these patients were also screened for mutations by 
immunohistochemistry and 10 patients were found to stain positive for p53. Two of these 
patients contained confirmed mutations in exons 7 and 8 (a codon 248 mutation and the 
p53-S269R mutation) while the remaining 8 patients appeared to harbour no mutations. 
One of the patients harbouring a mutant p53 was negative for p53 by 
immunohistochemistry, which is to be expected since the mutation (p53-6A) resulted in a 
truncated protein that is probably rapidly degraded. Since various tumour-derived p53 
mutations have been shown to have different effects on cells, the three novel p53 mutant 
constructs were prepared by site-directed mutagenesis and transfected into NIH-3T3 cells 
to examine their effects on cell growth and response to DNA damage. The mutations did 
not affect the growth rate of the cells, but the p53-S269R mutant was found to alleviate 
the requirement for serum factors when the cells were grown in serum-free medium. The 
mutations also affected contact inhibition of growth of the stably transfected cells to 
various degrees, with the p53-S269R and p53-+15 mutations enabling the cells to grow 
without contact inhibition. The cells stably transfected also responded differently to DNA 
damage. After exposure to 7Gy of 60Co radiation, only the p53-S269R mutant failed to 
arrest the cells in the Gl phase of the cell cycle, while the other two transfected cell lines 
were still able to undergo a G1 cell cycle arrest, albeit with lower efficiency than the 
untransfected cells or cells transfected with the wild-type construct. Thus only the p53­
S269R mutation found in these breast cancer patients behaved like a true p53 mutant. On 
examination of the survival rate of these patients, it was found that the majority of the 
patients were alive 5 years after diagnosis, and only one patient (with the p53-S269R 
mutation) died from the disease. This patient harboured a C -7 A base substitution at 
codon 269, which was the mutation that behaved the most aggressively in the transfection 
studies. Thus it appeared that the nature of the p53 mutation may affect the survival of 
these patients and their response to therapy, as only the patient with the aggressive p53 
mutation died from the disease, whereas the remaining patients with p53 mutations were 
still alive. These results also raise the possibility that the frequency of p53 mutations may 











mutations have different effects, with some mutations being more aggressive than others. 
Furthermore, p53 mutations may be a prognostic indicator for breast cancer, depending 










CHAPTER 1 INTRODUCTION 
1.1 Breast Cancer Risk Factors 
Breast cancer is the most common cancer in females in developed countries and recently 
there has been an increase in the incidence of the disease in developing countries. 
Although breast cancer occurs primarily in women, the disease does occur in males, 
however its occurrence in males is rare, with the female:male incidence ratio ranging 
from 70:1 to 130:1 (Henderson and Feigelson, 1997). 
Many risk factors are associated with breast cancer, but substantial evidence has linked 
the majority of these to hormones, which playa major role in the etiology of the disease. 
The known risk factors such as early menarche, late onset of menopause, obesity (in post­
menopausal women) and hormone replacement therapy, all result in increased exposure 
of the breast to estrogen, and to a lesser extent, progesterone. These hormones affect the 
proliferation of breast epithelial cells which is crucial in the development of a malignant 
phenotype. In addition to these risk factors, other criteria that result in decreased exposure 
to estrogen and progesterone tend to have a protective effect. Such factors include the age 
of the first full-term pregnancy, lactation and physical activity (Henderson and Feigelson, 
1997). 
1.1.1 Age 
The most important demographic risk factor in the development of breast cancer is 
increasing age. There is a rapid increase in the risk ofdeveloping the disease from the late 
teens until the age of 50. After the age of 50 the risk of developing breast cancer 
continues to increase, but the rate of increase of this risk is less than that before the age of 
50 (Pike, 1987). 
There is a wide variation in breast cancer rates between various countries as well as 
between various population groups. The rates of breast cancer are substantially higher in 
first world countries such as the USA, Canada, and northern Europe compared to Asia 











black American women are comparable with their white counterparts, but not to those for 
black African women. These rates appear to be at least partly related to early life 
experiences, such as diet and physical activity, rather than solely due to differences in 
genetic susceptibility, as evidenced by migratory Japanese women in the USA, who have 
increased rates of breast cancer compared to those women who remain in Japan (Buell, 
1973). If the women migrated at a young age, then their rates were comparable with their 
white American counterparts in the USA. 
1.1.2 Age at Menarche 
An early age of menarche is associated with an increased risk for developing breast 
cancer. Studies have indicated that the risk of developing the disease decreases by about 
20% with each year that menarche is delayed (reviewed by Henderson and Feigelson, 
1997). In addition, it appears that the development of regular menstrual cycles also has an 
effect on risk. Women who develop regular menstrual cycles within 1 year after the first 
menstrual period have more than double the risk of developing the disease than women 
whose regular menstrual cycles are delayed by 5 years or more (Henderson et al., 1988). 
1.1.3 Physical Activity 
Strenuous, as well as moderate, physical activity, is thought to decrease the risk of breast 
cancer. This is thought to occur by delaying menarche and the development of the breast. 
It has also been reported that physical activity significantly reduces the risk of breast 
cancer in young women less than 40 years of age (Bernstein et al., 1994). 
1.1.4 Age at Menopause 
The rate of increase in the age-specific incidence rate of breast cancer slows substantially 
at the time of menopause and the rate of increase in post-menopausal women is only 
about one-sixth the rate of increase in pre-menopausal women (Henderson and Feigelson, 
1997). The age of onset of menopause also appears to be important, with women who 
experience early menopause (before the age of 45) having about half the risk as women 












Women who have children have a lower risk of developing breast cancer than childless 
women, and it appears that this decreased risk is primarily associated with the age of the 
first child-birth (MacMahon et aI., 1970). Subsequent births have been shown to have 
only a small protective effect, whereas the main protective effect is associated with the 
age ofthe first full-term pregnancy (Yuan et aI., 1988). 
1.1.6 Weight 
A strong relationship between weight and breast cancer risk has been established and this 
relationship is also dependent on age. Women under the age of 50 have little or no 
increased risk with increasing weight, but women who are 60 years or older have an 
increased risk with increasing weight (de Waard et aI., 1977). It is, however, unclear 
whether this effect of weight on breast cancer risk is due to the increase in body fat or the 
increase in weight per se. 
1.1.7 Other Possible Risk Factors 
Dietary factors have also been implicated In breast cancer, particularly high fat 
consumption (Gray et aI., 1979). The involvement of high fat consumption is 
controversial as various studies differ in their findings with respect to its effect on the risk 
of developing the disease (Howe et aI., 1990; Hunter et aI., 1996). Dietary differences 
may explain the changes in breast cancer rates after migration, as well as the difference in 
incidence rates between different population groups (Armstrong and Doll, 1975). 
In contrast to fat consumption, an increase in dietary fiber may have a protective effect, 
although this is likely to be only a small effect, unlike in colon cancer where the 
protective effect of dietary fiber may be more pronounced (Willett et aI., 1992). Vitamin 
A has also been suggested to protect against breast cancer, although no definitive studies 
have yet been done (Hunter et aI., 1993). 
Alcohol consumption has been associated with an increased risk of developing the 











levels (Howe et aL, 1991). 
1.2 Prognostic Factors in Breast Cancer 
Prognostic factors in cancer can be defined as variables that playa role in recurrence of 
the disease, response to treatment, and patient survival. Identification of prognostic 
markers plays a role in understanding the molecular basis of the disease, thus aiding in 
treatment. At present, there is little consensus regarding the available information on all 
potential prognostic indicators, but there is agreement on a few prognostic factors for 
breast cancer, such as histologic type, stage and grade of the tumour. 
1.2.1 Histologic Type 
Malignant epithelial tumours of the breast can be divided into 3 categories: (1) non­
invasive tumours; (2) invasive tumours of various types and (3) Paget's disease of the 
nipple (Williams and Buchanan, 1987 and WHO, 1981). The most common breast 
cancers are invasive adenocarcinomas (characterised by being poorly differentiated) 
followed by invasive lobular carcinomas. Invasive breast tumours are divided into 
various subtypes such as medullary, mucinous, tubular and papillary carcinomas, all of 
which are rare forms of the disease and certain of these, such as tubular carcinomas, 
papillary carcinomas and mucinous carcinomas have been associated with a low risk of 
recurrence and have favourable features, namely a low histologic grade and low rates of 
axillary lymph node involvement and consequently correlate with a better prognosis 
(Ravdin, 1997). Only a small percentage of breast carcinomas are of a non-invasive 
nature and include ductal in situ carcinomas and lobular in situ carcinomas (Ravdin, 
1997). These non-invasive types have no metastatic potential and are associated with a 
low risk of recurrence. 
1.2.2 Staging 
The classical staging for breast tumours is the TNM system, where T refers to the tumour 
size, N refers to the lymph node involvement and M refers to the presence or absence of 
metastases. The tumour size is divided into various categories: a T 1 tumour is 0 2cm in 











tumour is ~ 5cm in its greatest dimension. These various stages in turn, are subdivided 
into "a" or "b" categories, where "all signifies no attachment to the underlying muscle and 
lib" signifies attachment to the underlying muscle. A T4 category also exists and this 
refers to a tumour of any size with a direct extension to the chest wall or skin (Salvadori, 
1984). 
Similarly the lymph node involvement (N) is divided into various categories: NO, no 
metastases in the homolateral axillary nodes; Nl, movable metastatic lymph nodes not 
fixed to one another or any other structure; N2, homolateral lymph nodes fixed to one 
another or any other structure and containing metastatic tumour; N3, homolateral 
supraclavicular or infraclavicular nodes containing tumour or oedema of the arm 
(Williams and Buchanan, 1987; Salvadori, 1984). The metastasis status is also sub­
divided into 2 categories; MO, no known distant metastases and MI, distant metastases 
present (Salvadori, 1984). 
In general, larger tumours and those with axillary lymph node involvement, tend to be 
associated with a poorer survival compared to smaller tumours which are node-negative. 
Furthermore, the number of lymph nodes affected are also important, with patient 
prognosis being poorer with increasing number oflymph nodes involved (Ravdin, 1997). 
1.2.3 Histologic Grade 
The histologic grade of a tumour is a subjective assessment of the degree of tubule 
formation, nuclear pleomorphism, elastosis and the frequency of hyperchromatic and 
mitotic figures in a tumour (Bloom and Richardson, 1957). It has been recognised as 
having potential value in predicting or evaluating prognosis, especially when combined 
with the tumour size and nodal status (Henson and Ries, 1991). The five year survival 
rate for patients decreases with increasing grade of the tumour, as well as increasing 
stage. When taken together, the five year survival rate of patients with stage I tumours 
remains the same, irrespective of the grade of the tumour. Patients with stage II tumours, 
however, have a poorer survival rate with increasing tumour grades. In addition to this, 











node-positive breast tumours of a high stage and a high grade have the poorest five year 
survival. 
Although tumour stage and grade are independent predictors of prognosis, their effect on 
patient survival seems to be additive in that high stage node-positive tumours with a high 
histologic grade are associated with a poor prognosis. 
1.2.4 Other Potential Prognostic Indicators 
In addition to the classic prognostic indicators mentioned above, other factors such as 
patient age have been shown to be important in predicting response to chemotherapy and 
may be a prognostic marker for breast cancer. Numerous studies have suggested that 
patients with a younger age, usually those under 35, have a poorer prognosis than older 
patients (de la Rochefordiere et ai., 1993; Bonnier et ai., 1995; Nixon et ai., 1994). The 
authors do not address whether the tumours in these younger patients are familial, but 
these tumours generally had the characteristics associated with poorer survival, such as a 
high grade, invasion of lymph nodes and necrosis. This suggests that if these tumours are 
familial, they are more aggressive than the sporadic form of the disease, which may 
account for the poorer prognosis in these patients. 
Other potential prognostic indicators are the estrogen receptor (ER) and/or progesterone 
receptor (PR) status of the tumour. Patients who are ER or PR positive tend to have a 
better survival than those patients who are ER or PR negative (Silvestrini et ai., 1995; 
Arriagada et ai., 1992). This may be due to the response of the hormone receptor positive 
tumours to chemotherapeutic agents such as tamoxifen. These studies, however, showed 
that these hormone receptors were only weakly prognostic. 
Measurement of the proliferative rates of cancer tissue by various techniques such as 
thymidine labelling index, S-phase fraction or immunohistochemistry has also been 
suggested to be of prognostic significance (reviewed by Ravdin, 1997). The p53 tumour 
suppressor has also been implicated as a potential prognostic marker for breast cancer, 












1.3 Hereditary Breast Cancer 
Although the majority of breast cancers are sporadic, about 5% - 10% of breast cancers 
are familial (Claus et aI., 1991). Patients with hereditary breast cancer tend to develop the 
disease at a relatively early age, and also tend to develop bilateral tumours. The familial 
nature of the disease suggests that a gene(s) could possibly be involved in this form of 
breast cancer. 
The gene that confers susceptibility to hereditary breast and ovarian cancer has been 
localised to chromosome 17q (Easton et aI., 1993) and a candidate gene, BRCAl, has 
been identified (Miki et at, 1994). It is estimated that mutations of this gene account for 
45% of families with a high incidence of familial breast cancer and approximately 80% 
of families with an increased incidence of both' early onset breast and ovarian cancers. A 
second locus, BRCA2, which maps to chromosome 13q, is also thought to account for a 
significant proportion of hereditary breast cancers, but not ovarian cancer (Wooster et al., 
1994). 
The BRCA1 gene has been partially characterised and encodes a protein of 1863 amino 
acids (Miki et aI., '1994). The gene itself spans approximately 100kb of DNA and 
contains 22 coding exons to produce a transcript of 7.8kb. The protein has certain 
characteristics, such as several zinc finger motifs, which suggest that it is a transcription 
factor. The localisation of this protein within the cell is, however, a contentious issue. It 
has been reported to be expressed exclusively in the cytoplasm (Chen et aI., 1995) or 
exclusively in the nucleus (Scully et aI., 1996). Scully et al (1996), however, have 
provided compelling evidence that BRCA1 could be located either in the nucleus or the 
cytoplasm, depending on the staining technique used, which could account for the 
conflicting data. Given the proposed structure of the protein and the postulate that it 
functions as a transcription factor, one would expect to find the majority of the protein in 
the nucleus, although the possibility of a cytoplasmic pool of the protein cannot be totally 











transcription factor in that one of the ways in which it acts as a tumour suppressor is by 
mediating cell cycle arrest by transactivating the expression of the cyclin-dependent 
kinase inhibitor p21 WAFlICIPl in a p53 -independent manner (Somasundaram et aI., 1997). 
The exact mechanism by which this transactivation occurs, however, is not clear. 
The mRNA for BRCAI is expressed most abundantly in the testis and thymus, with 
smaller amounts in the breast and ovary (Miki et aI., 1994). 
Mutations in the gene may occur throughout the coding sequence as well as in the 
regulatory sequences (Miki et aI., 1994; Futreal et aI., 1994). In addition to playing a role 
in hereditary breast cancer, LOH of the BRCAI locus has been detected in 30-70% of 
sporadic breast and ovarian cancers indicating that this gene may be involved in the 
sporadic forms of either breast or ovarian cancers (Futreal et aI., 1992; Jacobs et aI., 
1993; Sato et aI., 1991; Cropp et aI., 1994). Unfortunately, very few mutations have been 
found in the remaining allele in sporadic cases in which there is LOR at this locus. There 
may be a number of reasons for this. Firstly, somatic BRCAI mutations may fall in non­
coding sequences and these may affect mRNA levels. This scenario has been found in 
one BRCAI germline mutation (Miki et aI., 1994). Secondly it is possible that LOH at 
17q may not reflect somatic inactivation ofBRCA1, but rather another potential as yet 
unidentified tumour suppressor gene located in the same region may be involved (Futreal 
et aI., 1994). 
Breast tumours that anse due to mutations in the BRCAI gene tend to be slightly 
different histopatholo~ically from somatic breast tumours in that they are highly 
proliferating tumours, with the majority of them being grade 3 tumours (Eisinger et aI., 
1996). This suggests that management and treatment of these tumours should be different 
to that of sporadic cases. 
1.4 Genetic Alterations in Breast Cancer 
It is clear that accumulation of genetic alterations is required for the development of the 











deletions or rearrangements, gene amplification, loss of heterozygosity (LOR) at certain 
alleles and point mutations, which include small insertions or deletions. It has also 
become apparent that these genetic alterations that play a role in tumourigenesis affect 
genes which are involved in the regulation of cell growth and proliferation, either in a 
positive manner (cellular oncogenes) or in a negative fashion (tumour suppressor genes). 
Oncogenes are usually activated or amplified in tumours, whereas tumour suppressor 
genes have been associated with inactivating mutations such as LOH and point mutations 
that abrogate the function of the protein. 
Distinct areas of the genome have been shown to be amplified in primary human breast 
tumours: these include the mye gene located on chromosome 8q24 (Callahan and 
Campbell, 1989), the int21hst locus, a member of the FGF gene family (Callahan and 
Campbell, 1989), the bell gene on chromosome llq13 (Callahan and Campbell, 1989; 
Theillet et aI., 1990), the bek gene on chromosome 10q24 and the fig locus on 8p12 
(Adnane et a!., 1991). Amplification of c-mye, c-erbB2 and int2lhstlbell have each been 
related to either aggressive or metastatic breast cancer (Slamon et a!., 1987; Varley et aI., 
1987; Callahan and Campbell, 1989), and each of these gene amplifications may identify 
a particular subset ofbreast tumours (Adnane et aI., 1991). 
Certain genes have also been eported to be co-amplified in breast cancers. The c-erbB2 
oncogene is frequently co-amplified with the c-erb Al oncogene, which is a member of 
the steroid/thyroid hormone family of receptors (van de Vijver et aI., 1987). 
1.4.1 The Ras Genes 
The ras gene family consists of three major members, designated H-ras, K-ras and N-ras 
(Barbacid, 1987). All three genes are located on different chromosomes; N-ras on 
chromosome 1, H-ras on chromosome 11 and K-ras on chromosome 12. These genes are 
ubiquitous and there is a high degree of homology between their gene products, which are 
commonly referred to as p21. All the genes have 4 exons, with the K-ras gene having an 
alternative 4th coding exon which results in the production of 2 proteins that differ at 











The ras gene promoters do not contain TATA or CCAAT elements, but rather have 
multiple G/C boxes characteristic of housekeeping genes. These G/C elements have been 
implicated in the binding of the Sp 1 transcription factor (Ishii et ai., 1986). 
Mammalian ras genes can be constitutively activated and acquire properties that can lead 
to cellular transformation (Tabin et aI., 1982; Reddy et at, 1982; Taparowsky et at, 
1982). This usually occurs as single point mutations in their coding sequences, especially 
codons 12, 13 and 61. In vitro mutagenesis studies have shown that in addition to these 3 
codons, mutations in co dons 63, 116, and 119 can also confer transforming properties to 
RAS. 
The critical residue seems to be glycine at codon 12. A substitution of this residue by any 
f 
other amino acid (except proline) results in constitutive activation ofRAS (Seeburg et aI., 
1984). The glycine at position 13 is also important, although different substitutions at this 
site have different effects on the activation of the protein (Fasano et aI., 1984). The 
glutamine at position 61 is also crucial as substitution of this residue with any other 
amino acid, with the exception of proline and glutamate, results in a constitutively active 
protein (Taparowsky et aI., 1983; Brown et al., 1984). 
1.4.1.1 How RAS Functions 
The RAS proteins are involved in signal transduction, transmitting signals from the 
membrane into the cell. In order to do this, the ras p21 protein binds guanine nuc1eotides 
(both GDP and GTP) and possesses an intrinsic GTPase activity, both of which are 
crucial for normal RAS function (Temeles et aI., 1985). Mutants which are unable to bind 
guanine nuc1eotides are incapable of transforming N1H-3T3 cells (Willumsen et aI., 1986; 
Lacal et aI., 1986), and furthermore, the GTPase activity in constitutively activated RAS 
is considerably less than in the wild-type protein in that mutants hydrolyse GTP to GDP 
with less efficiency than wild-type RAS, and consequently remain active for longer 
(Manne et aI., 1985; Sweet et aI., 1984). 











exists in equilibrium between an inactive and an active state (Barbacid, 1987). In the 
inactive state, RAS binds GDP. When a signal is received upstream of RAS, the GDP is 
exchanged for GTP, leading to a conformational change in the protein, resulting in 
activation of RAS. Once in this active state, RAS interacts with its downstream effector 
molecules. The intrinsic GTPase activity of the molecule ensures that once the interaction 
between itself and the effector has taken place, the protein returns to the inactive 
conformation as the GTP is hydrolysed to GDP. 
1.4.1.2 RAS Protein Structure 
RAS proteins contain 4 defined domains (reviewed by Barbacid, 1987). The first domain 
spans the amino-terminal third of the protein and is highly conserved, with the first 85 
amino acids being identical between Ha-Ras, Ki-Ras and N-Ras. The second domain 
comprises the next 80 amino acids and is slightly less homologous (85%) between the 
different proteins. The third.domain is highly variable, and the last domain comprises the 
last four amino acids with a common Cys-A-A-X motif, where A is any aliphatic amino 
acid and X is any amino acid. Each of these domains has a specific function that is crucial 
for normal RAS. function. Residues 5-63, 77-92, 109-123, 139-165 and the carboxyl 
terminal Cys-A-A-X motif are the regions most critical for normal RAS function 
(Willumsen et aI., 1986). 
The amino terminus (residues 5-63) of RAS is involved in guanine nucleotide binding, 
with the glycine at position 12 playing a critical role (Barbacid, 1987). Consequently any 
mutations disrupting this residue would drastically alter the function of the protein, and 
would lead to a constitutively active form of the protein. 
It has been suggested that domains 77-92, 109-123, and 139-165 are involved in 
interacting with the downstream molecules (or RAS effector proteins) in the signal 
transduction cascade. 
The RAS proteins are anchored in the cytoplasmic side of the cell membrane via the 











1984a). Once the proteins are synthesised, the cysteine residue at position 186 becomes 
acetylated by palmitic acid, and this acetylation allows the proteins to anchor in the 
membrane. This modification is crucial for RAS function, since mutants lacking Cys 186 
remain localised in the cytoplasm and are unable to transform cells (Willumsen et aL, 
1984a; Willumsenet al., 1984b). 
1.4.1.3 Mechanisms of Activation of the ras Genes 
The most common way the ras genes acquire transforming properties is by point 
mutations in specific codons. However, overexpression of the wild-type ras gene can also 
lead to a certain degree of cell transformation, albeit to a lesser extent. 
Activated ras genes have been identified in a variety of tumours such as carcinomas of 
the bladder, colon, breast, kidney, liver, lung, ovary, pancreas and stomach, and are 
possibly the most frequently mutated oncogenes in human cancer, with an incidence of 
10-15%. The frequency of activated ras genes varies between tumour types, with a high 
incidence of mutated genes in pancreatic, colon and thyroid tumours and a low frequency 
in breast, ovary, oesophageal and gastric cancers (Bos, 1989). Activated ras oncogenes 
are not associated with any specific type of tumours and their activation does not 
correlate with the histopathological properties of the tumour (Barbacid, 1987). 
In addition to mutations, overexpression of the wild-type RAS may play a role in the 
transformation process. This could be brought about by mutations in the regulatory 
sequences of the ras genes, although there is no evidence for such mutations in human 
tumours (Barbacid, 1987). Expression of the ras genes in tumours has been reported to be 
increased 2-10 fold relative to the normal tissue in 50% of human tumours (Barbacid, 
1987; Slamon et aL, 1984; Spandidos and Agnantis, 1984; Spandidos and Kerr, 1984). 
The significance of this overexpression is unclear at present, but it may contribute to the 
malignant phenotype. 
Another possible mechanism that could lead to overexpression of wild-type ras is by 











et aI., 1985; Fujita et aI., 1985; Bos et a!., 1986; Filmus and Buick, 1985). The overall 
incidence ofras gene amplification, however, is probably not higher than 1% (Pulciani et 
al., 1985). 
ras Oncogenes are the most frequently activated oncogenes identified In sporadic 
tumours, and this frequent identification of these oncogenes raises the question of 
whether they are the cause of the malignant phenotype or merely a consequence of it. 
Some evidence suggests that ras oncogenes can become activated after cells have become 
transformed (Albino et aI., 1984; Tainsky et al., 1984; Vousden and Marshall, 1984), 
however substantial evidence, primarily from animal tumour models, suggests that the 
ras genes playa role in the initiation of the malignant phenotype. 
1.4.1.4 Carcinogen-Induced Tumours 
The ras genes have been shown to be activated in murine carcinogen-induced tumour 
model systems. In rats, the H-ras oncogene is activated in 86% of mammary carcinomas 
induced by nitroso-methyl urea (NMU) (Sukumar et aI., 1983; Zarbl et aI., 1985). This 
dropped to 23%, however, when the carcinogen was dimethylbenz(a)anthracene 
(DMBA). In other studies, the K-ras gene was found to be activated in 40% of kidney 
tumours induced by methyl(methoxymethyl)nitrosamine (DI\1N) and in 74% of lung 
carcinomas induced by tetranitromethane (TNM) (Sukumar et a1., 1986). Similar high 
frequencies of activated ras genes occur in mice treated with different carcinogens 
(reviewed by Barbacid, 1987). This high frequency of reproducible ras activation in 
carcinogen-induced tumours suggests that the ras genes play a causative role in the 
development of the malignant phenotype. 
Most carcinogens are mutagens and a large proportion of them form adducts on the DNA 
(reviewed by Singer and Kusmierek, 1982). These ad ducts can lead to the introduction of 
mutations into the DNA, which could result in activation of, amongst others, the ras 
genes (if these adducts happened to form in the coding regions of the genes). In fact, it 
has been shown that each allele of the H-ras gene in NMU-induced rat mammary 











case for DMBA-induced tumours, suggesting that NMU was directly responsible for the 
activation of the H-ras gene in those mammary tumours. Furthermore, only the G in the 
middle postion of codon 12 (GGA) was affected, thus strengthening the suggestion that 
NMU is directly responsible for the activation of this gene in NMU-induced rat 
mammary carcinomas. 
The idea that the ras genes are targets for chemical carcinogens is further supported by 
the findings that DMBA-induced skin tumours in mice involve the activation of H-ras via 
A ~ T transitions specifically at the second base of codon 61 (Quintanilla et al., 1986; 
Bizub et al., 1986). Taken together, these findings suggest that chemical carcinogens are 
directly responsible for activation of the ras genes, which is an early event in the process 
of carcinogenesis, with other genes developing subsequent mutations that would 
ultimately lead to the development ofa neoplastic phenotype. 
Although current evidence suggests that ras oncogenes are involved at an early stage in 
the initiation of tumourigenesis in animal models, and given the fact that the ras genes 
are ubiquitously expressed, it is somewhat surprising that not more tumour types contain 
a high frequency of ras gene mutations. In the case of breast cancer, the ras genes may 
only acquire mutations once the mammary gland has been stimulated to proliferate and 
differentiate after exposure to hormones during sexual development and these mutations 
may only manifest themselves during this period. Thus acquiring a ras gene mutation 
after sexual development might not lead to the induction of tumourigenesis, whereas 
early acquisition (before sexual development) of a ras gene may trigger carcinogenesis 
during proliferation and development of the mammary gland (Barbacid, 1987). 
1.4.1.5 Ras and the Cell Cycle 
A role for ras in the cell cycle comes from the evidence that transformation of Nlli3 T3 
cells with v-H-Ras results in an altered cell cycle (Liu et aI., 1995). These transformed 
cells grow faster, have a higher S phase content and also have a shortened cell cycle time 
compared to the control cells. The shortened cell cycle is due to a shortened Gl phase that 











observed for Nlli3T3 cells overexpressing cyclin D, and the shortened G1 phase could be 
reversed by inhibiting the expression of cyclin D in the ras-transformed cells (Liu et aI., 
1995). This overexpression of cyclin D in the ras-transformed cells occurred as a result of 
stabilisation of the existing mRNA, rather than an increase in transcription of the gene. 
These results suggest that signaling via the ras pathway leads to an altered cell cycle and 
may explain one of the ways in which ras plays a role in cell transformation. 
1.4.2 Mutations Affecting Tumour Suppressor Genes - p53 
The second class of genetic alterations in cancer is the inactivation or loss of tumour 
suppressor genes (Seemayer and Cavenee, 1989; Weinberg, 1989; Knudson, 1989). 
These genes are involved in suppression of cell growth during normal development. 
Numerous candidate tumour suppressor genes such as p53 (probably the best studied 
one), WT-1 (Wilms tumour), DCC (deleted In colon carcinoma), NF-1 
(Neurofibromatosis) and the retinoblastoma gene have been identified to date (reviewed 
by Marshall, 1991 and Weinberg, 1991). Inactivation of these genes has been proposed to 
occur by a "two-hit" mechanism in which loss of one allele and a point mutation in the 
remaining al1ele inactivate the gene. It has al~o been suggested, however, that loss of one 
allele is not a pre-requisite for inactivation of the gene, but rather the mutant protein may 
interact with the wild-type protein in a "dominant-negative" fashion and in this way 
abolish the normal function of the protein. This type of mechanism has been proposed for 
the p53 tumour suppressor gene (Baker et aI., 1989). 
As in the case of amplification of oncogenes, loss of genetic material has been identified 
at numerous loci in the genome in breast cancer patients: chromosome 1 p (Genuardi et 
ai., 1989; Devilee et aI., 1991a; Bieche et al., 1993), 1q (Chen et al., 1989; Gendler et aI., 
1990; Devilee et aI., 1991a), 3p (Callahan and Campbell, 1989), IIp (Callahan and 
Campbell, 1989), 13q (Lundberg et aI., 1987; Sato et aI., 1990), 17p (Mackay et aI., 1988; 
Cropp et aI., 1990; Sato et aI., 1990), 17q and 18q (Cropp et al., 1990; Devilee et aI., 
1991b) are all regions frequently lost in human breast cancer. All of these loci have been 
implicated in other tumour types and are thus thought to harbour tumour suppressor 











location of the p53 tumour suppressor) being the region most frequently lost (McBride et 
aI., 1986). It has been suggested that the large number of sites affected by allelic loss in 
breast cancer could signify a co-operative effect of multiple alterations which would 
favour progression to a malignant phenotype (Ben Cheickh et aI., 1992). Loss of Ip and 
11 p occurs concurrently with loss of 17p, whereas there has been no association with loss 
of 1 p and 11 p (Ben Cheickh et aI., 1992; Cropp et aI., 1990; Devilee et at, 1991 b; Sato et 
aI., 1990). There is, however, an association of deletions on chromosome 11 p with 
amplification of the c-erhB2 oncogene, and loss of 17p with amplification of the fig locus 
(Ben Cheickh et aI., 1992). It therefore appears that certain genetic aberrations may co­
operate in the process of tumourigenesis of breast cancer, such that specific sets of 
alterations may define specific sub-groups of breast tumours (Ben Cheickh et aI., 1992). 
The p53 gene is the best characterised tumour suppressor gene to date. It is involved in 
the negative regulation of cell proliferation by regulating gene transcription, monitoring 
DNA for damage and halting the cell cycle when damage is detected and it also plays a 
role in apoptosis. The human p53 gene is found on the short arm of chromosome 17 
(17p 13.1) and spans 20kb ofDNA (Lamb and Crawford, 1986). The gene consists of 11 
exons, ofwhich exon 1 is a non-coding exon. 
p53 is the most frequently mutated gene in human tumours and the majority of mutations 
are point mutations which fall within evolutionary conserved domains of the gene. The 
majority of these mutations cause conformational changes in the protein, rendering the 
protein inactive with respect to its normal function. Certain mutations may also lead to a 
gain of function in which the protein promotes cellular proliferation. 
1.4.2.1 History 
p53 was originally discovered in nuclear extracts from cells transformed with Simian 
virus 40 (SV40), where it forms an oligomeric complex with the virally encoded large T 
tumour antigen (Lane and Crawford, 1979). Because T antigen is needed for maintenance 
of the transformed state, it was suggested that this interaction between p53 and T antigen 











a tumour antigen. 
It was later discovered that cells transformed by a variety of agents expressed increased 
levels of p53 when compared to the homologous non-transformed cells (Crawford et aI., 
1981; DeLeo et al., 1979). More than one mechanism is involved in the regulation of the 
level of p53 protein in the cell (Reich et al., 1983). An alteration in the amount of p53 
mRNA i.e. an increase in transcription, or in the stability of the protein can lead to an 
increase in the amount of the protein in the cell. These mechanisms may operate 
independently or jointly in upregulating the levels of the p53 protein in the cell. 
Interaction of p53 with other proteins, such as the SV40 large T antigen, may be one 
explanation for the increased stability of the protein. This interaction would increase the 
half-life of the protein, thus increasing it's effective concentration. It was proposed that 
this increase in p53 levels was partially responsible for the altered growth characteristics 
of cell lines expressing increased levels of p53 (Reich et al., 1983). 
p53 was then classified as an oncogene when it was found that a number of eDNA and 
genomic p53 clones could immortalise cells in culture and cooperate with the ras 
oncogene in transforming these cells (Eliyahu et al., 1984; Parada et al., 1984; Jenkins et 
a1., 1984). It turned out, however, that all the p53 clones that could cooperate with ras in 
transforming cells in culture were mutant forms of p53 (Hinds et al., 1989). This led to 
the re-classification of p53 as a recessive oncogene or anti-oncogene (tumour suppressor 
gene), with a normal function of negatively regulating cell growth. Several diverse 
mutations are able to inactivate the wild-type function of the protein, resulting in cellular 
transformation in cooperation with ras. Furthermore, viral transforming proteins such as 
SV40 large T antigen, bind to wild-type p53 and abrogate its normal function in the cell, 
and in this way allow for transformation. Further evidence for the role ofp53 as a tumour 
suppressor gene came from the introduction of the wild-type protein into a human 












1.4.2.2 p53 Protein Structure 
The p53 gene encodes a protein of 393 amino acids. There are 5 regions of the protein 
which are highly conserved between species. The first region occurs at the N-terminus of 
the protein, with the other four conserved domains in the central region of the protein. 
The protein has the characteristics of a transcription factor. The N-terminal 
transactivation domain is acidic and is involved in the interaction with other proteins. The 
central region of the molecule is involved in sequence-specific DNA binding and the C­
terminal region contains the nuclear localisation signal (Shaulsky et aI., 1990b) and the 
oligomerisation domain (p53 exists as a tetramer in solution (Vogelstein and Kinzler, 
1992)). In addition to this, the C-terminal domain also plays a role in non-sequence 
specific DNA binding. 
1.4.2.3 The Function of Wild-Type p53 
p53 is involved in the negative regulation of cell growth and is important in cell cycle 
regulation. There are numerous mechanisms by which p53 carries out these functions; 
p53 blocks the cell cycle in Gl in response to various stimuli such as agents that induce 
DNA damage, for example UV light, y-irradiation and certain drugs. 
Initial studies have shown that p53 is a regulator of GTP synthesis, suggesting a role for 
the protein as a novel regulator of signal transduction, and in this way, it was able to 
controlthe cell cycle (Sherley, 1991) 
There is now conclusive evidence that p53 behaves as a transcription factor. Firstly it 
contains an acidic domain near its N-terminus, similar to that of other well characterised 
transcription factors (Fields and Jang, 1990; Raycroft et aI., 1999). Furthermore, when 
this acidic domain was fused to the GAL4 DNA-binding domain, the fusion protein could 
activate transcription from a GAL4 operon. This transcativation domain has been mapped 
to the region between co dons 20 and 42 of the p53 gene (Unger et aI., 1992). 











PuPuPuC(AJT)(AJT)GPyPyPy-3' consensus sequence(Kern et a1., 1992; Hupp et al., 
1992; Vogelstein and Kinzler, 1992). One copy of this 10 base pair motif is insufficient 
for binding, and the two copies necessary for binding can be separated by up to 13 base 
pairs of random DNA to preserve binding ofp53 to the DNA. The symmetry of this motif 
suggests that p53 may bind as a tetramer, which is consistent with biophysical data which 
indicate that p53 exists as a tetra mer in solution (reviewed by Vogel stein and Kinzler, 
1992). The fifty C-terminal amino acids of the protein have been shown to contain 2 
motifs required for heterogeneous oligomerisation (Kraiss et al., 1988), and the DNA 
binding domain of the protein has been mapped to the C-terminal region as well. 
Recently, a more well-defined p53 consensus binding site has been elucidated as 
GGACATGCCCGGGCATGTCC (Funk et a1., 1992). This sequence is a palindrome and 
p53 only binds to it in the presence of crude nuclear extract, suggesting that it may bind 
DNA after post-translational modification, or as a complex with other proteins. p53 has 
been shown to directly interact with the TATA binding protein (TBP) (Martin et a1., 
1993; Liu et al., 1993). This interaction may mediate the influence of p53 on transcription 
and involves TBP-associated factors (T AFs), specifically T AFn40, T AF n60 and 
TAFn230 (Thut et aI., 1995; Farmer et al., 1996). p53 also interacts weakly with TFIID, 
an important factor required for transcription initiation (Liu et a1., 1993). The region of 
p53 involved in this interaction was mapped to between residues 20 and 57 located in the 
acidic transactivation domain. 
There is evidence to suggest that p53 acts as both a transactivator (Kern et al., 1992; Funk 
et a1., 1992; Farmer et al., 1992) and an inhibitor of gene expression (Ginsberg et al., 
1991; Chin et a1., 1992; Kley d ai., 1992; Mack et a1., 1993). It would seem that wild­
type p53 behaves as an activator of transcription on genes with promoters containing p53 
binding sites, and it acts as an inhibitor of transcription on genes with promoters lacking a 
p53 consensus binding site. Various speculations have been made as to how p53 can act 
as both an inhibitor and an activator ofgene expression (Martin et a1., 1993). When p53 is 
complexed to TBP it acts as a repressor i.e. p53 represses the activity of promoters whose 
initiation is dependent on the presence of a T ATA box. This repression, however, was 











the p53-TBP complex is not favourable for interaction with other transcription factors, 
thereby inhibiting transcription in general (Mack et aL, 1993; Martin et al., 1993). A 
conformation favourable for activating transcription could be achieved by a mutant p53 
protein interacting with TBP, or by direct binding of wild-type p53 to the DNA. 
Furthermore, for promoters with p53 consensus binding sites, the presence of p53 on 
these promoters and its ability to bind TBP, may facilitate the nucleation ofTBP on these 
promoters, thus enhancing transcription activity (Martin et al., 1993). 
p53 has been shown to activate its own promoter (Deffie et al., 1993). The DNA response 
element of the p53 promoter involved in this activation is the NF-kB motif, which has a 
one base pair mismatch with the p53 consensus sequence. A direct interaction between 
this motif and p53 has, however, not been observed. p53 probably activates one or more 
transcription factors which do bind to this NF-kB site i.e p53 indirectly activates 
transcription from its own promoter (Deffie et al., 1993). Alternatively, p53 could interact 
directly with one of the transcription factors binding to the NF-kB sequence and thereby 
activate transcription. In addition to activating its own promoter, p53 has also been shown 
to regulate its own transactivation function. The region mapping between residues 92 and 
160 has a strong inhibitory effect on the activation domain of p53, which lies between 
residues 20 and 92 (Liu et al., 1993). 
1.4.2.4 Post-Translational Modifications of the p53 Protein 
1.4.2.4.1 Phosphorylation 
p53 function is regulated by phosphorylation, for which there are a number of sites 
distributed at both ends of the protein. Phosphorylation by casein kinase II at the C­
terminal seems to be important in DNA binding activity. The C-terminal region of p53 is 
important in controlling its activity (Hupp et al., 1992). Removal of the 30 C-terminal 
amino acids constitutively activates DNA binding, suggesting that it has a negative effect 
on DNA binding. Other modifications in this region, such as proteolysis by trypsin, 
interaction with E.coli dnaK (a protein that disrupts protein-protein complexes), and 
phosphorylation by casein kinase II (Hupp et a1., 1992) and the CDK7-cycH-p36 kinase 











serines 371, 376, 378, and 392 being potential phosphorylation sites (Lu et aI., 1997). In 
addition, mutation of Ser 386 in mouse p53 (the casein kinase II phosphorylation site) 
resulted in the loss of the growth suppressor function of p53, further suggesting that 
phosphorylation plays an important role in the anti-proliferative function of p53 (Milne et 
aI., 1992). It has been shown that interactions with proteins such as dnaK can stabilise the 
protein and maintain it in a conformation that is thermostabile and capable of DNA 
binding (Hansen et aI., 1996). In contrast, the calcium-dependant protein kinase C (PKC) 
phosphorylates murine p53 in vitro on several residues in the basic region of the C­
terminal, but PKC appears to bind to a domain in p53 distinct from the one containing the 
phosphorylated residues (Delphin et aI., 1997). The C-terminal region of murine p53 is 
able to stimulate sequence-specific DNA binding at micromolar co centrations, but this 
function is lost when it is phosphorylated by PKC. Human p53 is phosphorylated by 
protein kinase C on Ser 378 that activates the sequence-specific DNA binding of p53 
(Takenaka et aI., 1995). This activation of the DNA binding function of p53 is inhibited 
by phosphatases 1 and 2A and it is possible that these mechanisms may operate in vivo to 
regulate the activity of p53 as a transcription factor. 
p53 is also phosphorylated at the N-terminal at serines 15 and 37 by DNA-PK, an event 
that is important in activating the growth-suppressive functions ofp53 (Lees-Miller et aI., 
1992). DNA damage activates DNA-PK, which in turn phosphorylates p53, resulting in 
activation of the DNA binding activity of p53 and inhibition of p53 interaction and 
inactivation by mdm2 (Woo et aI., 1998). Earlier studies· also suggested that 
phosphorylation at the DNA-PK sites caused an alteration in the conformation of the p53 
protein, which could account for its inability to interact with mdm2 (Shieh et aI., 1997). 
p53 may also be phosphorylated at serine 15 by the ATM protein in vitro in response to 
DNA damaging agents (Banin et aI., 1998; Canman et aI., 1998). Additional 
phosphorylation sites at the N-terminal have been identified in mouse p53 and these are 
serines 7, 9, 18 and 37 (Wang and Eckhart, 1992). Serines 7 and 9 are phosphorylated by 
the dsDNA-dependent kinase (DNA-PK) in vitro, but it is not clear whether this also 











phosphorylation status of the protein changing as the cells progress through the cell cycle. 
In GO/G}, the protein is under-phosphorylated compared to the S phase. 
Recent evidence suggests that phosphorylation ofp53 at both the N- and C-termini is not 
crucial for the functional activity ofp53 (Ashcroft et aI., 1999). p53 molecules which had 
all of their phosphorylation sites simultaneously mutated were equally efficient at 
activating transcription of the CIP1, mdm2 and bax promoters as the wild-type protein. 
p53 proteins with only their C-terminal phosphorylation sites mutated did so with a 
reduced activity, which is consistent with the idea that C-terminal phosphorylation 
enhances DNA binding. Also, all of the mutants were as sensitive to degradation by 
mdm2 and were all stabilised after DNA damage by either actinomycin D treatment or 
UV irradiation. These results suggest that phosphorylation of p53 is not absolutely 
necessary for the regulation of its stability and imply that other mechanisms exist to 
stabilise the protein in response to DNA damage. Further studies have shown that the 
ATM protein that phosphorylates p53 at the N-terminus in vitro, is not required for its 
transactivation function or its ability to induce apoptosis suggesting that phosphorylation 
of the N-terminus is not a prerequisite for normal p53 function in vivo (Liao et aI., 1999). 
These results do not, however, preclude that phosphorylation may playa subtle role in the 
regulation of p53 function under certain conditions. 
1.4.2.4.2 Acetylation 
CREB binding protein CBP/p300 and PCAF are acetyltransferases and are co-activators 
of p53 and are required for full transcriptional activity of p53 (Bannister and Kouzarides, 
1996; Ogryzko et aI., 1996). Both of these proteins acetyl ate different residues ofp53 in 
vitro (Gu and Roeder, 1997; Liu et aI., 1999). PCAF acetylates Lys320 while p300 
acetylates Lys373, resulting in stimulation of sequence-specific DNA binding in vitro, 
suggesting that p53-mediated transcriptional activation may be modulated by acetylation. 
Furthermore, acetylation ofLys373 by p300 and Lys320 by PCAF was found to occur in 
vivo in cells exposed to UV or ionising radiation, but not in unexposed cells. This 











1.4.2.5 DNA Binding 
p53 binds to DNA in both a sequence-specific and a nonspecific manner. The sequence­
specific DNA binding and transactivation of genes is essential for p53 to suppress growth 
(Pietenpol et al., 1994). The C-terminal 47 amino acids contain the nonspecific DNA 
binding region that recognises and binds to damaged DNA. 
The region responsible for sequence-specific DNA binding maps to residues 102-292 in 
human p53, encompassing the evolutionary conserved domains II-V where most 
mutations have been detected (Srinivasan et a1., 1993; Pavletich et al., 1993). This 
domain consists of a ~ sandwich comprising two antiparallel ~ sheets. A loop-sheet-helix 
(LSH) motif binds in the major groove and is involved in contacts with the bases in the 
DNA while two large loops interact such that Arg248 makes contact with the minor 
groove of the DNA in the AfT rich portion of the consensus binding site (Prives, 1994). 
The sequence-specific DNA binding of p53 is dependent on reactive sulfhydryl groups 
and p53 must be in a reduced state in order to bind DNA in zinc dependent manner (Hupp 
et al., 1993; Rainwater et al., 1995). A number of cysteine residues in this region are 
believed to be important for zinc binding and mutation analysis in murine p53 revealed 
that cysteines 173, 235, and 239 are essential for transactivation by p53 (Rainwater et al., 
1995). These 3 cysteine residues interact directly with a zinc ion and it has been 
suggested that, by binding zinc, they can modulate the secondary structure of the protein, 
enabling it to adopt a conformation that allows interaction with the DNA (Rainwater et 
al., 1995). In human p53, the interaction ofp53 with the DNA is stabilised by a zinc atom 
which is held in place by four residues, Cys 176, His 179, Cys238 and Cys242, all of 
which fall in the two large loops that interact such that Arg248 can make contact with the 
minor groove (Prives, 1994). 
Several genes contain the p53 consensus-binding site, and some examples of p53 
activated genes are c-erbA, CIPI (el-Deiry et al., 1993), TGF-a (Shin et al., 1995), 
PCNA (Shivakumar et al., 1995; Xu and Morris, 1999), c-fos (Elkeles et al., 1999), 
matrix metalloproteinase-2 (Bian and Sun, 1997), IGF-BP3 (Buckbinder et al., 1995) and 











(Margulies and Sehgal, 1993; Wang et aI., 1995), c-jun, DNA topoisomerase IIa (Wang 
et aI., 1997) and ~-actin on the other hand, have all been shown to be repressed by p53. 
The effect of p53 on the human multidrug resistance promoter (MDR1) is, however, 
highly contentious. Drug resistance is a major problem in cancer chemotherapy which is 
associated with overexpression of the multi drug resistance gene. Various studies have 
shown that mutant p53 stimulates expression from the MDRI promoter, whereas wild­
type p53 has no effect or represses MDRI promoter activity in heterologous 
human/rodent systems and cell lines (Chin et aI., 1992; Zastawny et aI., 1993; Dittmer et 
aI., 1993). When a human MDRI CAT construct was transfected into NIH3T3 cells that 
are usually non-permissive for the expression of MDRI CAT because of endogenous 
p53, a His275 mutant p53 was able to activate expression from the MDRI promoter 
(Chin et aI., 1992). Co-transfection and re-introduction of wild-type p53 reversed this 
activation of the MDRI promoter by the mutant protein. These results therefore suggest 
that introduction of the mutant p53 into NIH3T3 cells inhibits/abolishes the negative 
effect of wild-type p53 on the MDRI CAT construct because of the dominant negative 
mode of action, thus resulting in activation ofMDRl CAT. In another study, the opposite 
effect was reported where wild-type p53 stimulated expression from the MDRI promoter 
whereas several mutant p53 proteins failed to do so and even slightly repressed 
expression of an MDRI CAT construct (Goldsmith et aI., 1995). This study utilised a 
human MDRI promoter, human p53 and human cell lines, as opposed to the previous 
studies where heterologous systems were used. Also, maximal stimulation of the MDRI 
CAT construct was observed 20-30 hours after transfection, at which time CAT activity 
dropped steadily and returned to basal levels 48 hours post-transfection, which is 
frequently used as the termination time for transient transfection studies. Thus 
discrepancies between the results may be due to the specific systems and cell lines used. 
In addition, it is possible that different p53 mutants may have different effects on the 
activation of the MDRI promoter. 
There also seems to be some controversy regarding the effect of wild-type p53 on the e­
jos promoter. Some evidence indicates that p53 activates transcription of the c-jos gene 











1992). In the case of p53 activation of c-fos, p53 was shown to bind to a site within the 
first intron of the gene and does not involve the basal promoter, whereas repression of c­
fos involved the basal promoter. It must be noted, however, that the repression study 
(Kley et aI., 1992) used a transient transfection assay using a construct lacking the first 
intron. Thus it is likely that p53 activates c-fos in vivo, but in the absence of the first 
intron it is capable of repressing transcription from this promoter due to interactions with 
other transcription factors. 
1.4.2.6 Stability of the Protein 
In normal cells p53 has a very short half·1ife of 20-40 minutes and consequently is 
present at very low levels. The levels of the protein increase about 10- to 20-fold in late 
Gl phase, just prior to the S phase. High levels of p53 may also be detected after DNA 
damage or following exposure to stimuli that induce differentiation or apoptosis. These 
high levels of protein are, however, transient. 
A possible explanation for the short half-life of p53 is the ability of wild-type p53 to 
activate the mdm2 gene whose product targets p53 for degradation via the ubiquitin­
proteosome pathway thus significantly reducing the steady state levels of p53 (Haupt et 
aI., 1997). Binding of mdm2 to the N-terminal transactivation domain of p53 is a 
prerequisite for degradation (Gottlieb and Oren, 1996). The C-terminal region of p53 also 
appears to be important for mdm2-mediated degradation since deletion of the C-terminus 
renders the protein resistant to mdm2 mediated degradation, suggesting a role for 
oligomerisation in degradation by mdm2 (Kubbutat et aI., 1998). Degradation of p53 by 
mdm2 more than likely occurs in cytoplasmic proteosomes since nuclear export is 
required for the degradation to take place (Freedman and Levine, 1998). 
The exact mechanism(s) by which p53 becomes stabilised after DNA damage are unclear, 
but given that p53 is degraded via the ubiquitin-proteosome pathway, a possible 
mechanism could involve repression of ubiquitin-mediated degradation via some 
signalling pathways induced by DNA damaging agents. Exposure of RKO cells (colon 











half life increasing to more than 3.5 hours in the irradiated cells (Maki and Howley, 
1997). Interestingly though, ubiquinated p53 was detectable in both untreated and y 
irradiated cells, but not in the cells exposed to UV radiation. In fact, ubiquitinated p53 
was found to disappear as early as 1 hour after exposure to UV radiation. These results 
suggest that stabilisation of the p53 protein in the UV irradiated cells is due to a loss of 
ubiquitination and further imply that different mechanisms are involved in stabilising p53 
in response to various DNA damaging agents. 
Proteolytic cleavage of p53 has also been implicated in regulating the stability of p53. 
Calpain cleaves p53 in vitro in the N-terminal domain, and inhibition of cal pain by 
protease inhibitors results in stabilisation ofp53 (Kubbutat and Vousden, 1997), 
1.4.2.7 Oligomerisation of p53 
p53 exists predominantly as a homotetramer in both the latent and activated forms, 
however, the role of oligomerisation is somewhat contentious (Vogel stein and Kinzler, 
1992; Milner et aI., 1991; Sturzbecher et aI., 1992; Hupp and Lane, 1994). It would 
appear that p53 is produced as a latent tetramer, which, upon modification of the C­
terminus, is converted to an active tetamer (Hupp and Lane, 1994), The C-terminal 
regulatory domain of p53 plays a major role in the activation of latent tetramers into 
active tetramers since a synthetic peptide derived from this domain has been shown to 
activate latent p53, supporting a model in which disruption of specific contacts between 
this regulatory domai  and other domains of the protein results in activation of the latent 
tetramer (Hupp et aI., 1995). Each monomeric unit of the tetramerisation domain 
comprises a turn (residues 324 M 326), a ~ strand (residues 326-334), a second turn 
(residues 335-336) and an a helix (residues 337-355). Each subunit interacts with another 
subunit such that the helices and ~ strands are antiparallel (Clore et aI., 1994 and 
reviewed by Prives, 1994). Two of these dimers interact, resulting in a tetramer. The 
formation of tetramers is important for DNA binding, but it appears, at least with respect 
to murine p53, that p53 can also bind in a sequence-specific manner to the DNA as a 
dimer. It has also been suggested that tetramerisation of p53 plays a role in the 











1.4.2.8 Subcellular Localisation of p53 
The localisation of p53 varies during the cell cycle. In mouse cells, newly synthesised 
p53 accumulates in the cytoplasm during the G1 phase of the cell cycle and then moves to 
the nucleus until just prior to the S phase (Shaulsky et aI., 1990a). After the initial round 
of DNA synthesis, the protein is translocated from the nucleus and again accumulates in 
the cytoplasm. The mechanism regulating the subcellular localisation of p53 is unclear, 
but the C-terminal region of the protein may playa role in it's localisation (Liang et aI., 
1998). The wild-type protein is localised in the cytoplasm, nucleus or both in a subset of 
MCF-7 (breast carcinoma), RKO (colon carcinoma) and Saos-2 cells. Mutation of lysine 
305 results in the sequestration of p53 in the cytoplasm in the MCF-7 and RKO cells, but 
the mutant protein is distributed in both nuclear and cytoplasmic compartments in the 
Saos-2 cells. In addition, cytoplasmic sequestration of the mutant p53 is dependent on the 
C-terminal region (residues 326-355). These results suggest that cis-acting sequences are 
involved in the regulation of localisation of p53 within the cell. Phosphorylation may also 
playa role in modulating the localisation of the protein in the cell via a phosphorylation 
site within the nuclear localisation signal (reviewed by Ozbun and Butel, 1996). 
A nuclear export sequence (NES) located within the C-terminal tetramerisation domain 
spanning residues 340-351 has recently been identified (Stommel et aI., 1999). Mutations 
in this region result in the accumulation of p53 in the nucleus. It is critical for the cell to 
export p53 out of the nucleus when it is no longer required, as prolonged wild-type p53 
activity may result in death of a normal cell. When a cell becomes damaged or is stressed, 
modifications of p53 may occur which facilitate tetramerisation of the protein. Because 
the NES occurs in the tetramerisation domain, formation of p53 tetramers would occlude 
the NES, resulting in accumulation of p53 in the nucleus. Once in the nucleus, wild-type 
p53 can bind DNA and transactivate genes and thus mediate a p53 stress-response. Once 
the cell has recovered, or in unstressed normal cells, modifications may result in 
dissociation of the tetramers, thereby exposing the NES. This would then lead to export 
of the protein from the nucleus, probably by binding to the nuclear export receptor, 











1.4.2.9 Regulation of Cell Growth by p53 
It has been hypothesised that p53 can negatively regulate cell growth in three ways; (1) 
repressing genes whose expression is mediated by a TAT A box, (2) activating genes 
containing p53 consensus binding sites, thereby blocking cell cycle control and (3) 
blocking the replication machinery and thus playing a role in DNA replication (reviewed 
by Ozbun and Butel, 1996). In addition, p53 binds to mismatched DNA suggesting that it 
may playa role in the recognition ofDNA damage. 
Wild-type p53 functions as a cell cycle control protein (Baker et aI., 1990; Diller et al., 
1990). Carcinoma cells overexpressing the wild-type gene were unable to progress 
through the cell cycle by becoming arrested in the G1 phase resulting in failure of these 
cells to complete S phase. Further evidence suggests that growth suppression mediated by 
wild-type p53 occurs prior to or near the restriction point (R-point) in the late G1 phase of 
the cell cycle (Lin et al., 1992; Pardee, 1989; Pardee, 1987). Once past this point, protein 
synthesis is no longer required for cells to enter S phase and initiate DNA synthesis. p53 
is able to block the cell cycle by activating the expression of genes such as p21 (CIP1), 
which is an inhibitor of cyclin-dependent kinases (cdks). A p53-dependent increase in 
p21 results in the inhibition of cyclin E-cdk2 kinase activity causing a Gl/S cell cycle 
arrest (el-Deiry et a!., 1993; Gu et aI., 1993). 
The transcription regulatory function of p53 is critical for G1 arrest in cells, which has 
been shown to be inhibited by mdm2 (Chen et aI., 1996). Interaction between the two 
proteins is required for this abrogation and has been confirmed using a mutant p53 (14119 
double-point mutant) which was unable to bind mdm2 but retained DNA binding activity 
(Chen et aI., 1996). Mdm2 had no effect on the GI arrest induced by this mutant, thus it is 
essential that p53 be able to bind to DNA and transactivate genes in order for it to cause a 
Gl cell cycle arrest. 
p53 has also been implicated in the regulation of other proteins, such as pRB which is 
involved in cell cycle control. The phosphorylation status of pRB changes as the cells 











state of pRB was found to be dependent on the presence of functional p53 after exposure 
of cells to 'Y-radiation. Cells harbouring functional wild-type p53 were found to have 
elevated levels of p53 and underwent a G1 arrest after exposure to 'Y-radiation. This 
correlates with a hypophosphorylated form of pRB in the cells (Slebos et aI., 1994). In 
contrast, cells containing mutant p53 fail to arrest in G I after exposure to ionising 
radiation and no hypophosphorylated pRB IS detected In these cells. 
Hypophosphorylation of pRB is dependent on an increase in p53 after DNA damage as 
inactivation of wild-type p53 by the HPV E6 protein results in a failure of these cells to 
arrest after DNA damage (Slebos et aI., 1994). Thus it appears that p53 plays a central 
role in the regulation of other proteins involved in ~ell cycle control in order to elicit a G1 
arrest after exposure to DNA damaging agents. 
Accumulation of p53 after DNA damage and the transactivation function of p53 may be 
regulated differently with respect to the cell cycle. The period during the cell cycle in 
which the cells are exposed to DNA damaging agents also seems to be important for p53 
accumulation. Exposure of synchronised cells to UVC in Go or early to mid GI phases of 
the cell cycle results in low levels of p53 accumulation, whereas cells exposed at the G1/S 
border show higher levels of p53 (Haapajarvi et a!., 1997). In contrast, the DNA binding 
capacity of p53 is activated after UV radiation during any phase of the cell cycle, 
suggesting that activation of the DNA binding and transactivation functions of p53 
induced by exposure to UV irradiation occurs independently of the cell cycle (Haapajarvi 
et aI., 1997). 
p53 is phosphorylated by p60cdC2 and cyclin Bcdc2, and it is possible that the under­
phosphorylated form of p53 exerts cell cycle control, suggesting that in order to allow 
progression through the cell cycle, p53 must be phosphorylated (Bischoff et aI., 1990). 
This is supported by more recent findings which show that p53 is phosphorylated by 
cyclin AlCdk2 and cyclin B /Cdc2 complexes but not by cyclin E/Cdk2 and cyclin 
D1/Cdk4 complexes (Wang and Prives, 1995). Since cyclin D1 and E are most abundant 
in early and late G1 respectively, this implies that p53 is in an underphosphorylated form 











act as a check point control, hence the role of p53 may be to monitor whether a cell 
should continue to progress through the cell cycle (Diller et al., 1990). Loss of this 
function, through mutation, for example, would enable a cell to escape this growth 
control and begin proliferating towards a transformed phenotype. Also, by regulating the 
progression of cells through the cell cycle, p53 plays a role in modulating the expression 
of certain growth response genes that are important for the progression from G1 into S 
phase. 
Emerging evidence suggests that p53 plays little role in normal cell cycle control, but 
rather is crucial in controlling the cell cycle in stressed cells (Kastan et al., 1991). In 
response to x-ray or drug-induced DNA damage, p53 levels are increased in normal cells, 
which then become arrested in the cell cycle until the damage is repaired. A response 
element to genotoxic stress has been identified in the p53 promoter (Sun et al., 1995). 
Exposure of cells to the anticancer agents 5-fluorouracil and mitomycin or UV light 
results in accumulation of p53, as well as an increase in p53 mRNA levels. The region of 
the p53 promoter required for this response to genotoxic agents has been shown to reside 
in a fragment of the p53 promoter between -70 to -40 (Sun et al., 1995). Cells containing 
mutant p53 genes, on the other hand, fail to arrest in the cell cycle and die. 
p53 may also playa role in regulating the cell cycle at a G2 checkpoint. Treatment of 
cells containing wild-type p53 with nocodazole (a microtubule-disrupting agent which 
can trap cells in mitosis) after irradiation results in very few cells entering mitosis, 
consistent with a G2 block (Bunz et al., 1998). Treatment of cells containing mutant p53, 
however, results in a large proportion of cells entering mitosis, indicating that p53 
controls a G2 checkpoint. This G2 checkpoint is also dependent on the presence of p21 
(CIP1), a cyclin dependent kinase inhibitor that is activated by p53. 
1.4.2.10 p53 in DNA Repair 
There is evidence suggesting that p53 plays a more direct role in DNA repair. Wild-type 
p53 has been shown to harbour an intrinsic exonuclease activity which might act in DNA 











This exonuclease activity has been mapped to the central core of the protein and is 
specific to the wild-type p53 as different mutant p53 molecules do not display this 3' -+ 5' 
exonuclease activity. The central core domain of p53 contains both the sequence-specific 
DNA binding activity and an exonuclease activity and these 2 functions of p53 are 
mutually exclusive. As is the" case for the sequence-specific DNA binding activity, the 
exonuclease activity is regulated by the C-terminal domain of p53 since C-terminally 
truncated p53 showed a higher exonuclease activity than full length p53 (Janus et aI., 
1999). The sequence-specific DNA binding activity and the exonuclease activity, 
however, are oppositely regulated by the C-terminal domain: the C-terminal domain 
activates specific DNA binding, but negatively regulates the exonuclease activity. Thus, 
in the absence of stress, when p53 is thought to be in an inactive state, p53 plays a role in 
maintaining the integrity of the genome by repairing spontaneous DNA damage via its 
exonuclease activity in a non-sequence specific manner. 
p53 has also been indirectly implicated in DNA repair and replication, by activating the 
. expression of the proliferating cell nuclear antigen, PCNA, a protein which functions in 
DNA replication and repair (Xu and Morris, 1999). Exposure of rat embryo fibroblasts to 
y radiation causes an increase in p53 levels, which in tum activates expression ofPCNA, 
which has been shown to be brought about by p53 binding directly to the PCNA 
promoter (Xu and Morris, 1999). 
1.4.2.11 Involvement of p53 in DNA Replication 
p53 has also been implicated in directly regulating DNA replication. Wild-type p53 is 
able to inhibit the replication of polyomavirus constructs in an in vitro system in a 
sequence-specific binding manner. Mutant p53 proteins that bind poorly to DNA (Trp248 
and His273) were unable to inhibit replication of the polyomavirus, suggesting that p53 
inhibits replication by altering the structure of the DNA, thereby hindering the binding of 
transcription factors necessary for replication (Miller et aI., 1995). Conversely, DNA 
replication may affect p53 function in that p53 is able to form a complex with the 
replication protein A (RP-A), a multi-subunit complex involved in both DNA replication 











presence of single-stranded DNA prevents p53 from complexing with RP-A (Miller et a1., 
1997). When complexed to RP-A, p53 is unable to bind to the W AF1 p53 binding site 
and consequently would prevent transactivation of the W AF1 gene. In the presence of 
single-stranded DNA, however, RP-A was not able to prevent p53 from binding to the 
WAF1 p53 consensus binding site (Miller et aL, 1997). The data suggests that in the 
absence of single-stranded DNA, p53 may be bound to RP-A and thus be unable to 
interact with consensus binding sites in various promoters, but in the presence of single­
stranded DNA that may arise due to replication or DNA repair, the p53 :RP-A complex 
dissociates with RP-A binding to the single-stranded DNA, leaving the p53 free to 
interact with the promoters ofvarious p53-responsive genes. 
p53 can directly recognise DNA damage in the form of insertion or deletion mismatches. 
Both wild-type p53 and its 14kDa C-terminal (residues 311-393) are able to bind 
mismatched DNA in vitro as determined by electron microscopy, with the predominant 
C-terminal complexes that bound to the DNA being tetramers. Electrophoretic mobility 
shift assays suggested, however, that p53 could bind to the mismatched DNA as 
monomers, dimers, tetramers and even higher oligomers, and also suggested that the C­
terminal region could bind to mismatched DNA as dimers and tetramers (Lee et al., 
1995). Furthermore, these protein-DNA complexes are stable with a half-life of more 
than 2 hours. These results impart a further important role for the C-terminal region of 
p53, that of recognition of and direct binding to damaged DNA. By forming a stable 
complex on mismatched/damaged DNA, p53 probably undergoes a conformational 
change resulting in resistance to degradation. The formation of this stable complex at the 
site of the DNA lesion may provide a scaffold for the binding of proteins involved in 
DNA repair. It may also result in p53-specific activation of genes involved in cell cycle 
control and/or apoptosis (Lee et a1., 1995). These findings are supported by evidence in 
vitro evidence that shows that wild-type p53 is able to induce the annealing of heat­
denatured double-stranded DNA (Reed et a1., 1995). The region of p53 responsible for 
this action is located between amino acids 318 and 393 in the C-terminal domain. This 
same segment of the C-terminal was also able to catalyse DNA strand transfer from 











induced by DNaseI or ionising radiation (Reed et a!., 1995). 
1.4.2.12 Polymorphic Variants of p53 
There are two polymorphic variants of p53 which differ at amino acid 72 (Matlashewski 
et a!., 1987). The variants contain either proline or arginine at codon 72 arising from a 
single base substitution (CCC or CGC). It has been shown that these two isoforms behave 
slightly differently and may playa role in tumours associated with HPY The E6 protein 
of HPV more efficiently targets the p53Arg for degradation via the ubiquitin pathway 
than the p53Pro variant (Storey et a!., 1998). The majority of HPV-associated tumours 
analysed to date are homozygous for the Arg variant. Subtle variations in the biological 
functions of these two isoforms have also been found. Both variants are structurally wild­
type as determined by monoclonal antibody reactivity and they both have similar 
affinities for p53 consensus DNA recognition sequences. The p53Pro variant, however, is 
a slightly stronger transcriptional activator than the p53Arg variant, which stems from 
differences in their interactions with various transcription factors. The Pro variant binds 
with a higher affinity to T AFII 32 and T AFII 70 than the Arg variant. Both isoforms 
suppress the growth of Saos-2 cells to a similar extent, but the Arg isoform is more 
efficient than the Pro isoform at suppressing colony formation in an E7-EJ-ras 
transformation assay. Both of the variants are capable of inducing equal levels of 
apoptosis, suggesting that the p53 genotype may affect design of treatment and 
management in those patients with p53 wild-type tumours(Thomas et aI., 1999). 
A silent polymorphism in the p53 gene has been identified in codon 213 (CGA to CGG). 
This is a rare polymorphism and occurs in, only 3.2% of lung and breast cancer DNAs 
examined (Carbone et a!., 1991). 
1.4.2.13 p53 and Apoptosis 
p53 promotes apoptosis only under certain circumstances, such as in response to DNA 
damage and may not be involved in all forms ofapoptosis (Shaw et aI., 1992; Lowe et aI., 
1993b; Clarke et aI., 1993). Immature thymocytes lacking p53 die normally when 











lOnISmg radiation, that is, they do not undergo apoptosis after exposure to ionising 
radiation. In contrast, thymocytes containing wild-type p53 undergo apoptosis after 
exposure to ionising radiation (Lowe et aI., 1993b; Clarke et aI., 1993). Both wild-type 
and p53 null thymocytes, however, undergo apoptosis in response to glucocorticoids or 
calcium. These results suggest that p53 is not necessary for apoptosis under normal 
circumstances, but is required when cells are exposed to DNA damaging agents and also 
indicate that the triggers for p53-dependent apoptosis are different from those during 
normal cell development. 
p53-dependent apoptosis occurs predominantly in the G1 phase when cells are growth­
arrested (reviewed by Ozbun and Butel, 1996). The mechanism by which apoptosis is 
promoted by p53 is unclear, but it may involve the levels of bax and bel2 in the celL A 
high level of bax and a low level of bel2 results in apoptosis, and p53 is able to control 
this bax:bel2 ratio in the cells by activating the expression of the bax gene and repressing 
expression of the bel2 gene. The exact downstream effectors of p53 directly involved in 
apoptosis are at present not clearly defined, but some evidence suggests that caspases 
such as caspase-9 are involved (Soengas et aI., 1999). p53 has also been implicated in the 
movement of Fas, a member of the TNF receptor family involved in apoptosis, from the 
cytoplasmic pool to the membrane such that it can interact with the Fas-ligand and 
initiate apoptosis (Bennett et aI., 1998). A model for p53-induced apoptosis has been 
proposed based on the identification and characterisation of p53-induced genes (PIGs). 
Somewhat astoundingly, only 14 out of more than 7000 transcripts identified in p53­
expressing cells are significantly overexpressed compared to p53 null cells after the 
induction of apoptosis (Polyak et aI., 1997). Some of these overexpressed genes were 
predicted to encode proteins which could generate reactive oxygen species (ROS) and 
based on the genes identified and biochemical and pharmacological experiments, a three­
step model was proposed: (1) activation of redox-related genes, (2) the formation of 
reactive oxygen species, and (3) oxidative damage of mitochondrial components, 
resulting in cell death (Polyak et aI., 1997). 











mice develop tumours very rapidly, and this correlates with the loss of p53-dependent 
apoptosis (Symonds et at, 1994). p53-dependent apoptosis is induced by abnormal cell 
growth and consequently, loss of wild-type p53 function contributes to the process of 
tumourigenesis as does mutant p53. Cells that lack p53-dependent apoptosis would be 
unable to respond to this abnormal cell proliferation by undergoing apoptosis, resulting in 
accumulation ofgene mutations that may promote tumour progression. 
p53-dependent apoptosis also plays an important role in the response of tumours to 
various anticancer agents. Cells expressing wild-type p53 are able to undergo apoptosis 
after exposure to various chemotherapeutic agents such as 5-fluorouracil, etoposide and 
adriamycin, whereas p53 null cells do not generally respond (Lowe et aI., 1993a). Since 
many chemotherapeutic agents involve a similar mechanism of action (DNA damage), it 
is essential to have wild-type p53 in order to respond to the treatment. These results may 
explain how tumours containing mutant p53 are resistant to chemo- and radiotherapy, as 
these p53 mutant tumours would not undergo p53-induced apoptosis and would continue 
to proliferate. 
1.4.2.14 p53 and Angiogenesis 
Angiogenesis is important for tumour survival in order to obtain nutrients. Tumour cells 
secrete cytokines that stimulate angiogenesis and the new blood vessels are important ih 
tumour cell metastasis. p53 has been implicated in the regulation of genes such as 
thrombospondin-l (TSP-l) that are involved in this process. Fibroblasts from Li­
Fraumeni patients secrete high levels of TSP-I at early passages, but after loss of the 
normal p53 allele during passaging, the level decreases (Dameron et aI., 1994). This loss 
of wild-type p53 and the reduced expression of TSP-l corresponds with the loss of the 
culture media to inhibit angiogenesis both in vitro and in vivo in a rat corneal model. Re­
introduction of wild-type p53 into these late passage cells resulted in an increase in TSP­
1 levels and also restored the anti-angiogenic phenotype. 
1.4.3 p53 Mutations in Human Cancers 











mutations varies among tumour types. Not all tumour types have a high frequency of 
mutations (peng et aI., 1993; Saylors et aI., 1991) but in most tumour types, mutations in 
the p53 gene occur in 20-50% of cases, while some tumour types have a mutation 
frequency as high as 80%. The mutations occur in all classes (base substitutions, 
insertions and deletions), however, the most prevalent mutations are point mutations 
resulting in amino acid substitutions. 
The spectrum of p53 mutations in a given cancer type can often be accounted for by 
environmental or chemical carcinogens. Skin cancer is linked to exposure to UV light, 
which causes pyrimidine dimers to form in the DNA, thus accounting for a large 
proportion of p53 mutations detected in skin cancer (Burren et al., 1998; Dumaz et al., 
1993). Hepatocellular carcinoma is another example in which a specific carcinogen, 
aflatoxin B, induces a high frequency of mutations in codon 249 of the p53 gene 
(Shimizu et al., 1999; Lunn et al., 1997; Aguilar et al., 1994). 
p53 mutations may have a prognostic value. The stage at which p53 mutations occur 
varies between tumour types, but it is generally thought that p53 mutations occur at an 
early stage in breast, cervix, oesophageal, lung and stomach cancer, whereas in tumours 
of the brain, liver, ovary and thyroid, mutations occur at a later stage in the development 
of these tumours. 
1.4.3.1 Properties of Mutant p53 
Most p53 mutants lose their wild-type function I.e. they are unable to act as tumour 
suppressors and to suppress growth. There are two hypotheses suggesting how mutant 
p53 inactivates wild-type p53. Firstly, the mutant p53 acts in a dominant negative fashion 
whereby the mutant form abrogates the function the wild-type protein, and secondly some 
mutants have been found to gain a function and consequently behave as oncogenes. There 
is evidence to support both of these hypotheses. 
1.4.3.2 Dominant Negative Theory 











tetramer, could provide an explanation as to how mutant p53 acts in a dominant negative 
fashion. The mutant subunit could form an oligomeric complex with a wild-type subunit 
thus preventing the wild-type subunit from functioning normally (Levine et a!., 1991). 
This represents a dominant loss of function mutation. This loss of function of the wild­
type subunit could be due either to it not being able to bind to DNA, or, once bound, it is 
unable to activate (or repress) transcription. It has been shown, for example, that the 
His175 mutation inhibits the ability of wild-type p53 to bind DNA, thus abrogating its 
normal function (Kern et aI., 1992). Supporting evidence for this theory comes from a 
codon 280 mutation found in nasopharyngeal carcinomas. This mutation commonly 
occurs in a heterozygous state and a thr280 point mutation showed a dosage-dependent 
dominant negative effect on wild-type p53 function (Sun et a!., 1993). In vitro assays. 
showed that this mutant is unable to activate transcription from a p53-responsive 
promoter and the Thr280 mutant inhibits wild-type p53 driven transcription in a dose­
dependent manner. Some inhibition is observed even with a 3: 1 ratio of wild-type:mutant 
and almost complete inhibition is observed at a ratio of 1:3 (wild-type:mutant). This 
mutant also affects the growth inhibition function of wild-type p53 in a dose-dependent 
fashion. Saos-2 cells transfected with the wild-type p53 undergo a growth arrest, and this 
arrest is inhibited by co-transfection with the Thr280 mutant. As for transcriptional 
inhibition, inhibition of the wild-type by the mutant occurrs as low as 3: 1 (wild­
type: mutant). The growth arrest induced by wild-type p53 is substantially blocked at a 
ratio of 1: 1 (wild-type:mutant) and is completely abrogated at a ratio of 1:3 (wild­
type:mutant). These results support the model that mutant monomers can form tetramers 
with wild-type monomers and furthermore, the more mutant monomers in the 
heterotetramers, the greater the effect on wild-type function. 
Numerous anogenital tumour-derived p53 mutants also showed various degrees of 
dominant negative effects on wild-type function when co-transfected with the wild-type 
gene into p53 null Saos-2 cells. p53 with a Leu 173 mutation showed the greatest 











1.4.3.3 Gain of Function Mutations 
The alternative hypothesis as to how mutant p53 acts is that the mutant form gains a new 
function which can overcome the negative regulatory properties of wild-type p53. 
Tumour-derived p53 mutants have been shown to activate a number of genes involved in 
cell proliferation, and in fact these mutants do not bind to the wild-type p53 consensus 
DNA binding site (Lanyi et aL, 1998). Furthermore, the C-terminal region containing the 
oligomerisation and nonsequence-specific DNA binding domains (spanning amino acids 
370 to 380) were shown to be required to activate the promoters of the EGFR, MDRl, 
PCNA and c-myc genes by these tumour-derived p53 mutants. In addition, the 
mechanism of activation of mutant p53 varied for the different promoters; various 
deletion constructs of mutant p53 lost their ability to transactivate the EGFR and MDRI 
genes, but not the PCNA or c-myc genes (Lanyi et al., 1998; Frazier et aL, 1998). Various 
p53 mutants, but not wild-type p53, are capable of transactivating the c-myc promoter in 
p53-null cells, demonstrating a gain of function rather than a dominant negative mode of 
action (Frazier et aL, 1998). Furthermore, exon 1 of the c-myc gene is required for this 
transactivation, suggesting that the p53 response element in the c-myc gene does not act 
as a classical enhancer and that the sequences to which p53 binds may have to be 
transcribed into RNA in order for p53 to activate c-myc expression (Frazier et al., 1998). 
A study on a large number of naturally occurring p53 mutants as well as various mutants 
designed to target specific regions of the protein provided further evidence that different 
p53 mutants have different effects with respect to transactivation and transcriptional 
. repression (Crook et aL, 1994). Deletion of conserved regions II, III, IV and V results in 
the loss of transcriptional activity, whereas deletion of conserved domain I and a small C­
terminal truncation (L\370) does not have a significant effect on transcritpional activation 
by the mutants. Of the numerous point mutations analysed, only two (pro 175 and 
Leu 181) retained transcriptional activation activity. In addition to activating transcription, 
p53 also plays a role in transcriptional repression and the various mutants were examined 
for their ability to affect transcriptional repression by wild-type p53. All the mutants 
studied, except for those containing a deleted conserved domain I or the truncated C­











repress transcription (Crook et aI., 1994). Furthermore, the various mutants were able to 
suppress growth of Saos-2 cells to various degrees, which correlated with their ability to 
transactivate a p53-responsive promoter. Those mutants that retain transcriptional 
activation activity are able to suppress the growth of Saos-2 cells, whereas those mutants 
that no longer retain tranactivation activity, fail to suppress growth of the Saos-2 cells. 
These mutants were also examined for their ability to co-operate with E7 and ras in 
transformation assays, and deletion of the conserved domains II-V results in the 
acquisition of transforming properties. Interestingly, both the mutants that retain 
transactivation function (the Pro175 and Leu181 mutants) fail to suppress transformation. 
Taken together, these results suggest that transcriptional activation by p53 correlates with 
suppression of growth in p53 null cells, but transcriptional transactivation is independent 
of the ability of p53 to suppress transformation by E7 and ras. These results imply that 
activation of gene expression by mutant p53 does not necessarily result the ability to 
suppress tumour formation. 
Some fairly strong evidence argues against the dominant negative theory. Wild-type p53 
is very rarely found together with mutant p53 in tumours. One allele usually has a 
mutation, while the remaining wild-type allele is lost. Also, introduction of mutant p53 
into cells lacking endogenous p53 enhances the transformed phenotype in vitro and 
tumourigenicity in vivo, suggesting that the mutants gain a function and act as oncogenes 
(reviewed by Ozbun and Butel, 1996). 
Different tumour-derived p53 mutants have different effects on cells thus while some 
mutants may retain some wild-type functions others may retain the ability to induce cell 
cycle arrest but lose the ability to induce apoptosis, whilst yet others may lose the ability 
to induce cell cycle arrest, but retain the ability to induce apoptosis (Mukhopadhyay and 
Roth, 1993; Ludwig et a1., 1996). Two tumour.,.derived p53 mutants (Pro175 and Leu181) 
are able to activate expression of the CIPI promoter, and consequently induce G1 cell 
cycle arrest, whereas mutants Leul73 and p53 22/23 (an N-terminal mutant) are unable to 
activate expression from the CIPl promoter and consequently unable to induce a G1 











the IGF-BP3 promoters. The Leu181 mutant, on the other hand, retains the ability to 
activate the bax promoter and the IGF-BP3 box A promoter, but not the IGF-BP box B 
promoter, while the Leu173 mutant has lost the ability to transactivate all of these 
promoters. This loss of activation is due to the inability of the various mutants to bind to 
the DNA. Activation of the bax gene results in apoptosis, consequently cells transfected 
with the Pro 175 and Leu 173 mutants do not undergo apoptosis , whereas the Leu 181 
mutant containing cells are still able to undergo apoptosis, albeit at a much lower level 
than wild-type cells. 
Codon 175 is one of the hotspots for mutations in human cancers, and a more detailed 
analysis of various codon 175 mutations revealed that mutations at this position can be 
divided into 3 classes: class I, which behaves like the wild type and retains both apoptotic 
and cell cycle arrest functions; class II, which retains cell cycle arrest function, but has 
lost apoptotic function, and class III, which has lost both activities (Ryan and Vousden, 
1998). An example of a class I mutant is Cys175 with Pro175, Lys175, Ile175 and Ser175 
all being class II mutants. Tyr175, Trp175, Asp175 and Phe175 have all lost both the 
ability to arrest the cells in Gl and apoptotic activity, and are thus classified as class III 
mutants. All class I and II mutants are able to transactivate the p21(CIPl) gene which is 
correlated with the ability of these mutants to arrest the cell cycle. These data support the 
idea that different tumour-derived p53 mutants can have different effects on different 
p53-responsive promoters, and consequently, by retaining the ability to bind to certain 
promoters, these mutants may retain some wild-type function. Conversely, other p53 
mutants lose all wild type function entirely. It is noteworthy and interesting that different 
p53 mutants which have different amino acid substitutions at the same codon behave 
differently. 
These results are supported by similar findings with different p53 mutants (Friedlander et 
a!., 1996a). p53Ala143 (a temperature sensitive mutant), His175 and Trp248 mutants are 
transcriptionally inactive at 37°C and consequently do not induce apoptosis. At the 
permissive temperature of 32°C, the temperature sensitive Ala143 mutant is able to 











mdm2 and eIP 1 promoters. Interestingly though, even at the permissive temperature, 
p53Ala143 does not transactivate the bax promoter or the IGF-BP3 promoters. These 
findings suggest that this mutant form of p53 can discriminate between different p53­
responsive target genes and point to discrete classes of p53-responsive genes. 
Tumour-derived p53 mutants have been shown to be able to bind to p53 consensus DNA 
binding sites at lower temperatures (Friedlander et al., 1996b). At 25°e, a number of 
tumour-derived p53 mutants are able to bind to RGC (Kern et al., 1991) and GADD45 
(Kastan et al., 1992) (sites in human genomic DNA containing p53 response elements) 
oligonucleotides, whereas at 37°e binding of the mutants to these oligonucleotides is 
undetectable. Furthermore, these mutants are able to transactivate the mdm2 promoter at 
26°e but not at 37°e, consistent with their ability to bind to DNA at a lower temperature. 
Not all of the mutants tested, however, are able to bind to DNA or transactivate the 
mdm2 promoter at 26°C. Surprisingly, an antibody directed to the N-terminal of p53 is 
able to stabilise the mutants and render them capable of binding DNA at 37°e. These 
results can have implications for treatment of tumours containing p53 mutants. Since 
sequence-specific DNA binding is a critical function of wild-type p53 and the majority of 
p53 mutants lack the ability to bind DNA in a sequence specific manner, it is possible 
that development of small molecules that stabilise mutant p53 may aid in the treatment of 
tumours containing mutant p53 (Friedlander et al., 1996b). 
1.4.3.4 Stability and Cellular Localisation of Mutant p53 
Many p53 mutants have been found to accumulate in the cytoplasm. Most mutations in 
p53 result in a conformational change in the protein resulting in increased stability of the 
mutants, which can be explained to some extent by their inability to activate expression 
of the mdm2 gene, such that they are not targetted for rapid degradation (Kubbutat et al., 
1997). In addition, in vitro studies have shown that p53 mutants lacking the ability to 
bind mdm2 were not down-regulated, but p53 mutants that retained the ability to interact 











1.4.4 p53 Status and Response to Cancer Therapy 
As a result of the involvement of p53 in the regulation of cell growth, DNA repair and 
apoptosis, tumours harbouring p53 mutations may respond poorly to therapy compared to 
tumours containing wild-type p53. Embryonic fibroblasts transformed with the 
adenovirus EIA and activated ras proteins formed tumours when injected subcutaneously 
into nude mice, irrespective of their p53 status (Lowe et aI., 1994). The number of 
tumours formed and their response to therapy, however, differed depending on the p53 
status. Cells containing wild-type p53 formed fewer tumours and responded better to 
gamma radiation than cells lacking p53. The p53 status also influenced the 
responsiveness to adriamycin, a chemotherapeutic agent that causes a regression of the 
tumours containing wild-type p53, but has little effect on those tumours lacking p53. This 
response to treatment was shown to be due to apoptosis, as treated tumours containing 
wild-type p53 showed a higher apoptotic rate than treated tumours lacking p53. More 
importantly, it was shown that acquired resistance to therapy was due to de novo p53 
mutations (Lowe et al., 1994). 
p53 status may therefore be important in prognosis and response to treatment, since it is 
possible that tumours with different p53 mutations may respond differently to various 
therapies, depending on the ability of the various mutants to abrogate the function of the 
wild-type protein (in instances where the wild-type allele is not lost) or the ability of the 
various p53 mutants to effect apoptosis by regulation ofgenes involved in this process. 
Breast cancer, like all other types of cancer, is a multigenic and highly complex disease. 
It is clear, however, that genes involved in the regulation of cell growth .and 
differentiation playa major role in the process oftumourigenesis. More specifically, it is 
mutations in these regulatory genes that cause these genes to function aberrantly 
ultimately leading to the formation of tumours. Examples of such genes include the ras 
family of genes, which are involved in the stimulation of cell growth, and tumour 
suppressor genes, that are important for the negative regulation of cell proliferation. 
Because genes such as the p53 tumour suppressor gene playa central and important role 











inactivate its normal function. Furthermore, mutations in this gene have been implicated 
in the response of cancer patients to therapy. Thus it is essential not only to identify these 
mutations, but also to determine their effect on the normal function of the protein, since it 
has been shown that different p53 mutations can have different effects on the wild-type 
function. By elucidating the nature and frequency of these mutations in cancer, it may be 
possible to group them into different subsets; those that may not dramatically alter the 
function of the protein, and those that would result in the total abrogation of wild-type 
function. Understanding of p53 mutations may be helpful in deciding on a treatment 
regimen and may also give some indication as to the patient prognosis and response to 
therapy. 
This study is aimed at identifying such mutations in the Ha-ras oncogene and p53 tumour 
suppressor gene in a group of breast cancer patients from South Africa. The study also 
examined the nature of the various p53 mutations detected with respect to their ability to 
arrest the cells in the Gl phase of the cell cycle, their effect on cell growth and their 
ability to transform cells. The results reported in this study suggest a correlation between 











CHAPTER 2: ANALYSIS OF MUTATIONS IN THE Ha-ras GENE 
2.1 INTRODUCTION 
Breast cancer is the most common cancer amongst women, and recent 
epidemiological studies have suggested that one in eight women will develop the 
disease during their lifetime (Feuer et al., 1993). In South Africa, the risk of 
developing breast cancer varies among different population groups with the highest 
incidence found in White and Asian females (1 in 15), a lower incidence in Coloured 
females (1 in 33) and the lowest incidence in Black females (1 in 68) (Sitas et al., 
1997). 
Breast tumours develop mainly from ductal or lobular hyperplasias that acqUIre 
cumulative genetic changes, resulting in clonal outgrowths of progressively malignant 
cells (Dickson et al., 1991). Mutated ras oncogenes have been found in about 10% of 
human tumours and are thus far the most frequent group of mutated oncogenes 
identified in human cancers (reviewed by Bos, 1989; Barbacid, 1990; and Barbacid, 
1987). In addition, the frequency of mutated ras oncogenes varies among different 
tumour types (Bos, 1989) with the highest incidence in tumours of the pancreas, 
where more than 80% of the tumours contain a mutated K-ras oncogene. The 
incidence of mutated ras oncogenes is also significant in tumours of the colon (K-ras) 
and thyroid (H-, K-, and N-ras). In several tumour types such as cancer of the breast, 
oesophagus, ovary, cervix, stomach, glioblastomas, neuroblastomas and lymphoid 
leukemias (Bos, 1989), however, activated or mutated ras oncogenes are rarely 
present. 
The ras oncogene becomes constitutively activated by a single point mutation within 
the coding sequence (Taparowsky et al., 1982; Tabin et al., 1982; Reddy et al., 1982; 
Seeburg et al., 1984), predominantly in codons 12, 13 and 61. It has also been found, 
however, that overexpression (between 10- and 100-fold) of normal ras oncogenes 
can also induce certain malignant phenotypes (Chang et al., 1982). 
A limited number of studies have shown that ras mutations occur infrequently in 











1995). In chemically-induced mammary carcinomas in rats, however, the Ha-ras gene 
has been implicated in the etiology of the disease (Sukumar et aI., 1983; Zarbl et al., 
1985), with mutations occurring mostly at either codons 12 or 13, depending on the 
chemical carcinogen used. Furthermore, the techniques used to identify ras mutations 
in human breast cancer varied from study to study and ranged from transfection 
assays to assess whether the ras oncogene could transform NIH-3T3 cells, to 
oligonucleotide hybridisation and RNase mismatch analyses. Some of these 
techniques (such as oligonucleotide hybridisation) are fairly insensitive at detecting a 
large number of mutations at various positions in the gene. 
This chapter analyses Ha-ras gene mutations In breast cancer patients from the 
"Coloured community" from the Western Cape area of South Africa, as well as in 
breast cancer cell lines. The "Coloured community" refers to a heterogeneous group 
of mixed ancestry, including San, Khoi, West African Negro, Madagascar, Javanese, 
and Western European origin. Exons 1 and 2 (encompassing codons 12, 13 and 61) of 
the Ha;.ras gene were screened for mutations using single strand conformation 
polymorphism analysis (SSCP), a technique that allows fairly rapid examination of 












2.2.1 Breast Tumour Samples and Cell Lines 
Forty primary breast tumours were obtained from the Breast Clinic at Groote Schuur 
hospital. Twenty three of the samples were fresh tissue samples obtained from 
patients who underwent mastectomies and 17 of the samples were paraffin-embedded 
tissue· sections. Thirty nine of the samples were infiltrating ductal carcinomas of 
various stages and 1 sample was a fibroadenoma (table 2.1). With the exception of 1 
sample from a male patient, all of the samples were from female patients. In addition, 
the majority of the samples (88%) were obtained from the "Coloured community", 4 
of the samples were from white patients and 1 sample was from a black patient. 
In addition to the 40 primary tumour samples, 4 breast cancer cell lines; T47-D, MCF­
7, MDA-MB-231 and ZR-7S, obtained from ATCC, were also analysed in this study. 
The human embryonic lung fibroblast, WI-38, was used as a normal control. 
Table 2.1: Tumour samples used in this study. 






2.2.2 Mutation A alysis of Exon 1 of the Ha-Ras Gene. 
2.2.2.1 peR-Amplification of Ex on 1 
DNA was isolated from the breast tumour samples and the cell lines as described in . . 
section 6.1. The polymerase chain reaction (PCR) was used to amplify exon 1 of the 
Ha-ras gene as outlined in section 6.3, using the primers listed in table 2.2, m a 
reaction volume of SO~t1. After amplification, SJ..LI of the reaction mixture was 
fractionated on a 1.5% agarose gel to check that the exon had been correctly amplified 
















Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Gly Gly 
GAGGAGCG ATG ACG GAA TAT AAG CTG GTG GTG GTG GGC GCC GGC GGT 
Val Gly Lys Ser Ala Leu Thr Ile Gln Leu Ile Gln Asn His Phe 
GTG GGC AAG AGT GCG CTG ACC ATC CAG CTG ATC CAG AAC CAT TTT 
Val Asp Glu Tyr Asp Pro Thr Ile Glu 










Figure 2.1: Amplification of exon 1 of the Ha-ras gene. (A); sequence of exon 1 with 
the primers H1211 and H12/2 depicted in the boxes. The amino acid sequence is shown 
above the gene sequence. (B); The peR product was electrophoresed on a 1.5% 
agarose gel, the gel stained with ethidium bromide (EtBr) and the bands visualised 
under UV light. The molecular weight markers (M) are shown on the left hand side of 












Table 2.2: peR primers and annealing temperatures used for the amplification of 
exons 1 and 2 of the Ha-ras gene 
Gene Exon Primer Pair Tm Fragment Size 
Ha-ras 1 Hl2/ l: 5' - GGGCCCTCCTIGGCAGGTGG - 3 ' 65 °C 206bp 
H1212 : 5' - CACCTGGACGGCGGCGCTAG - 3' 
Ha-ras 2 H61 /A: 5' - GGAGAGGCTGGCTGTGTGAA - 3 ' 56°C 230bp 
H611B : 5' - AAAAGACTTGGTGTIGTIGA - 3' 
2.2.2.2 Screening of Exon 1 for Mutations 
Activating mutations of the ras genes have been shown to occur at codons 12, 13 and 
61 (Taparowsky et a1. , 1982; Tabin et a1. , 1982; Reddy et al., 1982). Codon 12 is part 
of an MspI restriction endonuclease site and any mutation at this position would 
destroy this site. Screening for mutations is thus a simple process involving 
amplification of the exon and digestion with MspI. 
Codon 12 of the Ha-ras gene was therefore screened for mutations by amplifying 
exon 1 in the presence of 32p _dCTP and digesting the PCR product overnight with 
MspI at 37°C in the appropriate reaction buffer. 32p_dCTP was used as a tracer in 
order to visualise the small DNA fragments after digestion . The digested products 
were electrophoresed on 8% non-denaturing polyacrylamide gels, dried under vacuum 
and exposed to x-ray film for 16 hours. An additional MspI restriction site upstream 
of codon 12 served as an internal control (figure 2.2) . If the MspI site at codon 12 
remained intact, fragments of 105bp, 56bp and 45bp should be observed . If, however, 
the site is disrupted, the 56bp band would be part of a 161 bp fragment. The WI-38 
pattern represents the normal control and as can be seen, none of the patients showed 
any shift of the 56bp to 161 bp, indicating that no mutations were present in codon 12 
in any of the tumour samples. 
2.2.2.3 SSCP Analysis of Exon 1 of the Ha-ras Gene 
In order to screen the entire exon 1 of the Ha-ras gene for mutations, single strand 
conformation polymorphism (SSCP) analysis was used as described in section 6.3.2. 
Briefly, 100ng of patient or cell line DNA (section 2.2.1) was used as a template in a 












GGGCCCTCCT TGGCAGGTGG GGCAGGAGAC CCTGTAGGAG GACCCCGGGC 
CGCAGGCCCC TGAGGAGCGA TGACGGAATA TAAGCTGGTG GTGGTGGGCG 
12 
r----l 
CCGGCGGTGT GGGCAAGAGT GCGCTGACCA TCCAGCTGAT CCAGAACCAT 
TTTGTGGACG AATACGACCC CACTATAGAG GTGAGCCTAG CGCCGCCGTC 
CAGGTG 
00
B M I 
6 7 
PATIENT NO. 
8 9 10 11 12 13 
Figure 2.2: Analysis of exon 1 of the Ha-ras gene. (A); the sequence of the PCR 
product. The exon is underlined and the MspI restriction site encompassing codon 12, 
as well as an upstream MspI site which serves as an internal control, is depicted in bold 
lettering. (B); exon 1 of the Ha-ras gene was amplified in the presence of 32p-dCTP 
and the PCR products digested with MspI. The digested products were resolved on a 
non-denaturing 8% polyacrylamide gel, the gel was dried and exposed to x-ray film for 
16 hours. WI-38 is the normal control, U represents undigested DNA and C the 
digested DNA. The sizes of the bands are indicated by the arrowheads on the right 











out in the presence of 32p_dCTP in a final volume of 50~1. 3~1 of the labelled PCR 
product was mixed with 3~1 offormamide loading buffer, denatured at 95°C for 5min 
and loaded immediately onto non-denaturing 6% polyacrylamide gels. The samples 
were electrophoresed at 70W for 10min and then at 30W for 4-6 hours. 
SSCP analysis is based on the theory that single-stranded DNA will migrate through a 
non-denaturing polyacrylamide gel as a function of it's secondary structure. This 
secondary structure is governed by the sequence of the DNA, thus any change in the 
sequence of the DNA could theoretically lead to an altered conformation and 
consequently an altered migration in a non-denaturing polyacrylamide gel. This, 
however, is not always the case in that some mutations do not alter the secondary 
structure of the DNA sufficiently to cause a conformational change. In order to 
alleviate this problem and maximise the number of mutations detectable, the non­
denaturing polyacrylamide gels in this study were electrophoresed under 4 different 
sets of conditions; (1) room temperature, (2) room temperature in the presence of 5% 
(v/v) glycerol, (3) 4°C and (4) 4°C in the presence of 5% (v/v) glycerol. 
All electrophoretic mobility patterns were compared to the WI-38 DNA, which 
represents the normal sequence. From figure 2.3(A) it is clear that the majority of the 
samples have a similar migration pattern compared to the normal WI-38, with only 
the T47-D cell line and patient 10 showing an altered electrophoretic mobility pattern. 
Gels run at room temperature (figure 2.3B) and at room temperature in the presence of 
5% (v/v) glycerol (figure 2.3C), however, show that, in contrast to the data observed 
in figure 2.3(A), only patients 10, 13, 14 and 16 and the T47-D cell line are different 
from the other samples, but similar to the normal WI-38 cell line (arrowheads). As the 
T47-D cell line and patient 10 showed an altered migration pattern in figure 2 .3(A) 
and additional changes have been detected under the conditions used in figures 2.3(B) 
and 2.3(C), this suggests that these samples may have mutations in exon 1. These 
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Figure 2.3: Mutation detection by SSCP. Exon 1 of the Ha-ras gene was PCR 
amplified in the presence of J2p-dCTP as described in chapter 6. 3III of the PCR 
product was mixed with 31ll of formamide loading buffer (section 6.14), denatured at 
95°C for 5min and loaded immediately onto non-denaturing 6% polyacrylamide gels. 
The samples were electrophoresed at 30W for 4-6 hours at (A); 4°C, (B); room 
temperature and (C); room temperature in the presence of 5% glycerol. The gel were 
dried under a vacuum at 70°C and exposed to x-ray film for 16-48 hours. WI-38 is the 
normal control DNA and altered electrophoretic mobility patterns can be observed in 












2.2.2.4 Sequence Analysis of Exon 1 'Jf the Ha-ras Gene 
The WI-38 and T47-D cell lines and patients 10,13,14 and 16, as well as a number of 
other samples showing an altered migration pattern in figures 2.3(B) and 2.3(C), were 
subjected to sequence analysis to determine the exact nature of the mutation. 
Sequence analysis revealed that the base change observed in these samples was a T --t 
C transition in the wobble position of codon 27 (CAT --t CAC) which did not alter the 
amino acid sequence (figure 2.4). Thus the assumed normal sequence in this study, 
namely the WI-38, has an altered sequence from that published in the Genbank 
database (accession #: J00277). This base substitution has been noted previously as an 
allelic difference in bladder cancer (Capon et aI., 1983a; Taparowsky et aI., 1982), 
and although the sequence differs from the published sequence, there is no change in 
the protein sequence as a result of this base substitution. These sequence data suggest 
that this base change is an allelic difference and signifies a polymorphism at this 
position in the DNA in the Ha-ras gene, as some samples have the T variant and 
others have the C variant, with both variants resulting in the same amino acid 
sequence. 
2.2.2.5 Digestion of Ha-ras Exon 1 peR Product with Dram 
The base substitution described above resulted in the creation of a DraUI restriction 
enzyme site (figure 2.5A), allowing rapid detection of this allele by digestion of the 
PCR product with DraIn. Those samples with the substitution should yield DNA 
fragments of 153 bp and 53 bp, whereas those samples without the substitution should 
remain uncut. 
Out of a total the 40 patients screened, 16 had the T --t C substitution at codon 27 
giving an allele frequency of 0.4. A number of healthy control individuals (16) were 
also screened for this substitution and 9 of the 16 had the T --t C substitution at codon 
27, corresponding to an allele frequency of 0.563 (table 2.3). It appears that the C 
allele is more frequent in the control popUlation than in the cancer patients, however 
this difference is not significant (p=0.235) and may be due to the small sample size. It 
is clear that the homozygous C allele is rare as it only occurs in 3 out of the 16 cancer 




















Figure 2.4: Sequence the two variants of Ha-ras exon 1 by 
SSCP. Sequence reactions were perfonned as described in section 1 and analysed 
on 6 % polyacrylamide containing 42% urea as described in 1. 
gels were dried under a vaccuum and exposed overnight to film at 
variation in sequence was found to either a T, as shown in bold in 
shown in bold in (B) in wobble position of codon 27. This 











Table2.3: Distribution of the Ha-ras polymorphism at codon 27 
amongst patients and controls showing the number of 











2.2.3 Mutation Analysis of Exon 2 of the Ha-ras Gene 
2.2.3.1 Amplification of Exon 2 
Mutations in codon 61 of the Ha-ras gene have also been shown to constitutively 
activate the GTPase activity, thus exon 2 of the Ha-ras gene (encompassing codon 61) 
was PCR amplified using primers H61/A and H611B (table 2.2) as described in 
section 6.3 (figure 2 .6A). The PCR reaction was carried out as outlined in section 
6.3 .1, using 100ng of DNA as a template. In order to check for efficient amplification, 
5~1 of the amplified product was electrophoresed on a non-denaturing 8% 
polyacrylamide gel and the bands visualised under UV light after staining the gel with 
ethidium bromide (O.25~glml) . Figure 26(B) shows an example of a polyacrylamide 
gel with the amplified product of230bp indicated by the arrowhead . 
2.2.3.2 Screening of Exon 2 for Mutations using SSCP Analysis 
DNA from patient samples and breast cancer cell lines was amplified using primers 
H61 /A and H611B as described in section 2 .2.3.1 in the presence of 32p_dCTP. 3~1 of 
the amplified product was mixed with 3~1 of formamide loading buffer, heat­
denatured at 95 °C for 5min and loaded immediately onto non-denaturing 6% 
polyacrylamide gels . The gels were electrophoresed under the conditions indicated in 
figure 2.7 (A-D). Samples were initially electrophoresed into the gels at 70W for 
lOmin, and subsequently at 30W for 4-6 hours. The gels electrophoresed at room 
temperature were prevented from overheating by cooling them with a fan . Under all 
the conditions used , no alterations in electrophoretic mobility patterns were detected 
between any of the breast cancer cell lines or the breast tumour samples and the 
normal control, indicating the absence of any mutations in ex on 2 of the Ha-ras gene 















Asp Ser Tyr Arg Lys Gln Val Val Ile Asp Gly Glu 
TCCTCCTGCAG GAT TCC TAC CGG AAG CAG GTG GTC ATT GAT GGG GAG 
Thr Cys Leu Leu Asp Ile Leu Asp Thr Ala Gly Gln Glu Glu Tyr 
ACG TGC CTG TTG GAC ATC CTG GAT ACC GCC GGC CAG GAG GAG TAC 
Ser Ala Met Arg Asp Gln Tyr Met Arg Thr Gly Glu Gly Phe Leu 
AGC GCC ATG CGG GAC CAG TAC ATG CGC ACC GGG GAG GGC TTC CTG 
Cys Val Phe Ala Ile Asn Asn Thr Lys Ser Phe 












Figure 2.6: PCR amplification of exon 2 of the Ha-ras gene. (A); sequence of the 
230bp product after PCR amplification with primers H611A and H611B which are 
boxed. The amino acid sequence is also shown above the DNA sequence. (B); after 
amplification, 5~l of the product was electrophoresed at 150V on a non-denaturing 8% 
polyacrylamide gel. Bands were visualised under UV light after staining with ethidium 
bromide (O.25~g!ml). Molecular weight markers are shown on the left hand side of the 
figure and the expected band of 230bp is indicated by the arrowhead on the right hand 
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Figure 2.7: ssep analysis of exon 2 of the Ha-ras gene. Exon 2 of the Ha-ras gene 
was amplified using primers H611A and H611B in the presence ofJ2p-deTP. 3~1 of the 
peR product was mixed with 3~1 offormamide loading buffer, heat-denatured at 95°e 
for 5min, and loaded immediately onto non-denaturing 6% polyacrylamide gels. The 
gels were electrophoresed initially at a constant power of 70W for 10min, and then at 
a constant power of 30W for 4-6 hours under the following conditions: (A); room 
temperature, (B) room temperature containing 5% (v/v) glycerol, (e), 4°e and (D) 4°e 
in the presence of 5% (v/v) glycerol. A fan was placed in front of the gels at room 
temperature in order to prevent excessive heating. The gel was dried at 700 e and 
exposed to x-ray film for 16 hours. WJ-38 represents the normal control and no 













In this chapter, exons 1 and 2 containing the mutation hotspots in codons 12, 13 and 
61 in the Ha-ras gene were analysed for mutations. These codons have been 
implicated in the constitutive activation of the Ha-ras protein in several tumours 
(Taparowsky et aI., 1982; Bos, 1989; Barbacid, 1987; Tabin et aI., 1982; Reddy et aI. , 
1982). 
Previous studies have shown that mutations in the Ha-ras gene occur very rarely in 
human breast cancer (Spandidos, 1987; Rochlitz et al., 1989; Barbacid, 1990). 
Various techniques were used in these studies to detect ras mutations, including 
oligonucleotide hybridisation, RNase mismatch cleavage analysis and restriction 
length polymorphism analysis More recently SSCP has bee  reported as an 
alternative technique for detecting mutations in the ras genes in human tumours 
(Suzuki et ai., 1990; Bauer-Hofmann et aI. , 1992). In this study, SSCP and RFLP 
analysis were used to detect mutations in the Ha-ras gene. 
The C ~ T mutation in codon 12 that results in loss of an MspI site of the Ha-ras 
gene was shown not to be present in the patient DNA analysed in this study. In 
addition, on screening the entire exon for other possible mutations by SSCP analysis, 
no such mutations were detected . These results support the findings by Rochlitz et al 
(1989) and Spandidos (1987) that mutations in codon 12 of the Ha-ras gene are a rare 
event in human breast tumours. Screening of exon 2 of the Ha-ras gene by SSCP 
analysis also revealed no mutations in any of the breast tumour samples used in this 
study. 
Other solid tumours, such as colon cancer have a high frequency of ras mutations 
(Bos et aI., 1987; Vogelstein et a!., 1988; Capon et aI., 1983b; Laurent-Puig et a!., 
1991; Moerkerk et a!., 1994) thus the reasons for the absence of mutations in the Ha­
ras gene in human breast cancer are unclear. Since the ras genes are normally 
expressed in most tissues (Leon et al., 1987; Furth et ai., 1987; Chesa et ai., 1987) 
cellular factors may be involved in the normal activation of the gene during cell 
growth. Exposure to chemical carcinogens could also influence the activation of the 











that exposure to N-nitroso-N-methylurea (NMU) and dimethylbenz(a)anthracene 
(D:MBA) leads to the induction of mammary carcinomas in rats, and moreover, that 
the tumours induced by NMU all contained a G ~ A transition in the second 
nucleotide of codon 12 (Sukumar et ai. , 1983; Zarbl et ai. , 1985). The tumours 
induced by D:MBA, on the other hand, did not contain mutations in codon 12, but had 
mutations in the two adenine residues of codon 61 instead. Furthermore, exposure to 
DMBA resulted in fewer tumours harbouring a ras mutation compared to the number 
of NMU-induced tumours, implying that DMBA-induced tumours had fewer ras 
mutations than NMU-induced tumours . These findings imply that exposure to 
chemical carcinogens can directly lead to the constitutive activation of the Ha-ras 
gene and subsequently the formation of a tumour. Given that the ras genes are 
expressed in all tissues and that other cellular factors may be involved in the normal 
activation of these genes, a possible explanation as to why mutations in the Ha-ras 
gene are infrequent in human breast cancer may be that humans are not exposed to the 
appropriate carcinogens in order to induce the mutation, or that the doses are not high 
enough, or that the carcinogens are not efficiently absorbed into the mammary cells. 
Another possibility is that the DNA repair mechanisms in these cells are efficient and 
that mutations do not accumulate. 
A polymorphism, however, was detected in codon 27. Sequence analysis revealed the 
base change to be a T ~ C transition in the third position of the codon. This change 
was silent and did not cause any alteration in the amino acid sequence of the protein. 
Although the C allele of the polymorphism appeared to occur more frequently in the 
control group than in the patients, the difference in allele frequency was not 
significant and could be explained by the relatively small number of control 
individuals. More samples would have to be analysed in order to confirm these initial 
findings . Polymorphisms in the Ha-ras gene have been previously reported, although 
these have tended to be localised in the variable tandem repeat (VTR) in the 3' 
flanking region of the gene (Capon et ai, 1983a). The literature is somewhat 
contradictory regarding whether a given Ha-ras allele is associated with the risk of 
developing breast cancer or not. A number of studies have reported no significant 
difference in the distribution of either common or rare alleles between control groups 











Furthermore, no association was found between rare Ha-ras alleles and breast cancer. 
Other groups on the other hand, have reported a significant association between 
certain Ha-ras alleles and breast cancer (Saglio et aI., 1988; Lidereau et aI., 1986) 
implying that patients harbouring specific Ha-ras alleles have an increased risk of 
developing breast cancer. This discrepancy may be due to etlmic or racial differences 
of the patients in the various studies. The data presented in this study suggest that 
there is no significant association between the presence of the codon 27 
polymorphism in breast cancer and that this polymorphism has no affect on the 
relative risk of developing the disease. It is possible, however, bearing in mind that 
the majority of patients in this study were of a single population group, that the 
frequency of this allele may vary among different racial groups in South Mrica. 
In summary, this chapter has shown that mutations in the Ha-ras gene are rare in 
breast cancer patients, confirming previous findings (Spandidos, 1987; Rochlitz et aI., 
1989; Barbacid, 1990). It should be cautioned, however, that mutations might occur in 
exons 3 and 4 of the gene which were not analysed in this study. Although no 
mutations were identified, a polymorphism was detected in codon 27 and this proved 











CHAPTER 3: ANALYSIS OF MUTATIONS IN THE p53 GENE IN 
BREAST CANCER 
3.1 INTRODUCTION 
The p53 tumour suppressor gene codes for a nuclear phosphoprotein that negatively 
regulates cell proliferation. Wild-type p53 is a sequence specific DNA binding protein 
and acts as a transcription factor that is able to activate or repress genes containing a p53 
consensus DNA binding sequence (Kern et ai., 1991; el-Deiry et ai., 1992; Funk et ai, 
1992; Margulies and Sehgal, 1993; Wang et ai, 1995). p53 is the most frequently 
mutated gene in human tumours and most of the mutations result in loss of wild-type p53 
function and consequently, loss of cell cycle controi. Mutant p53 has a longer half-life 
than wild-type p53 and it can still form complexes with a host of cellular regulatory 
proteins (such as hsc70) which is thought to playa role in cell transformation (Finlay et 
aI., 1988). In addition, some mutations abolish the wild-type function by disrupting the 
ability of p53 to bind to DNA and consequently abolish it's transcriptional activity (Kern 
et ai. , 1991; Raycroft et aI., 1991). It has also been reported that different mutants exhibit 
distinct biological activities, such as gain of function, where the mutant protein binds 
promiscuously to DNA sequences that the wild-type protein does not normally bind to, 
resulting in constitutive activation of genes that may playa role in cellular transformation 
(Halevy et aI., 1990; Ludes-Meyers et aI., 1996). 
Aberrations in the p53 gene have been reported in 50-55% of all human tumours 
(Hollstein et aI., 1994; Hollstein et ai., 1991; Hainaut et aI., 1997) whilst in breast cancer, 
alterations in this gene have been detected in 45-50% of cases, depending on the 
technique used to detect mutations (Osborne et aI., 1991; Cattoretti et aI., 1988; Bartek et 
ai., 1990a). These abberations include single base substitutions and small insertions and 
deletions in 25-30% of breast cancer cases, as well as loss of heterozygosity (LOH) in 
approximately 50% of primary breast tumours (Mackay et ai., 1988; Devilee et aI., 1989; 











Mutations in the p53 gene in breast tumours seem to be restricted to the common 
histological variants of the disease such as invasive ductal and medullary carcinomas, 
whereas the frequency of mutations in the rarer histological variants such as mucinous 
and papillary carcinomas is much lower (Marchetti et aI., 1993). A probable explanation 
for this anomaly is that the latter variants are associated with a higher differentiation 
status, and thus a more favourable prognosis . It has also been suggested that the high 
frequency of alterations at the p53 locus in human breast cancer could allow mutations in 
the p53 gene to serve as a molecular marker for breast cancer (Runnebaum et aI., 1991). 
Mutations in the p53 gene occur over a wide region of the gene, although there are certain 
hotspots covering exons 5, 6, 7 and 8 (Hollstein et aI., 1991). These hotspot regions 
encompass 4 of the 5 evolutionary conserved domains of the p53 gene (Soussi et aI., 
1990) and, moreover, the majority of mutations occur at codons which are conserved 
between species (Wang et aI., 1995). Analysis of p53 mutations in breast cancer has 
clearly shown that they are clustered in exons 5-8, with codons 175, 248 and 273 being 
more frequently mutated than other codons (figure 3 .1) A possible explanation for the 
higher frequency of codon 248 and codon 273 mutations is that they are critical for p53 
function. Arg273 is involved in contact with the phosphate backbone of the DNA in the 
major groove, while Arg248 is involved in multiple hydrogen bonds in the minor groove 
(Cho et aI., 1994). Any mutations at these sites would therefore have a detrimental effect 
on the binding of p53 to DNA. 
This chapter describes the screening of the breast cancer patients and breast cancer cell 
lines (see chapter 2) for mutations in the p53 gene in order to determine the frequency of 
p53 mutations in this population of breast cancer patients, as well as to determine the 
nature of these mutations. PCR-SSCP and DNA sequence analysis was used to detect 
mutations. In addition, immunohistochemistry was used to study the levels of the p53 
protein in these patients as it has previously been shown that mutant p53 protein has a 
longer half-life than the wild-type protein and therefore may accumulate in either the 
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DNA was isolated from the cell lines and the 40 primary breast tumour samples as 
described in section 6.1. The 40 primary breast tumour samples consisted of both fresh 
tissue samples as well as paraffin embedded tissue sections as outlined in section 2.2.1. 
Exons 5-9 and 11 of the p53 gene were individually amplified and screened for mutations 
by PCR-SSCP and sequence analysis. 
3.2.1 Analysis of Exon 5 of the p53 Gene 
3.2.1.1 Amplification of Exon 5 
Exon 5 of the p53 gene was PCR amplified using primers p53-5A and p53-5B (section 
6.3.1) as indicated in figure 3.2(A). The primers were situated within introns 4 and 6, thus 
ensuring amplification of the entire exon, including the splice junctions. The annealing 
temperature used in the PCR reaction is shown in table 6.1 . In order to check for efficient 
amplification of exon 5, 5111 of the PCR product was electrophoresed on a 1 % agarose gel 
and the bands were visualised under UV light after staining with ethidium bromide to 
confirm the presence of the expected 310bp DNA fragment of (figure 3.2B). 
3.2.1.2 SSCP Analysis of Exon 5 
Exon 5 was screened for mutations by SSCP analysis as described in section 6.3 .2. The 
PCR reactions were carried out in the presence of 32p_dCTP and electrophoresed through 
non-denaturing 6% polyacrylamide gels as previously described. Figure 3.3 shows SSCP 
gels using different conditions, these being 4°C in the presence of 5% (v/v) glycerol, 4°C 
in the absence of glycerol, room temperature in the absence of glycerol and room 
temperature in the presence of 5% (v/v) glycerol. As can be seen, no alterations in 
electrophoretic mobility patterns were detected in any of the patient or cell line samples 
compared to the normal WI-38 cell line. Although patients 15 and 16 appear to have an 
altered electrophoretic mobility pattern compared to the normal WI-38 cell line, this 













p53-5A Tyr Ser 
ITGTTCACTTGTGCCCTGACTITTCAACTCTGTCTCCTTCCTCTTCCTACAG TAC TCC 
Pro Ala Leu Asn Lys Met Phe Cys GIn Leu Ala Lys Thr Cys Pro 
CCT GCC CTC AAC AAG ATG TTT TGC CAA CTG GCC AAG ACC TGC CCT 
Val GIn Leu Trp Val Asp Ser Thr Pro Pro Pro Gly Thr Arg Val 
GTG CAG CTG TGG GTT GAT TCC ACA CCC CCG CCC GGC ACC CGC GTC 
Arg Ala Met Ala Ile Tyr Lys GIn Ser GIn His Met Thr Glu Val 
CGC GCC ATG GCC ATC TAC AAG CAG TCA CAG CAC ATG ACG GAG GTT 
Val Arg Arg Cys Pro His His Glu Arg Cys Ser Asp Ser Asp 

















Figure 3.2: PeR-Amplification of ex on S of the pS3 gene. (A); primers pS3-SA and 
pS3-SB used in the peR reaction to amplify the 310bp fragment of the pS3 gene are 
boxed. (B); 100ng of DNA was used as template and the peR reaction was carried out 
in a final volume of SOIlI as described in section 6.3.1. To check for efficient 
amplification, Sill of the peR product was electrophoresed on a 1 % agarose gel and the 
bands visualised under UV light after staining with ethidium bromide (0.2Sllg/ml). The 
molecular weight markers (M) are shown on the left hand side of the figure and the 
expected 31 Obp fragment is indicated by the arrowhead on the right hand side. All sizes 
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Figure 3.3: SSCP analysis of exon 5 of the p53 gene. Exon 5 was amplified using 
primers p53-5A and p53-5B in the presence of 32p_dCTP as described in section 6.3.1. 
3111 of the PCR product was mixed with 3111 of formamide loading buffer, heat­
denatured at 95°C for 5 min, and then loaded onto non-denaturing 6% polyacrylamide 
gels. The samples were initially electrophoresed through the gel at 70W for 10 min, and 
then for 4-6 hours at 30W, in 1 X TBE under the following conditions: (A); 4°C in the 
presence of 5% (v/v) glycerol, (B); 4°C in the absence of glycerol, (C); room 
temperature in the absence of glycerol and (D); room temperature in the presence of 
5% (v/v) glycerol. The room temperature gels were prevented from excessive heating 
by cooling with a fan. The gels were dried and exposed to x-ray film for 16 - 48 hours 
at -70°C. AJI electrophoretic mobility patterns should be compared to that of the WI-38 
cell line, the normal control. There were no differences between any of the patient 











3.2.2 Analysis of Exon 6 
3.2.2.1 PCR Amplification of Exon 6 
Exon 6 of the p53 gene was amplified using primers p53-6A and p53-6B under the 
conditions outlined in section 6.3.1. The sequence of the amplified product, indicating the 
position of the primers, as well as the amino acid sequence, is shown in figure 3.4(A). As 
for exon 5, the primers are situated in the introns flanking exon 6, thus incorporating the 
splice junctions in the PCR product. 5~1 of the amplified product was electrophoresed on 
a 1 % agarose gel to check for correct amplification of the expected fragment of 201 bp 
(figure 3.4B). 
3.2.2.2 SSCP Analysis of Exon 6 
SSCP analysis of exon 6 was carried out as described previously by including a trace 
amount of 32p -dCTP in the PCR reaction and subsequent electrophoresis of the resulting 
PCR products through non-denaturing 6% polyacrylamide gels using different 
electrophoretic conditions (figures 3.5A-D). As indicated in the figures, no mutations 
were detected in any of the breast cancer patient samples, however an altered 
electrophoretic mobility pattern was found for the T47-D breast cancer cell line 
(arrowhead in figure 3.5B, C and D). This mutation only separated out under 3 of the 
conditions, but not when the gel was run at room temperature in the absence of glycerol 
(figure 3.5A). 
In order to identify the exact nature of the mutation, the exon was re-amplified and the 
resulting PCR product was subjected to direct sequence analysis as described in section 
6.6.1. The sequence data revealed the mutation to be a C ---7 T transition at codon 194 
resulting in a Leu ---7 Phe amino acid substitution. 
3.2.3 Analysis of Exon 7 of the p53 Gene 
3.2.3.1 PCR Amplification of Exon 7 
Exon 7 was PCR amplified under the conditions described in section 6.3.1 and table 6.1, 
using primers p53-7 A and p53-7B. The sequence of the amplified product, as well as the 













p53-6AI Leu Ala 

ITGGTTGCCCAGGGTCCCCAG~CCTCTGATTCCTCACTGATTGCTCTTAG GT CTG GCC 

Pro Pro GIn His Leu Ile Arg Val Glu Gly Asn Leu Arg Val Glu 
CCT CCT CAG CAT CTT ATC CGA GTG GAA GGA AAT TTG CGT GTG GAG 
Tyr Leu Asp Asp Arg Asn Thr Phe Arg His Ser Val Val Val Pro 
TAT TTG GAT GAC AGA AAC ACT TTT CGA CAT AGT GTG GTG GTG CCC 
Tyr Glu Pro Pro Glu 













Figure 3.4: PeR-amplification of exon 6 of the p53 gene. (A); exon 6 was amplified in 
a peR reaction using primers p53-6A and p53-6B as indicated in the boxed areas. To 
check for efficient amplification, 5 ~ of the peR product was electrophoresed on a 1 % 
agarose gel (B) and the bands were visualised under a UV light after staining the gel 
with ethidium bromide (0.25!J.glml). The molecular weight markers (M) are shown on 
the left hand side of the figure while the 201 bp peR product is indicated by the 
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Figure 3.5: SSCP analysis of exon 6 of the p53 gene. Exon 6 was amplified in the 
presence of J2p-dCTP using primers p53-6A and p53-6B as described in section 6.3.1. 
3111 of the PCR product was mixed with 3111 of formamide loading buffer, heat­
denatured at 95°C for 5 min and then loaded onto a non-denaturing 6% polyacrylamide 
gel. The samples were electrophoresed at 70W for 10 min and then at 30W for 4-6 
hours under the following conditions: (A); room temperature, (B); room temperature in 
the presence of 5% (v/v) glycerol, (C); 4°C and (D); 4°C in the presence of 5% (v/v) 
glycerol. The room temperature gels were cooled with a fan in order to prevent 
excessive heating. The gels were then dried under a vacuum at 70°C for 1 hour and 
exposed to x-ray film for 16 - 48 hours . Under these conditions, no alterations were 















Val Gly Ser Asp Cys Thr Thr lIe His Tyr Asn Tyr Met Cys Asn 

GTT GGC TCT GAC TGT ACC ACC ATC CAC TAC AAC TAC ATG TGT AAC 

Ser Ser Cys Met Gly Gly Met Asn Arg Arg Pro lIe Leu Thr lIe 
AGT TCC TGC ATG GGC GGC ATG AAC CGG AGG CCC ATC CTC ACC ATC 
lIe Thr Leu Glu Asp Ser 









Figure 3.6: PeR-amplification of exon 7 of the pS3 gene. Exon 7 was peR amplified 
using primers pS3-7 A and pS3-7B as shown in (A) and described in section 6.3.1. Sill 
of the peR product was electrophoresed on a 1% agarose gel (B) and the bands 
visualised under UV light after staining the gel with ethidium bromide (O.2Sllglml). 
The molecular weight markers (M) are shown on the left hand side of the figure and the 
expected 237bp fragment is indicated by the arrowhead on the right hand side. All 











exon, thus incorporating the splice junctions in the PCR product. Analysis of the PCR 
product on a 1% agarose gel showed the correct 237bp product, indicated by the 
arrowhead on the right side of figure 3.6(B). 
3.2.3.2 SSCP Analysis of Exon 7 
Figure 3.7 represents SSCP gels using the different electrophoretic conditions for exon 7. 
Results from these SSCP experiments show that patients #6 and #27 both had altered 
electrophoretic mobility patterns (indicated by the arrowheads in the figures) , indicating 
the presence of mutations in these 2 samples. The mutation in patient #6 separated out 
from the normal sample under all the conditions tested, however, the mutation in patient 
#27 could only be distinguished from the normal when the samples were electrophoresed 
at room temperature in the presence of glycerol (figure 3.7B) and at 4°C in the absence of 
glycerol (figure 3.7C). No other patients showed altered electrophoretic mobilities for 
exon 7. 
3.2.3.3 Sequence Analysis of the Exon 7 Mutations 
Since SSCP does not reveal any information about the exact nature of the mutation, 
sequence analysis on the mutant PCR products was done in order to determine the site 
and nature of the mutation. Exon 7 from patients #6 and #27 was re-amplified and the 
PCR products were cloned as described in section 6.4. Briefly, the PCR products were 
phosphorylated using T4 polynucleotide kinase (Amersham), blunt-ended using the 
Klenow fragment of DNA polymerase I (Amersham) and ligated into pUC-19 previously 
digested with SmaI and dephosphorylated with calf intestinal phosphatase (Roche 
Biochemicals). The ligation reactions were transformed into competent E.Coli DK-l cells 
and a number of colonies were picked and screened for inserts by either restriction 
endonuclease digestion or PCR, as outlined in section 6.4 .6. A number of recombinant 
clones were subjected to DNA sequence analysis using the Pharmacia Biotech 
T7SequencingTM Kit as described in section 6.6.2. 
Sequence analysis of the mutation from patient #6 revealed the deletion of a single 
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Figure 3.7: SSCP analysis of exon 7 of the p53 gene. Exon 7 was amplified in the 
presence of 32p-dCTP using primers p53-7 A and p53-7B as described in section 6.3 .1. 
3111 of the PCR product was mixed with 3111 of formamide loading buffer, heat­
denatured at 95°C for 5 min and then loaded onto non-denaturing 6% polyacrylamide 
gels. The samples were electrophoresed through the gel at 70W for 10 min and then at 
30W for 4-6 hours, in 1 X TBE, at room temperature (A); at room temperature in the 
presence of 5% (v/v) glycerol (B); at 4°C (C) and at 4°C in the presence of 5% (v/v) 
glycerol , The gels were dried under a vacuum at 70°C for 1 hour and exposed to x-ray 
film for 16-48 hours. Under these conditions, patients #6 and #27 have altered 
electrophoretic mobility patterns (arrowheads). No other patients or cell lines showed 


























Figure 3.8: Sequence analysis of the exon 7 mutations. The exon 7 PCR product for 
patient #6 was cloned and sequenced as described in sections 6.4 and 6.6.2. The 
sequence reactions were heated at 75°C for 2min before loading onto a denaturing 6% 
polyacrylamide gel which had been pre-electrophoresed until the temperature of the gel 
had reached 50°C. The samples were electrophoresed for 3 hours after which the gel 
was dried and exposed to x-ray film for 16 hours. (A) ~ the normal sequence 
corresponding to the site of the mutation in patient #6, (B)~ the deletion of an adenine 











of a termination codon further downstream at position 263. 
The mutation in exon 7 from patient #27 was a single base substitution of a G ~ A at 
codon 248 (figure 3.9) resulting in the substitution of a glutamine for an arginine in the 
protein sequence. 
3.2.3.4 Restriction Endonuclease Analysis of the Exon 7 Mutations 
The deletion of the adenine residue from patient #6 created a new RsaI restriction 
endonuclease site in exon7 (figure 3.1 OA). In order to confirm this mutation and as a 
rapid screening procedure, exon 7 was re-amplified and digested with RsaI. The resulting 
DNA fragments were resolved on a non-denaturing 8% polyacrylamide gel. Since there is 
only one RsaI site in the wild-type, 2 fragments were expected, while the introduction of 
the new RsaI restriction site would result in 3 fragments. The additional expected 135bp 
fragment created by the new restriction site can be clearly seen in the mutant lane (figure 
3.10B). The small DNA fragment of27bp between the two sites is not visible on the gel 
as runs off in the dye front. It is also evident from the presence of the 163bp, 135bp and 
74bp bands, that there is a mixture of both normal and mutant sequences in the PCR 
product. There are two possible explanations for this; (1) the patient is heterozygous for 
the mutation or (2) the tissue sample from which the DNA was isolated was 
heterogeneous and contained both normal and tumour cells. 
The exon 7 mutation from patient #27, on the other hand, abolished an existing MspI 
restriction endonuclease site as shown in figure 3.11(A). Thus to further confirm the 
presence of this mutation, exon 7 from patient #27 and the normal WI-38 cell line were 
re-amplifled and equal amounts of PCR product digested with MspI. The resulting DNA 
fragments were resolved on a non-denaturing 8% polyacrylamide gel and as can be seen 
from figure 3.11(B), the expected DNA fragments of 130bp and 107bp are obtained for 
the wild-type sequence. The mutant also shows the digested DNA fragments observed in 
the wild-type, but with a large amount of undigested product. This implies that the MspI 
site was destroyed and suggests that the patient was either heterozygous for the mutation, 




































Figure 3.9: Sequence analysis of the exon 7 mutation in patient #27. The exon 7 peR 
product for patient #27 was cloned and sequenced as described in sections 6.4 and 
6.6.2. (A); the normal sequence corresponding to the mutation site in patient #27, (B); 
the mutation corresponding to a G --) A base substitution at codon 248 (shown in red) 












13940 13960 13908 
1 1 1 
GCTTGCCACAGGTCTCCCCA AGGCGCACTGGCCTCATCTT GGGCCTGTGTTATCTCCTAG 
14000 14020 14040 
1 1 I '" GTTGGCTCTGACTGTAC CAC CATCCACTACAACTACATGT GTACAGTTCCTGCATGGGTG 
14060 14080 14100 
I I I 
















Figure 3.10: Digestion of the exon 7 PCR product from patient #6 with RsaI. (A); the 
mutation in patient #6 created an RsaI restriction site (asterisk) while the existing 
upstream RsaI site is indicated in red. (B); ex on 7 from patient #6 was re-amplified and 
the resulting PCR product was incubated with RsaI for 16 hours at 37°C. The resulting 
DNA fragments were resolved on an 8% polyacrylamide gel and visualised under UV 
light after staining the gel with ethidium bromide (O.25~g/ml). The molecular weight 
markers (M) are shown on the left hand side of the figure and the fragment sizes are 
indicated by arrowheads on the right hand side. All molecular sizes are in base pairs. U 













13940 13960 13908 
I I I 
GCTTGCCACAGGTCTCCCCA AGGCGCACTGGCCTCATCTT GGGCCTGTGTTATCTCCTAG 
14000 14020 14040 
I I I 
GTTGGCTCTGACTGTACCAC CATCCACTACAACTACATGT GTACAGTTCCTGCATGGGTG 






















Figure 3.11: MspI digestion of the exon 7 PCR product for patient #27 . (A); the G ~ 
A base substitution in codon 248 from patient #27 destroys an MspI restriction site, 
shown in red . (B); exon 7 from patient #27 was re-amplified and the PCR product was 
incubated with MspI at 37°C for 16 hours and the DNA fragments analysed on an 8% 
polyacrylamide gel. U represents the uncut PCR product and C represents the PCR 
product digested with MspI. The sizes of the DNA fragments are shown in base pairs on 











3.2.4 Analysis of Exons 8 and 9 of the p53 Gene 
3.2.4.1 PCR Amplification of Exons 8 and 9 
Exons 8 and 9 of the p53 gene were co-amplified as a result of the small intron (92bp) 
between them, using primers p53-89A and p53-89B described in section 6.3.1 to give a 
PCR product of 445bp in length (figure 3.12A). The PCR product was digested with StyI 
to separate the two exons from each other before analysis by SSCP. The primers were 
situated in the flanking introns, thus incorporating the splice junctions into the PCR 
product. To check for the correct PCR product size, 5III of the PCR product was 
electrophoresed on a non-denaturing 8% polyacrylamide gel (figure 3.12B) to confirm 
that exons 8 and 9 were successfully amplified by producing the expected 445bp 
fragment. The StyI digested fragments of 261 bp and 184bp are also indicated in the 
figure. 
3.2.4.2 SSCP Analysis of Exons 8 and 9 of the p53 G ne 
Exons 8 and 9 of the p53 gene were co-amplified in the presence of 32p _dCTP as 
described in section 6.3.1 and the PCR product digested with StyI endonuclease in order 
to produce two fragments , the one containing exon 8 and the other exon 9 (figure 3.12A). 
Figure 3. l3(A-D) represent SSCP gels usmg different electrophoretic conditions for 
exons 8 and 9. Results from this screening indicated that patient #7 had an altered 
electrophoretic mobility pattern that separated under all of the conditions used while 
patient #28 had a mutation in exon 8 that separated out from the normal only when the 
samples were electrophoresed in the presence of glycerol at 4°C (figure 3. l3(D)). The 
MDA-MB231 cell line also harboured a mutation in exon 8, as evidenced by it's altered 
banding pattern when the samples were electrophoresed at 4°C in the presence of 
glycerol (figure 3.13D). This mutation and the mutation in patient #28 could not be 
distinguished from the wild-type when the samples were electrophoresed at room 
temperature in the absence of glycerol (figure 3.13A), at room temperature in the 















Gly Asn Leu Leu Gly Arg 
GCCTCTTGCTTCTCTTTTCCTATCCTGAGTAG T GGT AAT CTA CTG GGA CGG 
Asn Ser Phe Glu Val Arg Val Cys Ala Cys Pro Gly Arg Asp 
AAC AGC TTT GAG GTG CGT GTT TGT GCC TGT CCT GGG AGA GAC 
Arg Arg Thr Glu Glu Glu Asn Leu Arg Lys Lys Gly Glu Pro 
CGG CGC ACA GAG GAA GAG AAT CTC CGC AAG AAA GGG GAG CCT 
His His Glu Leu Pro Pro Gly Ser Thr Lys Arg 
CAC CAC GAG CTG CCC CCA GGG AGC ACT AAG CGA G GTAAGCAAG 
CAGGACAAGAAGCGGTGGAGGAGF1CCAAGGt;TGCAGTTATGCCTCAGATTCACTT 
Styl 
Leu Pro Asn Asn Thr Ser 
TTATCACCTTTCCTTGCCTCTTTCCTAG CA CTG CCC AAC AAC ACC AGC 
Ser Ser Pro Gin Pro Lys Lys Lys Pro Leu Asp Gly Glu Tyr 
TCC TCT CCC CAG CCA AAG AAG AAA CCA CTG GAT GGA GAA TAT 
Phe Thr Leu Gin 













Figure 3.12: Amplification of exons 8 & 9 of the p53 gene. (A); exons 8 & 9 were co­
amplified as described in section 6.3.1 using primers p53-89A and p53 89B as 
indicated. (B); in order to check for efficient amplification, 5~1 of the PCR product 
was electrophoresed on a non-denaturing 8% polyacrylamide gel and the bands 
visualised under UV light after staining with ethidium bromide (O . 25~glml). The 
molecular weight markers (M) are shown on the left hand side of the figure and the 
amplified 445bp PCR product is indicated by the arrowhead on the right hand side. 
The 26lbp and 184bp fragments obtained after digestion with StyI are also indicated 
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None of the samples showed any mutations in exon 9, although patient #27 appears to 
have an altered migration pattern when electrophoresed at 4°C in the presence of glycerol 
(figure 3 .13D) . This altered migration pattern, however, was a false positive as it was not 
reproducible. 
3.2.4.3 Sequence Analysis of the Exon 8 Mutations 
In order to determine the exact nature of the mutations detected by SSCP in exon 8 in the 
MDA-MB231 cell line and patient 7 and 28, the PCR products were subjected to DNA 
sequence analysis. 
Exon 8 and 9 of the MDA-MB231 cell line was re-amplified and the resulting amplified 
product was sequenced directly as described in section 6.6 .1 using a PCR Product 
Sequencing Kit (Amersham). DNA sequence analysis revealed the mutation to be a single 
G ~ A base substitution at position 280, resulting in an Arg ~ Lys amino acid 
substitution (results not shown). This mutation has been described previously (Bartek et 
aI., 1990b). 
The exon 8 and 9 PCR product from patient #7 was also sequenced directly but it was not 
possible to get an unambiguous sequence and it was decided to clone the PCR product for 
sequence analysis. The PCR product was cloned as outlined in section 6.4 and a number 
of clones were sequenced. The mutation was found to be an in frame ISbp duplication 
resulting in the duplication of 5 amino acids corresponding to codons 268 - 272 (figure 
3.14). 
As a consequence of this mutation, a new AluI restriction site was introduced into the 
DNA sequence (figure 3 .1SA). This new restriction site enabled the mutation to be easily 
confirmed and screened for by digest ing the PCR-amplified product with AluI, which 
would release a ISbp DNA fragment. Exon 8 and 9 were thus re-amplified in the 
presence of trace amounts of 32p_dCTP to visualise such a small fragment. The expected 
lSbp DNA fragment can be clearly seen in the mutant lane, thus confirming the presence 
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Figure 3.14: Sequence analysis of the exon 8 mutation in patient #7. The exon 8/9 
PCR product of patient #7 was cloned and sequenced using the dideoxy sequencing 
method with the Phannacia 17SequencingTM Kit as described in section 6.6.2. Sequence 
reactions were heated at 75°C for 2 min and fractionated on a denaturing 6% 
polyacrylamide gel, which had been pre-electrophoresed until the temperature of the 
gel had reached 50°e. The samples were electrophoresed through the gel for 3 hours, 
after which the gel was dried at 70°C under a vacuum for 1 hour and exposed to x-ray 
film for 16 hours at -70°e. The wild-type WI-38 sequence is shown in (A) and the 













14361 14381 14401 
I I I 
TTGGGAGTAGATGGAGCCTG GTTTTTTAAATGGGACAGGT AGGACCTGATTTCCTTACTG 
14421 144 41 14461 
I I I 
CCTCTTGCTTCTCTTTTCCT ATCCTGAGTAGTGGTAATCT ACTGGGACGGAACAGCT TTG 
14481 14501 14521 
AGGT~CAGCTTT~GGTGI tGTGTTTGTGCCTGTCCTGG bAGAGACCGGCGCACAGAGG 
14541 14561 14581 
I I I 
AAGAGAATCTCCGCAAGAAA GGGGAGCCTCACCACGAGCT GCCCCCAGGGAGCACTAAGC 
14601 14621 14641 
I I I 
GAGGTAAGCAAGCAGGACAA GAAGCGGTGGAGGAGACCAA GGGTGCAGTTATGCCTCAGA 
14661 14681 14701 
I I I 
TTCACTTTTATCACCTTTCC TTGCCTCTTTCCTAGCACTG CCCAACAACACCAGCTCCTC 
14721 14741 14761 
I I I 
















Figure 3.15: Restriction endonuclease digestion of the exon 8/9 PCR product from 
patient #7. (A); sequence of the exon 8 mutation in patient #7. The duplicated bases are 
represented by the boxed sequence. The 15 base pair duplication results in the creation 
of an A1ul restriction site (red sequence in the boxed region). All other A1ul restriction 
sites are depicted in red . (B); exon8/9 from patient #7 was re-amplified in the presence 
of 32p_dCTP using primers p53-89A and p53-89B and the PCR product incubated with 
A1ul for 16 hours at 37°e. The DNA fragments were resolved on a non-denaturing 20% 
polyacrylamide gel. The gel was dried under a vacuum for 1 hour at 70°C and exposed 
to x-ray film for 16 hours at -70°e. Molecular weights in base pairs are indicated on the 
left hand side of the figure. The expected 15bp fragment in the mutant is indicated by 











Direct sequence analysis of the exon 8/9 PCR product from patient #28 revealed the 
mutation to be a single C ~ A base substitution at codon 269 (figure 3.16), resulting in a 
serine ~ arginine substitution. 
3.2.5 Amplification of Exon 11 of the p53 Gene 
Exon 11 was amplified using primer p53-11A and p53-11B under the conditions outlined 
in table 6.1 and described in section 6.3.1. Figure 3.17(A) shows the sequence of the 
PCR-amplified product and the position of the primers flanking the exon, thus 
incorporating the splice junctions. Figure 3.17(B) represents a 1 % agarose gel showing 
the 245bp product. 
3.2.6 Sequencing ofExons 5-11 in all Patients 
Since only a limited number of mutations had been detected by SSCP analysis, it was 
decided to sequence all the previously described exons, as well as exon 11 in all patients 
in order to ensure that no mutations had gone undetected by SSCP analysis . The sequence 
analysis supported the SSCP data and confirmed that no mutations had gone undetected 
by SSCP analysis. A summary of the SSCP and sequencing results is shown in table 3.1. 
Although the number of mutations was very small, there was no correlation between the 
presence of the mutations and the stage of the tumour. Although 3 of the patients with 
mutations were under 50 years of age, there was also no significant association 
(p=0.1323) between the age of the patient and the presence of mutations. These results 
are summarised in table 3.2. 
3.2.7 Analysis of Patient Survival 
The survival rates of this population of breast cancer patients was compared with their 
oestrogen receptor, p53 and lymph node status (figure 3 .18). The overall survival of this 
group of patients was quite good, with over 70% of the patients still alive after 5 years of 
being diagnosed with the disease (figure 3.18A). It is clear that there is no significant 
difference between the survival of patients with or without p53 mutations, although this 




















































Figure 3.16: Sequence analysis of the ex on 8 mutation in patient #28. Exon 8/9 was re­
amplified and the PCR product subjected to direct sequence analysis as described in 
section 6.6.l. The sequence reactions were heated at 7SoC for 2 min and loaded onto a 
denaturing 6% polyacrylamide gel, which had been pre-electrophoresed in order to 
heat it to SO°c. The samples were electrophoresed at a constant power of SOW for 3 
hours, after which the gel was dried and exposed to x-ray film for 16 hours at -70°C. 
The wild-type sequence is shown in (A) and the mutant sequence shown in (B). 
Sequence analysis revealed the mutation to be a C ~ A base substitution at codon 269, 















~GACCCTCTCACTCATGTG~TGTCATCTCTCCTCCCTGCTTCTGTCTCCTACAG C CAC 
Leu Lys Ser Lys Lys Giy Gin Ser Thr Ser Arg His Lys Lys Leu 
CTG AAG TCC AAA AAG GGT CAG TCT ACC TCC CGC CAT AAA AAA CTC 
Met Phe Lys Thr Giu Giy Pro Asp Ser Asp Ter 










Figure 3.17: Amplification of exon 11 of the p53 gene. Exon 11 was PCR-amplified 
using primers p53-11A and p53-11B (A) as described in section 6.3.1. (B); 5~1 of the 
PCR product was electrophoresed on a 1% agarose gel and the bands visualised under 
UV light after staining with ethidium bromide (O.25~g/ml). The molecular weight 
markers (M) are shown on the left hand side of the figure with the amplified product 











Table 3.1: Summary of the mutations In study SSCP 
DNA sequence analysis. 
NO. OF SAMPLE'" BASE CHANGE;; I EXON AMINO ACID CHANGE
IMUTATIONS I 
5 0 ­ -
6 1 1= T4;-D C~T (194) LEU ~PHE 
7 2 Framesltift6 tJ.A (239) 
Iat codon 
I 
27 ARG~ GLNG~A (248) 
8 3 28 C~A ~69) SER~ARG 
I
7 lSbp 5 amino acid duplication 
IvIDA-MB-231 G~A (280) ARG~LYS 
9 0 
11 0 
* numbers indicate patient number 
# numbers in brackets number 
Table 3.2: Summary 
had mutations in 
a normal p53 was no 
Only 4 of the 39 patients 
patient had a fibroadenoma 
association between tumour 
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Figure 3.18: Patient survival curves. Survival times were estimated using the method of 
Kaplan and Meier for (A) the overall survival, (B); patients without (-Y'-) and withe -0-) 
p53 mutations, (C); oestrogen receptor (ER) positive (-.-) and ER negative (-e-) 
tumours and (D); lymph node positive (- 0 -) and lymph node negative (-i1-) tumours). 
The overall survival (---) is shown in each figure for comparison. 
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(figure 3.18B) . Similarly, there was no significant difference in patient survival with 
respect to either the oestrogen receptor status or involvement of lymph nodes (figures 
3.18(D) and (E) respectively). 
3.2.8 Immunohistochemical Detection of p53 Protein 
Wild-type p53 protein IS, In the majority of cases, undetectable by 
immunohistochemistry, and one of the characteristics of mutant p53 is that it has an 
extended half life, rendering it detectable by either Western blotting or 
immunohistochemical staining. Since only a small number of p53 mutations were 
detected by SSCP and DNA sequence analysis of exons 5-11, the patient tumour samples 
were screened for p53 protein using immunohistochemistry in order to determine whether 
a higher frequency of mutations may be present in the regions of the gene not screened by 
SSCP and sequence analysis in this population. 
Tissue sections were probed for p53 protein using an anti-p53 antibody that recognises an 
epitope in the N-terminus of both the human wild-type and mutant forms of the protein. 
Sections were treated as described in section 6.11. With this technique, 10 patients 
showed a positive result. It is clear from figure 3.19 that there are various intensities of 
p53 staining, with some tumours staining only very weakly (B) and (E) and other tumour 
samples staining very strongly (C), (D) and (F) . The tissue sections for patient #27 
harbouring the G ---) A base substitution at codon 248, and patient #28 with the C ---) A 
substitution at codon 269 are shown in figures 3 .19(B) and (C) respectively. Patient #6 
with the deletion of a single A residue at codon 239 came up negative for the presence of 
p53 protein which may be explained by the rapid degradation of the truncated protein. 
Unfortunately, no material was available for patient #7 with the 15bp insertion. A 
summary of the immunohistochemistry results is shown in table 3.3. 
Of the 10 patients staining positive for p53, only two had mutations In the exons 
analysed. Thus In order to determine whether the remaining eight 
immunohistochemically positive patients contained mutations in the N-terminal region of 











mutations were detected in these 2 exons either. 
Table 3.3: Summary ofthe p53 immunohistochemical positive patients 
p53 MUTATION STATUS*i TUMOUR STAGE NO. OF SAMPLES i 
1 Wild-type I 2 
I 1 Mutant 
I 







* p53 mutatIOn status for exons 2, 4, 5-9 and 11 
From the table, it is clear that p53 protein was detected more frequently in higher stage 
tumours (II-IV), with the majority of cases occurring in stages II and ill. The staining 
intensity of some patients varied, which may have something to do with the nature of the 
mutation (figure 3.19(B) and (C)). In addition to patient #28 with the C ~ A mutation at 
codon 269, only one other patient who showed detectable levels of p53 protein had died 
from the disease, whilst another patient (#16) died from other causes. 
In summary, ofthe 40 breast cancer patients screened for mutations in the p53 gene, only 
4 were found to harbour mutations in exons 5-9 and 11, and only an additional 8 patients 
-










Figure 3.19: Immunohistochemical staining of p53 protein. Tissue sections from the 
breast cancer patients were processed as described in section 6.11 and probed for p53 
protein using the DO-7 anti-p53 antibody, which recognises an epitope on the N-terminus 
of the protein. The antibody was detected using DAB as a substrate. (A); a section from a 
patient who is negative for p53 protein, (B); p53 staining from patient #27, (C); a tissue 
section from patient #28, (D); patient #31, (E); patient #17 and (F); patient #14. Patient 
#27 is a stage I tumour, #31 a stage IT tumour, and 14, 17 and 28 are stage III tumours. 


























The frequency of alterations in the p53 gene has been reported to be between 40 - 50%, 

and more specifically, the frequency of point mutations (including small deletions and 

insertions) has been reported to be about 25 - 30% (Lou et aI, 1997; Runnebaum et aL, 

1991; Sj6rgen et aL, 1996). In this study of South African breast cancer patients, a fairly 

low frequency of p53 mutations were found in primary breast tumours. Only 4 out of 40 

(10%) primary breast tumours examined contained mutations in the p53 gene. Moreover, 

no mutations were present in the previously reported hotspot regions of exons 5 and 6. 

The mutations were restricted to exons 7 and 8. It cannot, however, be ruled out that 

mutations do exist in the regions (exons 2,3,4 and 10) not Investigated in this study. 

Of the 4 mutations identified in the breast cancer patients in this study, three have not 
previously been described. These are the single base deletion in codon 239, the point 
mutation at codon 269 and the 15bp duplication of codons 268-272. Previous studies 
have shown a large deletion, as well as a point mutation at codon 239 (Aas et al., 1996; 
Andersen et a1., 1993). The only codon 269 mutation previously reported for breast 
cancer is a silent change in patients with familial breast cancer (Glebov et a1., 1994) and 
only one point mutation has been reported for codon 268 (Seth et aI, 1994). The fourth 
mutation at codon 248 has been reported in many studies and has been found to be 
frequently mutated (Aas et a1., 1996; Andersen et a1., 1993; Shiao et a1., 1995; Davidoff 
et al., 1991; Faille et al., 1994). Codon 248 has been shown to be highly methylated 
(Rideout et al., 1990), thus deamination of a methylcytosine could account for the high 
frequency of mutations at this site (Magewu and Jones, 1994). The two mutations 
identified in the breast cancer cell lines (T47-D and MDA-MB231) have been previously 
documented (Nigro et aI., 1989; Bartek et a1., 1990b). 
Although PCR-SSCP analysis is frequently used to screen for mutations, it is not 100% 
effective and even under different conditions, it is possible to miss some mutations. It 
was therefore decided to use direct DNA sequence analysis on all the PCR products in 
order to minimise the possibility that some mutations may have escaped detection by 












by SSCP were also detected and no further were 
detected by direct sequence PCR products. Thus the discrepancy 
the presented in this chapter and those reported by others is not to the 
some mutations may gone Un(let(~ct~~a 
Immunohistochemical techniques have also utilised to detect protein 
accumulation, which has associated p53 (Bartek et 1991). It 
however, been shown that immunohistochemical detection p53 expression is not 
an absolute indicator a gene mutation (Sjorgen et aI., 1 Chakravarty et a1., 
1996). this study, only 10 out the 40 (25%) patients were positive for 
accumulation as determined by immunohistochemistry, with two of these point 
mutations. Interestingly, those patients showing detectable levels protein tended to 
be skewed A possible explanation for the detectable 
p53 levels, but lacking mutations, may be p53 in these patients is not 
targetted degradation. It has been shown that the N-terminal domain of p53 is critical 
for interaction with mdm2 and its degradation (Gottlieb Oren, 1996). 
Therefore, in to whether the domain in these I-'UL''-'''L'' 
contained mutations that may impede its interaction with mdm2 protein, exons 2 and 
were mutations by but no 
were detected. The possibility cannot ruled out, however, that those with 
detectable protein and without in the exons 
harbour mutations in the remaining exons and 10) of the presence of 
mutations in tumours has been associated with a poor prognosis and can be a prognostic 
indicator recurrence and survival it been that detection p53 
mutations has a prognostic value than immunohistochemical detection for 
overexpression of the protein et al., 1996). 
Although mutation of the gene is one most and common 
aberrations in human not all tumours contain p53 mutations. A low frequency of 
mutations has found in both testicular (Peng et al., 1 ) medutloblastomas 











The possibility exists that low frequency p53 mutations this study could 
be due to mutation spectrum between race 
majority of the patients in this were of a population group, Reports the 
United have shown there is a difference survival between Black and White 
patients with breast cancer, that status the 3 can 
different race groups having same tumour (Shiao et , 1996; Shiao et 
, 1995). Black patients with mutations had a poorer survival rate than 
those without p53 which did not apply to patients, to 
White patients who had p53 protein accumulation had a poorer survival rate those 
without protein accumulation, which not apply to patients, Interestingly, of 
those patients who died from the Blacks often had mutations without 
detectable levels the mutant whereas Whites often had 
accumulation but lacked mutations. In the patients In study (of which 
were of a mixed race), accumulation did not significantly the survival 
rate. Only 1 patient (a black female) with protein no accompanyIng 
mutation, died from disease, and only 1 patient mixed ancestry) with both 
protein accumulation and a mutation died from 
The in this chapter suggest the majority (90%) the patients would 
have a good as tumours lacked a mutation, survival curves 
indicate that a proportion (82%) these individuals were still alive 4 years after 
were initially diagnosed with the favourably with 
patients p53 mutations In other (Kovach et aL, 1996), results 
presented here differ from those by et al 1996 in they that 
mutations were associated with a poor prognosis, study show 
that the presence p53 mutations did not significantly effect 
results may skewed, though, as a low number mutations 
It may be possible that the nature of mutation playa role in determining 
whether tumours a particular of mutation would have a poor prognosis, This 











the and the nature of p53 mutations amongst race (Shiao et 
al., 1995). patients a high (80%) of G:C to at 
sites, whereas this type of mutation only occurred 62. White patients 
with p53 mutations. p53 mutations have also associated with a poorer survival in 
Black patients, but not in White patients, with Black p53 mutations 
having an increased of from the to Black without 
mutations (Shiao et ai, 1995). South Africa, is known about the survival rates 
between race groups, but from elsewhere suggest that the survival patients from 
different race may It is quite clear from the presented this 
chapter that the p53 status different race groups, "Coloured" 
population a low frequency of mutations, corresponding to a good survival rate. 
The majority mutations the are point mutations et ai, 
1 1; et aI., 1 In this study, however, 2 out of the 4 (50%) mutations 
were microdeletions/insertions. unusually high frequency of these types mutations 
has previously reported (Kovach et ai., 1996) in a different of breast cancer 
from the region of United The reason high 
number insertions/deletions is unclear, but it has suggested that exogenous and 
endogenous factors could implicated in the generation of these types mutations 
by and Cooper, 1991 and Jego et aI, 1993). 
mutations to to radiotherapy and 
(Lowe et Lowe et 1994). This is due to a 
defect in p53-dependant apoptosis, which is induced by many drugs. 
Consequently, a with a p53 
than in a patient lacking a p53 mutation. Thus it should be expected that the majority of 
the patients in this study would favourably to treatment. All these patients 
were subjected to surgery (mastectomy axillary clearance) and in addition, 17 
patients underwent tamoxifen treatment, 12 patients chemotherapy 
(cyclophosphamide, and 5-fluorouracil) while 9 patients had no additional 












subjected to tamoxifen treatment and 4 to none of the 
patients who had surgery only from the the 4 patients with p53 
mutations, one had no treatment other than surgery while 2 had hormone therapy In 
addition to and the fourth chemotherapy addition to Of 
patients who died, only 1 had a mutation accompanied p53 protein accumulation, 
while another patient, undergoing hormone treatment, had protein accumulation, 
but without a p53 In addition to the 9 patients died from a 
further 2 from other causes and the remaining 29 patients only 2 have shown a 
recurrence of disease. majority of the patients are alive with no 
''',"''''',"" In study p53 mutations or p53 protein did not to a 
significant effect on survival did not appear to be In choice of 
treatment. 
summary, results in that mutant does not a significant 
role the of cancer the "Coloured" population in South and 
the possibility that this population group could "resistant" to mutations in this 
This may due to the patients not being to certain environmental 
carcinogens which could result in more widespread mutation in p53 
also the possibility that tumours of the same type can genetically diverse 












CHAPTER 4: FUNCTIONAL ANALYSIS OF NOVEL p53 
MUTANTS 
4.1 INTRODUCTION 
Development of a neoplastic or a malignant tumour is a process, in which 
immortalisation of the cell is thought to a critical event (Farber, 1 In addition to 
immortalisation, clonal expansion and the accumulation of multiple aberrations 
also play an important role in the a normal cell into a cancerous one. p53 
plays an important role in both these events, which explains why mutations in 
are most common alterations found sporadic cancers (Vogel stein, 1990), 
Amongst many functions, p53 cell cycle arrest near restriction point in 
late G1 (Lin et aL, 1992), or apoptosis, thus preventing the replication of defective DNA 
(Clarke et 1 Kastan et aL, 1991; et 1993a; et 
at, 1992). This is achieved by induction of p21IWAFl (el-Deiry et aL, 
1993), an inhibitor of most of the cyclin-dependent kinases (Xiong et 
function p53 is critical in its ability to arrest cells the G1 phase of the cycle in 
to DNA damage, (Kastan et 1 1; Kuerbitz et aL, 1 thus allowing DNA 
repair to place prior to DNA replication in order to ensure that mutations are 
from the In addition to the in late phase of the cell 
cause growth arrest in the G2/M phase in the absence DNA damage 
et aL, 1995), probably via the same as the arrest that 
activates p211W AFl 
It has been demonstrated that immortalisation primary human mammary epithelial 
cells by gene illV -16 is accompanied by a marked degradation of the p53 
protein (Band et ,199 a phenomenon that has also been observed in primary human 
mammary epithelial cells after y-radiation et aL, 1 results confirm that 











Based on the evidence of p53 is associated with immortalisation of 
it is possible that mutated proteins also participate in the immortalisation process. It 
shown that various mutants can immortalise cells by abrogating G 1 cell 
cycle arrest induced DNA damage (Gao et al., 1996; Fushimi et aI., 1997; Kikuchi-
Yanoshita et al., 1995). it has also been shown that certain mutants are not 
capable of cells, even though they some growth (Williams 
et . Dumenco et It seems that only p53 mutants are of 
immortalising cells, implying that the nature of the mutation is important 
This chapter is at whether novel p53 mutations In 
the breast cancer patients 3) are capable of imparting a growth advantage to 
normal and whether the various mutants have the ability to arrest cells in late G1 












In to elucidate of the mutant p53's chapter 3, it was 
to construct p53 mutants by and to 
transfect mutant genes into to on growth rate and their 
ability to arrest the in the G 1 of the cell after damage. 
4.2.1 Construction of Mutants by Site-Directed Mutagenesis 
A wild-type cDNA as as a mutant cDNA (p53 which contains a -+ 
Ala substitution at codon 143, were kindly by Dr B et 
1990). Site-directed mutagenesis was out on wild-type cDNA as described 
below. 
1.1 Subdoning of the Wild-Type p53 cDNA into pUC-19 
wild-type cDNA was supplied a pCMV-Neo-Bam expression vector (Baker et 
aI., 1990) and had to be subcloned into 19 no primers were available for the 
parent vector. The p53 pCMV-Neo-Bam 
endonuclease. The 1 8kb fragment was cloned into 
digested pUC-19 as described in section 6.9.1. transformation competent 
cells, a of colonies were screened the 1"\,-",,,,,,n and orientation 
of was determined DNA using universal pnmers. 
4.2.1.2 Site-Directed Mutagenesis 
Once the and of wild-type p53 eDNA pUC-19 was confirmed, 
the was used as a template for site-directed mutagenesis. containing 
mutation and mutations to create unique restriction endonuclease sites 
were synthesised and used in conjunction with the forward reverse primers of pUC­
19 in a PCR reaction, as III and outlined 4.1. 
for p53-L'.A mutant had a KpnI restriction and those 
p5 15 mutants contained Asp700 restriction as indicated in table 
4.2(A) shows a schematic representation of the position of the various mutant primers in 
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Figure 4.2: Amplification of mutant PCR products. The wild-type pS3 cDNA was 
cloned into pUC-19 and used as a template to amplify various fragments containing the 
introduced mutations. (A); the relative positions of the mutant pS3 primers described in 
section 6.9.2 in the pS3 eDNA with the wild-type pS3 eDNA depicted as the solid line 
and the pUC-19 vector sequence by the dotted line. Primers lA and lB correspond to 
the single A deletion mutant from patient #6 (chapter 3) and contain an introduced 
KpnI restriction endonuclease site; primers 2A and 2B correspond to the C ~ A base 
substitution at codon 269 from patient #28 (chapter 3); and primers 3A and 3B 
correspond to the lSbp insertion mutant from patient #7 (chapter 3). Primers 2A and 2B 
as well as primers 3A and 3B contain an introduced Asp700 restriction endonuclease 
site. Also shown is the position of the pUC-19 forward (Fp) and reverse (Rp) primers. B 
are BamHl sites and S is a SmaI site. Each A mutant primer was used in a PCR reaction 
with the Rp primer to generate the mut(A) PCR products, and each B mutant primer 
was used together with the Fp primer to generate the mut(B) PCR products . 
Amplification was carried out in a final volume of 100J..l1 using Deep Vent polmerase 
(New England Biolabs) in order to minimise the number of mismatches which might be 
inserted randomly by the enzyme. (B); lOJ..lI of the PCR products were electrophoresed 
on a 1 % agarose gel and the bands visualised under UV light after staining the gel with 
EtBr (O.2SJ..lglml). The molecular weight markers (M) are shown on the left hand side 
of the figure, and are represented in base pairs. The various PCR products obtained 











amplified products for each mutant are shown figure 
Ligation of Products into pUC-19 




4.2.1.4 Sequence Analysis of the Mutant cDNAs 
order to confirm that the correct mutations were created and no other had 
introduced by PCR, the clones were analysed by sequence as described 
m 6.6.2. A number of clones were sequenced in order to obtain one each that 
contained the correct p53 mutant had correct with the 
deleted residue indicated by the arrowhead and the KpnI restriction site 
which did not alter ammo indicated figure 4.4(A). sequence 
around the the mutation for the the mutated base are shown 
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Figure 4.3: Cloning of mutant cDNA's. The mutant PCR products shown in figure 4.2 
were digested with various restriction enzymes and ligated to pUC-19 digested with 
EcoRI and HindUI in a triple ligation reaction as outlined in 4.2.1.3. Sill of the ligation 
reaction was used to transform competent E.coli DK-l cells. Colonies were picked from 
agar plates and propagated as described in section 6.4.6.2. An aliquot of the cultures 
was screened for inserts by PCR with the pUC primers. SJ..ll of the PCR products were 
electrophoresed on 1.S% agarose gels and the bands visualised under UV light after 
staining the gels with EtBr (O.2Sllglml). (A); the I1A mutant; (B); the S269R mutant and 
(C); the lSbp duplication mutant. The molecular weight markers (M) are shown in base 
pairs on the left hand side of the figures and a control reaction (CT) with the wild-type 
pS3 cloned into pUC-19 as a template is shown in (A) and (B) to indicate the size of the 
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Figure 4.4: Sequence analysis of mutant pS3 clones. The clones containing the correct 
sized inserts in figure 4.3 were subjected to sequence analysis as described in section 
6.6.2. The sequencing reactions were separated on denaturing 6% polyacrylamide gels 
which were then dried and exposed to x-ray film. (A); the sequence corresponding to 
the i1A mutant with the point mutation indicated by an arrowhead and the newly 
created Kpnl restriction site depicted in red, (B); the sequence of the S269R mutation, 
with the point mutation indicated by an arrowhead and (C); the sequence of the lSbp 











In order to ensure that no other mismatches or incorrect bases were present in the various 
cDNAs, the entire cDNA for each clo ne containing the correct mutation was sequenced. 
4.2.1.5 Subcloning of the Mutant p53 cDNAs into pcDNA3 Expression Vector 
In order to express the various p53 mutant cDNAs, they had to be subcloned into a 
mammalian expression vector. pcDNA3 was used as it contains the ampicillin resistance 
gene, providing a selectable marker when grown in bacteria, as well as the neomycin 
resistance gene as a selectable marker in mammalian cells . pcDNA3 also contains a 
multiple cloning site downstream of the CMV promoter and a bovine growth hormone 
polyadenylation site downstream of the multiple cloning site (figure 4.5). 
The p53-L1A, p53-S269R and p53-+15 mutant clones in pUC-19 were digested with 
BamHI to release the full length cDNA and then subsequently with SmaI (which shortens 
the cDNA by about 300bp) in order to enable the insert to be cloned in the correct 
orientation into. the expression vector (figure 4.5). The SmaI site is located just 
downstream of the termination codon in the 3' untranslated region. This also allows the 
mRNA from the transfected gene to be distinguished from the endogenous message. The 
digested mutant p53 cDNAs, as well as the wild-type p53 cDNA and the SCX mutant 
cDNA, were ligated into pcDNA3 which had been digested with BamBI and EcoRV. 
Colonies were screened for the presence of inserts after transformation of the ligation 
reactions into competent E.coli cells. Plasmid DNA was isolated from a number of 
colonies and screened for inserts by digestion with BamHI and XbaI (the XbaI site is 
downstream of the EcoRV restriction endonuclease site, figure 4.5) and analysis on 1.5% 
agarose gels (figure 4.6). The correct insert size is 1.5kb, as indicated by the arrowheads. 
Similar screening was carried out for the wild-type p53 cDNA and the p53-SCX mutant 
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Figure 4.6: Subcloning of the mutant cDNA's into pcDNA-3. The mutant p53 cDNA's 
cloned into pUC-19 (figure 4.4) were subcloned into pcDNA-3 after release from pUC­
19 by BamHI and SmaI digestion and ligation into pcDNA-3 digested with BamHI and 
EcoRV. The ligation reactions were transformed into competent E.coli cells and 
colonies screened for inserts by restriction endonuclease digestion. DNA from 
overnight cultures was isolated and incubated with HindIII, which cuts 5' of the cDNA, 
and XbaI, which is situated downstream of the EcoRV site in pcDNA-3. The resulting 
DNA fragments were resolved on 1.5% agarose gels and the bands visualised under UV 
light. (A); the p53-~A mutant, (B); the p53-S269R mutant, and (C); the p53-+ 15bp 
mutant. U represents uncut plasmid in all the figures and the numbers indicate various 
clones digested with HindIII and Xbal. C represents the digested DNA. The molecular 
weight markers are shown in base pairs on the left hand side of the figures and the 











4.2.2 Transfection of p53 Constructs into Nill-3T3 Cells 
In order to ascertain whether the mutant p53 affected the growth of cells, the constructs 
described above were transfected into NIH-3T3 cells. Initially the constructs were 
transfected into MCF-12A cells, which are normal human breast epithelial cells, but after 
isolating a number of stable clones, no expression of any of the constructs could be 
detected. No expression of the constructs was detected in stably transfected FGO cells (a 
human skin fibroblast cell line) either and it was decided to transfect the constructs into 
NIH-3T3 cells, a mouse fibroblast cell line. The calcium phosphate method was used to 
transfect the DNA into the cells (section 6.10). 
4.2.3 Northern Blot Analysis of RNA from Stable Transfectants 
Northern blot analysis was used to determine whether the stably transfected clones 
described above were expressing p53 mRNA. RNA was isolated from the clones as 
described in section 6.7.2 and 5~g was electrophores d on 1% agarose gels containing 
8% formaldehyde, transferred onto Hybond-N nylon membranes and probed with a 
radiolabelled fragment of the p53 cDNA. As a control, and also to determine whether the 
constructs were active, the p53-SCX mutant cDNA was transiently transfected into 
SVWI-38 cells (transformed human embryonic lung fibroblasts). The RNA from these 
cells was separated in parallel with the RNA from the NIH-3T3 transfectants (figure 4.7). 
In the control (SV) lanes, the middle band corresponds to the endogenous transcript and 
the bottom band corresponds to the transcript from the transgene. The top band is non­
specific cross hybridisation of the probe. In the top panel the 3T3 lane represents RNA 
from untransfected NIH-3T3 cells, and as can be seen, the human probe for p53 used to 
screen the blots does not detect the mouse p53 RNA. The specific transcripts for the 
various constructs are indicated by arrowheads on the right hand side of the panels. It is 
clear from figure 4.7 that some clones strongly express the RNA, whereas others express 
it weakly (compare clones S3 and S9 with clone S6 for the p53-S269R mutant and clones 
W2 and W5 with clone W3 for the wild-type). A possible explanation for this is that the 
number of copies of the plasmid may be different in the various clones. Based on the 
above data, various clones were selected for further analysis. These were clone #W2 for 
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Figure 4.7: Northern blot analysis for p53 mRNA in stably transfected Nlli-3T3 
clones. RNA was isolated from the clones as described in section 6.7 and 5!lg 
electrophoresed on a 1% agarose gel containing 8% formaldehyde. The RNA was 
transferred onto Hybond-N membranes and the blots probed with a 32P-Iabelled 
fragment of the p53 eDNA. After hybridisation, the blots were washed and exposed to 
X-ray film for 16-48 hours. The various panels show examples of northern blots for 
each of the constructs indicated on the right hand side of the figures. 3T3 in the top 
panel represents the untransfected cells and SV represents a transiently transfected 
transformed human embryonic lung fibroblast cell line (SVWI-38). The transfected 
transcripts are indicated by arrowheads on the right hand side of the figures. The 
middle band in the control lanes corresponds to the transcript of the endogenous p53 
gene and the top band is non-specific cross hybridisation of the probe. Clone numbers 











clone #+3 for the p53-+ 15 mutant and clone #X4 for the p53-SCX mutant. 
4.2.4 Analysis of Transfected p53 Protein in the Stably Transfected Clones 
Once the expression of the p53 plasmid in the clones had been established, the clones 
were analysed for protein levels using immunohstochemistry as described in section 
6.11 .1. Cells were plated on glass slides and allowed to attach and grow overnight at 
37°e. The cells were then fixed and probed with the DO-7 anti-p53 antibody (Dako), a 
mouse monoclonal antibody recognising the N-terminus of both human and mouse p53. 
The antibody was detected using DAB as a substrate, resulting in a brown colour. Figure 
4.S(A) represents immunohistochemistry on the untransfected NIH-3T3 cells, and as 
expected, no detectable p53 protein was observed as the cells have only wild-type p53 
and under normal growth conditions, the protein levels are too low for detection by 
immunohistochemistry, or Western blots. p53 was located predominantly in the nucleus 
of the NIH-3T3 cells transfected with the wild-type protein, whilst faint staining was 
observed in the cytoplasm as well (figure 4.SB). In the p53-L1A mutant, however, it was 
clear that p53 was expressed only in the cytoplasm since there was no brown staining in 
the nuclei at all (figure 4. SC). This is not unexpected as the mutation results in a 
frameshift which introduces a termination codon at position 263 resulting in a protein that 
has lost it's nuclear localisation signal, located at the C-terminal end of the protein. 
Consequently the protein remained in the cytoplasm. The p53-S269R mutant was present 
in both the nucleus, and to a lesser degree in the cytoplasm (figure 4.8D). It is unclear as 
to why all of the cells failed to stain for the protein, but since the cells were not treated in 
a pressure cooker as an antigen retrieval step, the epitope might not be fully accessible to 
the antibody, or the cells might not have been permeabilised sufficiently to allow the 
antibody to enter. The p53-+ 15 mutant protein stained strongly in the cytoplasm, with 
weak staining in the nuclei whilst the p53-SCX protein was detected only cytoplasmically 
















Figure 4.8: Expression of the transfected p53 constructs in NIH-3T3 cells. The stable 
clones expressing the transfected plasmids were screened by immunohistochemistry as 
described in section 6.11.1. Cells were plated on glass slides and incubated at 37°C 
overnight and p53 was detected using antibody DO-7 (Dako). (A); untransfected NIH­
3T3 cells, (B); cells transfected with the wild-type construct, (C); cells transfected with 
the p53-~A construct, (D); cells transfected with the p53-S269R construct, (E); cells 
transfected with the p53-+ 15 construct and (F); cells transfected with the p53-SCX 
construct. The brown staining indicated a positive result and the blue staining is 











It was also clear that the different mutants had different effects on the morphology of the 
cells. The wild-type p53 as well as the p53-~A and p53-+ 15 mutants did not seem to alter 
the morphology of the cells drastically, in that they remained thin and spindly. The p53­
S269R and p53-SCX mutants, however, altered the morphology in that the cells became 
slightly more rounded and flat while in the case of the p53-SCX mutant, the cells seemed 
to be bigger in size than the untransfected cells. 
4.2.5 Analysis of the Growth Rate of the Transfected Cells 
4.2.5.1 Growth in Complete Medium 
In order to determine whether expression of the mutant p53 proteins had any effect on the 
inherent growth rate of the cells, a fixed number of cells were plated in medium 
supplemented with 10% foetal bovine serum (FBS) and harvested at various times after 
plating. The doubling time of the various clones was analysed and calculated using 
Graphpad Prism software (table 4.1). The growth curves are shown in figure 4.9. 
Although the transfectants all seemed to have a slightly faster doubling time than the 
untransfected cells, this difference, however, was not significant (table 4.1) 
4.2.5.2 Growth in Serum-Free Medium 
The growth of the cells in serum-free medium was also analysed , since transformed cells 
tend to have a lower dependance on serum factors for growth. Once again, 30 000 cells 
per well were plated in 6-well plates in full medium and allowed to adhere to the dishes. 
After 24 hours, the medium was removed and replaced with serum-free medium. The 
cells were harvested 24, 48, 72 and 96 hours after seeding and the cell number 
determined for calculation of the doubling times as shown in table 4.1. Although there 
was a slight difference in doubling time between the various clones, these differences 
were not significant (figure 4.10). 
Comparison of the growth rates of the various clones grown in complete medium and 
serum free medium showed a significant increase in doubling time for the wild-type clone 
(p = 0.0077) as well as the p53-~A mutant (0.0284), the p53-+15 mutant (p = 0.0483) and 












for the p53-S269R mutant (p = 0.2990) when cultured in serum-free medium versus to 
full medium. 
Table 4.1: Doubling time of the various stable transfectants in full and serum 
free media. Doubling times were calculated using Graphpad Prism 
software. 30 000 cells were pi ated per well in 6-well plates and 
incubated at 37°C for various time intervals after which the cell s 
were harvested by trypsinisation and the cell number determined 
using a Coulter counter 




N1H-3T3 2l.14 ± l.28 
Wild-type 19.83 ± 3.72 0.5961 
p53-f'j,A 19.01 ± 1.73 0.7478 
p53-S269R 19.75 ± 0.44 0.9711 
p53-+ 15 19.15±0.83 0.7729 
p53-SCX 20.30 ± 0.85 0.8427 
Serum-Free Medium 
NIH-3T3 27.95 ± 4.94 
Wild-type 33.46 ± 2.97 0.1735 (0.0077) 
p53-f'j,A 54.03 ± 17.98 o 1223 (0.0284) 
p53-S269R 24.98 ± 7.58 0.1457 (0 .2990) 
p53-+ 15 33.22 ± 8.63 0.9659 (0.0483) 
p53-SCX 27.37 ± 3.64 0.0880 (0.0304) 
P values are for the doubling times of the p53 transfected cells compared to the 
untransfected cells. P values in brackets represent the comparison of the growth of the 
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Figure 4.9: growth of transfected with the mutant p53 constructs. 
Cells were seeded in 6-well plates at a density 30000 cells/well in complete medium 
containing 10% bovine serum (FBS) and incubated at Cells were 
24, 48, 72 96 hours plating and counted in a Coulter counter. The 
v .........:>.:"••u. 
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Figure 4.10: Growth rate of cells transfected with the various mutant p53 constructs 
in serum-free medium. 30 000 cells were seeded into 6-well plates in full growth 
medium and incubated for 24 hours at 37°C in a humidified incubator. The cells from 
one well of each dish were harvested and the medium removed from the other wells in 
the plate. Serum-free medium was added and the cells were returned to 37°C and 
harvested 48, 72 and 96 hours after plating. The arrowheads in each panel indicate the 











4.2.5.3 Effect of Mutant p53 on Contact Inhibition of Growth 
Normal cells become contact inhibited when they reach confluency and it has been shown 
that transformed or tumour cells do not display this feature when they become confluent 
In order to determine the effect of overexpression of the various mutants on contact 
inhibition of growth, cells harbouring the mutant p53 genes were plated at a high density 
(200 000 cells) in 60mm tissue culture dishes. The cells were incubated at 37°C and 
harvested at 24, 48, 72 and 96 hours after plating for determination of cell numbers. As 
expected, both the untransfected cells and the cells transfected with the wild-type 
construct exhibited contact inhibition of growth, although the wild-type cells appeared to 
be contact inhibited at a slightly higher cell density than the untransfected cells (figure 
4.11). The p53-S269R mutant and the p53-+ 15 mutant however, did not seem to show 
any contact inhibition over the time course of the study. No significant conclusion can be 
reached on the p53-~A mutant data as at the end of the study (96 hours) there were less 
cells than the wild-type transfectants and they had not become contact inhibited. A 
possible explanation is that at high densities these cells grow more slowly than those 
transfected with the wild-type plasmid. This result was consistent and reproducible and it 
might be that the cells would become contact inhibited if allowed to grow for longer than 
96 hours. The p53-SCX mutant behaved like the wild-type transfectant in that it exhibited 
contact inhibition at a high cell density. 
4.2.6 Anchorage-Independent Growth of the Transfected Cells 
One of the characteristics of a transformed cell is the ability to grow and form colonies in 
soft agar in the absence of a solid support. 5 xl03 cells were mixed with 5ml of 0.35% 
agar (Sigma) in normal growth medium and overlayed onto a 0.6% agar base (also in 
normal growth medium) in 60mm dishes as described in section 6.12. After 3 weeks the 
plates were examined for the presence of colonies. The untransfected cells (figure 4.12A) 
formed numerous small colonies, however, no colonies were bigger than 0.2mm in 
diameter. Similarly the cells transfected with the wild-type p53 construct formed 
numerous small colonies that were only slightly larger than the untransfected cells (figure 
4.12B). The p53-~A mutant formed very few colonies, and those that did form were 
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Figure 4.11: Contact inhibition of growth of cells harbouring mutant p53 genes. Cells 
were plated at a density of 200 000 cells per 60mm tissue culture dish, in complete 
medium containing 10% FBS, and incubated at 37°C for 24, 48, 72 and 96 hours, after 
which the cells were harvested and cell number determined in a Coulter counter. The 
curve for the wild-type cells is plotted with the cells harbouring the various mutants in 
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significantly larger than 0.2mm in diameter, with the p53-S269R mutant having an 
average of 15 large colonies per plate, the p53-+ 15 mutant having an average of 4 large 
colonies per plate and the p53-SCX mutant an average of 6 colonies per plate (figures 
4.12 C-F and table 4.2). In addition, the colonies formed from the latter 3 mutants were 
more amorphous in shape than those formed by the untransfected and wild-type clones 
(compare figure 4.12 A and B with D, E and F). The wild-type and untransfected colonies 
were more round than the mutant colonies. 
4.2.7 Effect of Ionising Radiation on the Cell Cycle Kinetics 
One of the roles of p53 is that it responds to various shocks to the cell to prevent the cell 
from entering the S phase of the cell cycle when exposed to stress. When normal cells 
harbouring wild-type p53 are exposed to ionising radiation, approximately 50% of the 
cells will arrest in the G1 phase and the other 50% will arrest in the G2 phase with the 
time taken to reach the maximum G2 block being dependent on the cell type (Baker et aI., 
1990; Diller et al ., 1990). Cells harbouring a mutant p53 do not exhibit the G1 block and 
the majority of the cells will arrest in the G2 phase of the cell cycle (Ludwig et al., 1996; 
Friedlander et aI., 1996; Ryan and Vousden, 1998). In order to determine if the novel 
tumour-derived p53 mutants identified in chapter 3 behave like ''true'' p53 mutants, the 
various transfected cells were exposed to ionising radiation (7Gy of 60Co) and analysed 
at various time points after exposure to determine the number of cells in the G1 and G2 
phases of the cell cycle. 
The results for the various cell lines in this study are shown in figures 4.13-4 .18. The 
untransfected Nlli-3T3 cells display normal behaviour when exposed to ionising 
radiation, reaching a maximum G2 block at 6 hours after exposure to the radiation (figure 
4.13) with approximately 43% of the cells being in the G2 phase. This block did not last 
very long and after 12 hours the cells had returned to their normal cycling pattern (in 
comparison with the un-irradiated control). 
The cells transfected with the wild-type p53 behaved exactly the same as the 





















Figure 4.13: Effect of ionising radiation on the ceU cycle of the untransfected NIH-3T3 
cells, 200 000 cells were seeded into 25ml tissue culture flasks in full medium and 
incubated at 37°C overnight in a humidified incubator to allow them to adhere to the 
flask, Cells were then exposed to 7Gy of 60Co radiation and returned to 37°C. The cells 
were harvested at the various times indicated in the figure and stored overnight in ice­
cold 70% EtOH, The cells were then incubated in the presence of RNAse A and 
propidium iodide and sorted on a flow cytometer as described in section 6,13 , The 
number of events are shown on the Y-axis and fluorescence on the X-axis , Marker Ml 
corresponds to G 1 phase cells, M2 to G2 cells and M3 to S phase cells, The area under 
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(figure 4.14) with approximately 43% of the cells occurring in the G2 phase of the cell 
cycle. As with the untransfected cells, the G2 block did not last very long and by 12 hours 
the cells had returned to their normal cycling pattern. 
The pS3-,1A mutant (figure 4.1S) showed a slightly different pattern in that the un­
irradiated cells had a slightly higher population of cells in the G2 phase compared to the 
untransfected cells or cells transfected with wild-type pS3. This cell line, however, had a 
maximum G2 block at 4 hours post-irradiation with slightly more than SO% of the cells 
occurring in the G2 phase, although there were still a signifIcant number of cells in the G 1 
phase (23%). Once again, the cells had returned to normal after 12 hours. This suggested 
that this mutant did not behave as one would expect of a "true" mutant. 
The pS3-S269R mutant (figure 4.16) in turn had a different profile, with more cells 
occurring in the G2 phase of the cell cycle in the un-irradiated control cells. This cell line 
attained a maximum G2 block between 6 and 8 hours post-irradiation, and behaved like a 
mutant pS3 in that the majority of the cells (73%) were in the G2 phase with only a small 
percentage (13%) in the G1 phase. Furthermore, the G2 block was prolonged as even 12 
hours after irradiation there were still a significant number of cells remaining in the G2 
phase. 
Both the pS3-+ IS and pS3-SCX mutants (figures 4.17 and 4.18 respectively) behaved in a 
similar fashion after exposure to 60Co radiation. Both showed maximum G2 blocks at 6 
hours after exposure to radiation with approximately 60% of the cells occurring in the G2 
phase for the pS3-+ IS mutant and 49% of the cells for the pS3-SCX mutant. The blocks 
in both cases did not last long and by 12 hours post irradiation both cell lines had 
resumed to normal cycling, compared to the control. Both of these mutants did not 
behave exactly as "true" mutants, however, they also did not behave in a similar fashion 
to the wild-type. 
In all the figures, the percentages given did not add up to 100%, due to cell debris and 






















Figure 4.14: Effect of ionising radiation on the cell cycle of cells transfected with wild­
type p53 . The cells were treated as described in the legend to figure 4.13, except the 
cells used were NIH-3T3 cells stably transfected with the wild-type p53 cDNA. All 
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s: 4.43 s: 6.49 s: 7.96 
Figure 4.15: Effect of ionising radiation on the cell cycle of cells transfected with 
thep53-~A mutant. The NIH-3T3 cells stably transfected with the p53- ~A mutant were 
exposed to ionising radiation as described in the legend to figure 4.13 and the 
percentage of cells in each phase of the cell cycle was determined as previously 
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Figure 4.16: Effect of ionising radiation on the cell cycle of cells transfected with the 
p53-S269R mutant construct. NllI-3T3 cells which were stably transfected with the 
p53-S269R mutant p53 cDNA were exposed to ionising radiation as previously 
described and the fraction of cells in each phase of the cell cycle was determined. All 
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FL2-A F12-A FL2-A 
% Area % Area % Area 
G1: 33.13 G1: 42.10 G1: 53.55 
G2: 53.52 G2: 41.62 G2: 33.34 
5: 9.48 5: 10.74 5: 6.66 
Figure 4.17: Effect of ionising radiation on the cell cycle of cells transfected with the 
p53-+15 mutant construct. Nlli-3T3 cells which were stably transfected with the p53­
+15 mutant cDNA were exposed to 7Gy of 60CO as previously described, and the cells 
were then sorted on a flow cytometer after being incubated at 37°C for the various time 
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Figure 4.18: Effect of ionising radiation on the cell cycle of cells transfected with the 
p53-SCX mutant construct. Nlli-3T3 cells stably transfected with the p53-SCX mutant 
cDNA were exposed to ionising radiation as described in the legend to figure 4.13 and 
the percentage of ce11s in each phase of the cell cycle was determined after the cells 
were harvested at the various time points after exposure to the radiation. The markers 
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The p53 tumour suppressor protein is involved in a number of cellular processes such as 
transcription, DNA repair, cell cycling and apoptosis (Harris, 1996). Mutations in the 
gene encoding this protein result in mutant forms of the protein that are not able to carry 
out these functions and thus contribute to the process of tumourigenesis. 
The work in this chapter focussed on analysing the functional defects of the three novel 
tumour-derived p53 mutants described in chapter 3, especially their effects on the growth 
rate, response to radiation-induced DNA damage and transformation of normal cells. The 
three mutants were constructed by site-directed mutagenesis and stably transfected into 
NIH-3T3 cells. In addition to the three mutants described in chapter 3, the, wild-type form 
of the gene as well as a known mutant, p53-SCX (Baker et al., 1990) were also 
transfected into NIH-3T3 cells. These various forms of the gene were originally 
transfected into normal breast epithelial cells, but after isolating a number of stable 
clones, none were found to express the transgene. It was thus decided to use NIH-3T3 
cells. 
While the wild-type form of the protein was predominantly located in the nucleus, the 
expression patterns of the various mutants varied. The p53-S269R mutant was also 
located predominantly in the nucleus, with some cytoplasmic expression, albeit far less. 
The p53-+15 mutant was located predominantly in the cytoplasm, with some minor 
nuclear location, while the p53-L1A and p53-SCX mutants were located solely in the 
cytoplasm. The cytoplasmic location of the p53-L1A mutant was not surprising since the 
mutation results in a frameshift which introduces a termination codon at position 263. 
This results in a truncated protein lacking the C-terminal region containing the nuclear 
localisation signal. The protein is therefore not translocated to the nucleus after 
translation. 
The presence of p53 in the cytoplasm is not a novel finding since previous studies have 
reported the accumulation of p53 in the cytoplasm in tumours. Cytoplasmic p53 has been 











1996) and is correlated with poor survival and advanced stage of the disease. In contrast, 
however, reports on endometrial carcinoma have shown that cytoplasmic overexpression 
of p53 correlates with a better survival than nuclear expression (Soong et al., 1996). 
Cytoplasmic p53 accumulation has also been detected in primary breast cancers (Moll et 
a1., 1992; Domagala et aL, 1993; Stenmark-Askmalm et a1., 1994) where it occurred 
mainly in lobular carcinomas (Domagala et a1., 1993). It seems that cytoplasmic 
accumulation of p53 is a fairly common occurrence in human tumours and itls effect on 
survival and prognosis seems to vary between tumour types. 
The significance of cytoplasmic p53 is controversial in that many studies have shown 
that, in the majority of cases, cytoplasmic p53 protein is wild-type (Moll et aI., 1992; 
Moll et a1., 1995; Ali et al., 1994). It has been suggested that cellular proteins may bind to 
p53 and in this way sequester it in the cytoplasm (Moll et al., 1992), which may represent 
an alternate mechanism to mutational inactivation of p53 function. It has also been 
suggested that the conformation of the protein plays a role in its intracellular distribution 
(Zerrhanet al., 1992). Thus it is possible that the p53-+15 and p53-SCX mutants 
described in this study may be confined to the cytoplasm as a result of some 
conformational change brought about by the mutation. This is certainly a strong 
possibility in the case of the p53-+15 mutant as an additional five amino acids have been 
added to the protein and it is conceivable that the addition of these extra amino acids may 
alter the conformation of the protein. It may be that altering the conformation of the 
protein enables it to interact more readily with other cellular proteins which would then 
sequester them to the cytoplasm. It is still possible that these p53 mutants which remain 
in the cytoplasm can stiJI act in a dominant negative fashion in that they may form 
tetramers with the endogenous wild-type form of the protein, and thus assist in 
sequestering it in the cytoplasm. One of the amino acids duplicated in the 5 amino acid 
insertion is a serine, and this may introduce a new potential phosphorylation site. Thus 
another explanation for the cytoplasmic localisation of the mutant protein is that the 
phosphorylation status may be altered, and it has been suggested that phosphorylation 
may be involved in the subcellular localisation of the protein in the cell (reviewed by 











cytoplasm due to aberrant phosphorylation. 
No significant difference was detected in the growth rate of any of the cells when grown 
in the presence of 10% serum, however, when the cells were grown in the absence of 
. serum, there was a significant increase in the doubling times for the NIH-3T3 cells 
transfected with the wild-type p53, the p53-ilA, the p53-+ 15 and the p53-SCX mutants, 
as well as for the untransfected cells. There was, however, no significant change in the 
doubling time for the p53-S269R mutant. These results suggest that cells showing a 
decreased growth rate in the absence of serum had a dependance on serum factors for 
growth, whereas the p53-S269R mutant, which showed no change in growth rate in the 
absence of serum, had no dependance on serum factors for growth. A previous study has 
shown that a human hepatocellular carcinoma (HCC) cell line transfected with the wild­
type p53 also showed no alteration in growth rate when compared to the same cell line 
transfected with the p53-SCX mutant if the cells were grown in the presence of 10% 
serum. However, if the two cell lines were grown in the absence of serum, there was a 
remarkable change in the growth rate of the wild-type transfected cells, but not of the 
p53-SCX transfected cells (Terai et aI., 1997). Furthermore, there were distinct 
morphological changes in the wild-type transfected HCC cells as opposed to the p53­
sex transfected cells. No such morphological changes were observed in the NIH-3T3 
transfected cel1s in this study when the cells were switched from medium containing 
serum to serum-free medium. This is probably due to the different cell types used in the 
two studies. 
Although the various mutants did not have any effect on the growth rate ofthe cells when 
grown in the presence of serum, they did, however, to various degrees, affect the contact 
inhibition of the cells when grown at high cell density. Both the untransfected cells and 
those transfected with the wild-type p53 exhibited contact inhibition of growth when the 
cells were grown at a high density, whereas the p53-S269R and p53-+15 mutants did not 
show any decrease in growth and continued to proliferate in an exponential fashion, even 
at very high cell numbers. It cannot be ruled out, however, that the cells would eventually 











this study. The p53-SCX mutant behaved differently from the other 2 mutants in that the 
cells did become contact inhibited when grown at a high cell density. These results 
suggest that the different p53 mutants have differing effects on the growth of the cells at 
high cell densities and imply that the p53-+ 15 and p53-S269R mutants impart some 
property to the cells which enable them to grow more aggressively at a high cell density 
than the other mutants, and have allowed the cells to lose their ability to regulate their 
growth when in contact with neighbouring cells. 
In addition to causing loss of contact inhibition of growth, the p53-S269R, p53-+ 15 and 
p53-SCX mutants allowed growth in soft agar, while cells transfected with the p53-~A 
mutant were not able to. This ability to grow in an anchorage-independent manner further 
demonstrates the aggressive growth of the p53-S269R, p53-+15 and the p53-SCX mutant 
cell lines since the ability to form colonies in soft agar is an indication of the transformed 
status of a cell. 
Although the p53-S269R, p53-+ 15 and p53-SCX mutants could all form colonies in soft 
agar and the colonies were of a similar size, the number of colonies for each cell line 
differed. The p53-S269R mutant was able to form the highest number of colonies with an 
average of 15 colonies per plate, and the p53-+ 15 mutant the least, with an average of 3 
colonies per plate. This suggests that the degree to which these cells have been 
transformed differs according to the specific mutant they harbour. Although the p53-SCX 
mutant cells did not result in any significant growth advantage when grown in tissue 
culture dishes nor was contact inhibition of growth at high densi,ty affected, it did affect 
the in vitro growth of the cells in soft agar. This result contradicts a previous report which 
showed that the p53-SCX mutant did not affect the in vitro growth of a colonic epithelial 
cell line (Williams et aI., 1994). These contradictory findings suggest that the same 
mutant p53 might affect cells from different origins, and possibly different species, in 
different ways. Other studies have also demonstrated that transfection of cells with a 
murine p53 mutant construct corresponding to a common human codon 249 mutation in 
hepatocellular carcinomas results in a growth advantage of the transfected cells in serum­











1995). This result contradicts the findings for the p53-+15 and p53-SCX mutants, which 
did not give the cells a growth advantage in serum-free medium, but did, however, allow 
them to form colonies in soft agar, while the p53-S269R mutation gave the cells a growth 
advantage in serum-free medium as well as allowing colony formation in soft agar. Taken 
together, these results suggest that various p53 mutations impart different growth 
advantages to cells. 
The various mutants described in this chapter also have differing effects on the growth 
arrest of the cells following exposure to ionising radiation. The untransfected cells, as 
well as the cells transfected with the wild-type p53, both showed a characteristic G1 arrest 
and a Gz block, which reached a maximum at 6 hours after irradiation. The p53-+15 and 
p53-SCX mutants also showed a maximum Gz block 6 hours post-irradiation, and 
although the fraction of cells arrested in the G1 phase of the cell cycle decreased when 
compared to the control cells, a significant number of cells were G1 arrested, which is 
more characteristic of a wild-type protein than a mutant. This finding is in agreement 
with other studies that have shown that not all p53 mutations affect the ability of the 
protein to elicit a G1 cell cycle arrest. Two other tumour-derived p53 mutants, Pro 175 and 
Leu181 were also able to arrest cells in G1 (Ludwig et aI., 1996) by retaining the ability to 
activate the p21 CIP1 gene, a cyclin kinase (CDK) inhibitor. It is possible that the large 
number of cells still present in G] after irradiation is due to the presence of the 
endogenous murine p53 gene and a reason for the decrease in the proportion of cells 
arrested at Gl as compared to the control cells is that the mutant p53 interacts and forms 
tetramers with the endogenous wild-type protein. Human p53 has been shown to interact 
with and form oligomers with murine p53 and in fact these heterologous oligomers have 
a similar affinity for DNA as both human or mouse oligomers alone (Hall and Milner, 
1995). The fact that a significant number of cells were G1 arrested suggests, however, that 
these two mutants are not completely dominant over the wild-type and as a result of the 
mutations may have altered conformations, decreasing their affinity to form complexes 
with the endogenous wild-type protein. 











significant population of cells arrested in G1. The reasons for this could be similar to 
those suggested above. The p53-S269R mutant, however, showed the characteristics of a 
true p53 mutant, at least with respect to it's ability to affect the cell cycle after irradiation, 
in that the G1 arrest was almost completely abrogated. Furthermore, while in the control 
cells and the other mutants the G2 block was transient and fairly short (by 12 hours post­
irradiation the cells had resumed cycling), the block in the p53-S269R transfected cells 
was more prolonged and 12 hours after exposure to radiation, the majority of the cells 
were still blocked in the G2 phase of the cell cycle. This suggests that these cells might 
have a better chance of survival on exposure to radiation in that they remain in G2 for a 
longer time and consequently may be more unlikely to undergo apoptosis, which occurs 
predominantly when the cells are growth-arrested in G1 (reviewed by Ozbun .and Butel, 
1996). Consequently, mutations that may have arisen as a result of the radiation would be 
propagated and may result in further growth advantage of the cells. The small number of 
cells which were arrested in the Gl phase of the cell cycle for the p53-S269R mutant 
could have arisen due to the presence of the endogenous wild-type p53 protein. This 
mutation behaved in a similar manner to other tumour-derived p53 mutants which were 
also incapable of arresting the cells in G1 (Ludwig et aI., 1996). A Leu173 and an N­
terminal mutant also failed to arrest the cells in G1 as a result of their inability to activate 
the p21 CIPI gene. 
The findings that the different p53 mutants affected the G1 arrest of the cell cycle 
differently agree with other studies which have also demonstrated that the p53-SCX 
mutant, as well as a 175(His) and a 248(Trp) mutant p53 do not inhibit the p53-dependent 
G1 arrest after exposure to gamma radiation, whereas a 273(His) p53 mutant did affect 
the cell cycle (Williams et aI., 1995; Pocard et aI., 1996). Theses studies also found that 
loss of wild-type p53 function alone was not sufficient to directly affect the growth rate 
of the cells and ~the authors suggested that the mutation may contribute to malignant 
progression by creating genomic instability due to the inhibition of the Gl arrest. 
Furthermore, other mutations would be required to get a clonal outgrowth of the p53 
mutant cells. The results in this chapter' support this finding and confirm that different 











mutations at codon 175, a frequently mutated codon in human tumours, can behave 
differently with respect to the ability of the various mutants to abrogate the G1 cell cycle 
arrest cRyan and Vousden, 1998), and a codon 248 mutation retains tumour suppressor 
functions (Mukhopadhyay and Roth, 1993). The results presented in this chapter with the 
3 novel p53 mutants support previous findings that different mutations have different 
effects on the function of the protein, where some mutations allow cells to lose the ability 
to regulate their growth while others have little or no effect on the function of the protein. 
The fact that different mutations at a single codon can affect the function of the protein to 
varying degrees (Ryan and Vousden, 1998) suggests that the nature of the mutation is 
important in determining the effect that it will have. The results presented in this chapter 
support this idea as the 3 novel mutations described are all different types of mutations (a 
deletion, an insertion and a point mutation) that all affect the function of the protein 
differently. 
In summary, all the mutants did not significantly affect the inherent growth rate of the 
cells, but had differing effects on the contact inhibition of the cells. They also affected the 
Gl arrest of the cells to various degrees after exposure to 60Co radiation and were all 
capable of growth and colony formation in soft agar, with the exception of the p53-.1A 
mutant. The results obtained suggest that the p53-S269R mutant behaves in the most 
aggressive manner as it shows no dependance on serum factors and it also almost 
completely abrogates the Gl block of cells after exposure to radiation. Taken together, the 
results presented in this chapter and those reported by others, clearly demonstrate that 
different p53 mutations have different biological effects on normal cells and the potential 
of different p53 mutations to behave in a dominant negative fashion can vary, depending 











CHAPTER 5: CONCLUSION 
5.1 CONCLUSION 
Breast cancer is a disease responsible for the majority of deaths among women 
worldwide. Like all other types of cancer, it is a multi genic disorder with an 
accumulation of mutations that results in the transformation of a normal cell and 
subsequent clonal expansion of this cell into a tumour. These mutations occur in genes 
that either positively (oncogenes) or negatively (tumour suppressor genes) control cell 
growth and proliferation. Mutations in oncogenes result in the constitutive activation of 
these genes, while mutations in tumour suppressor genes lead to their inactivation or loss 
of function. Thus by the simultaneous activation of genes which stimulate cell growth 
and the inactivation of genes which retard cell growth, these mutations result in the loss 
of cellular growth control and ultimately in the formation of a tumour. 
This study focussed on mutations in two such genes, the Ha-ras oncogene and the p53 
tumour suppressor gene in a population of breast cancer patients from the Western Cape 
region of South Africa. The majority of these patients were of a mixed race (Coloured), 
and of the 40 patients studied, 39 were female and one was male. 
Mutations in codons 12, 13 and 61 of the Ha-ras oncogene have been shown to 
constitutively activate the protein. No activating mutations were found in any of these 
codons in any of the patients in this study. These results support other findings that 
mutations in the ras genes are a rare occurrence in breast cancer and suggest that 
mutations in other oncogenes may playa role in breast cancer (Kraus et aI., 1984; 
Spandidos, 1987). 
Although no activating mutations were found in the Ha-ras gene, a polymorphism was 
detected in codon 27. This silent mutation resulted in the creation of a new restriction 
endonuclease site, thus enabling rapid screening of the patients for this polymorphism. 











was similar to that of healthy control samples. It must be noted, however, that only a 
small number of control samples could be obtained and that larger numbers of healthy 
controls should be examined for this polymorphism in order to get statistically significant 
results. 
The tumour suppressor gene screened in this study was the p53 gene. This gene encodes a 
nuclear phosphoprotein that plays a critical role in negatively regulating cell growth. It 
also detects DNA damage and arrests the damaged cells in the G1 phase of the cell cycle. 
If the damage is too extensive, then p53 can also induce apoptosis of the damaged cell to 
ensure that any genetic mutations that have arisen due to the damage are not propagated. 
In addition to these functions, p53 has also been directly implicated in DNA repair. 
It is the most frequently mutated gene found in human tumours, with the frequency of 
mutations varying between different tumour types. The data presented in this study 
showed that only a small number of mutations (10% of patients) in the p53 gene were 
detected by SSCP and DNA sequence analysis. Of four mutations detected, three have 
not previously been described. These results contrast with other studies that have shown 
that p53 mutations are a relatively frequent occurrence in breast cancer (Osborne et aI., 
1991; Cattoretti et aI., 1988; Bartek et aI., 1990a) and also suggest that mutations in this 
gene do not playa role in the aetiology of the disease in the group of patients investigated 
in this study. It is possible that mutations in other tumour suppressor genes are involved 
in tumourigenesis in these patients. 
Immunohistochemical staining, which has also been used as a tool to detect pS3 
mutations, revealed a total of 10 patients with detectable levels of p53 protein. 
Unfortunately there was no material for immunohistochemistry on the patient with the 
lSbp insertion, but two of the remaining three patients with p53 mutations had detectable 
levels of pS3 protein. The patient with the deletion resulting in a truncated protein (pS3­
~A) failed to show detectable levels of p53 protein, and this may be due to it's rapid 
degradation. Thus eight patients showed an accumulation of pS3 protein, but did not 











the presence of mutations has been noted previously (Shiao et at., 1996; Shiao et at., 
1995) and may be due to a defect in the p53 degradation pathway. p53 is degraded via the 
ubiquitin pathway when it interacts with mdm2 (Haupt et aI., 1997). This interaction 
occurs at the N-terminal of p53 (Gottlieb and Oren, 1996) coded for by exons 2-4. The 
eight patients that were positive for p53 by immunohistochemistry were screened for 
mutations in exons 2 and 4 in order to ascertain whether these exons contained mutations 
and none were found. It is possible that the mdm2 protein is defective in these patients, 
and since the stabihty of p53 is to a large extent governed by its interaction with mdm2, a 
defective mdm2 protein would result in the stabilisation of p53 and consequently high 
levels of the protein were detected in these patients. The possibility cannot, however, be 
ruled out, that mutations exist in the exons not screened (exons 3 and 10) in these 
patients. 
Depending on the nature of the mutation, various tumour-derived p53 mutants may have 
different effects on normal cells. Some mutations may totally abrogate the wild-type 
function, whereas others may have little effect, thereby enabling the protein to retain it's 
normal tumour suppressor function (MUkhopadhyay and Roth, 1993). It has also been 
documented that different tumour-derived p53 mutants can affect the function of the 
wild-type protein to various degrees (Ludwig et aI., 1996; Friedlander et aI., 1996a; Ryan 
and Vousden, 1998). Therefore, to examine the effect of the three new mutations 
identified in this study, the mutant cDNAs were transfected into NIH3T3 cells and stable 
clones expressing the mutant proteins were selected. None of the mutants had any 
significant effect on the growth rate of the cells when grown in full medium. When the 
cells were grown in serum-free medium, however, all of the transfectants exhibited a 
significant decrease in growth rate, with the exception of the S269R mutant, which 
showed no difference in growth rate in the presence or absence of serum. Furthermore, 
this mutant resulted in lack of contact inhibition ofgrowth when seeded at a high density. 
The ability of cells to form colonies on soft. agar is an indication of anchorage­
independent growth. When cells expressing the various mutants were cultured on soft 











DNA damage after exposure to ionising radiation. Taken together, these results indicate 
that the different p53 mutants have different effects on normal cells and have differing 
potentials in their ability to aid in cellular transformation. This may be due to the nature 
of the mutation, as it has been shown that even different mutations at the same position 
may have widely differing effects (Ryan and Vousden, 1998). It must be remembered that 
these three p53 mutants were expressed in cells containing endogenous wild-type p53 as 
well, thus it may be that the varying effects on growth rate and response to DNA damage 
may, in part, be governed by the ability of the different mutants to interact with and 
inactivate the wild-type protein in a dominant negative fashion, Nevertheless, the results 
presented in this study are consistent with those of others in that different tumour-derived 
p53 mutants can have different effects on cells (Ludwig et aI., 199p; Friedlander et aI., 
1996). 
The p53 status of a tumour may also play a role in the response of patients to both 
chemo- and radiotherapy. The disease-free survival of the patients used in this study was 
found to be very high, with over 70% of the patients still alive 5 years after diagnosis. 
Lymph node status, oestrogen receptor status,and p53 status did not seem to affect the 
survival of the patients. The reason for the lack of association between the p53 status and 
patient survival may be due to the small number of mutations detected. Interestingly, only 
one patient with a p53 mutation died from the disease, this was the patient with the 
S269R mutation, which had the most detrimental affect on the control of cell growth 
when transfected into normal cells. Although only a small number of mutations were 
examined in this study, these preliminary results suggest that the p53 status of a tumour 
can playa role in the response of a patient to therapy, as the majority of the group did not 
have p53 mutations and most of the patients were still alive 5 years after diagnosis. 
Furthermore, of those patients with p53 mutations, only one died from the disease, with 
this being the most aggressive mutation. The other three mutations did not have any 
significantly detrimental affect on cell growth or response to DNA damage, thus one 
could say that they retained some wild-type function and consequently the patients were 
able to respond favourably to treatment. It would be unwise to claim that p53 status alone 











But the status of the p53 gene in breast tumours may be a key factor in the response of a 
patient to therapy. 
In summary, the results in this study imply that genetic mutations in breast cancer may 
vary between population groups, and it may be possible that different population groups 
may accumulate different genetic alterations, but still develop the same type of tumour. 
Furthermore, with respect to p53 mutations, the data presented here demonstrate that the 
p53 status of a tumour may playa role in the response of patients to therapy. The data 
also show that different p53 mutations have different effects on cells, and consequently 
different p53 mutations may affect the outcome of a patient to varying degrees. This 
makes it important to identify p53 mutations in tumours and to investigate their 
functional significance, as they may have a critical bearing on patient survival. By 
analysing various p53 mutants, it may be possible to develop some classification of 
mutations that would aid in the choice of treatment modality. 
5.2 FUTURE WORK ARISING FROM TillS STUDY 
1) 	 Since very few mutations were detected in these patients, it would be important to 
screen other population groups, such as whites or blacks, with breast cancer, in order 
to ascertain whether this low frequency of p53 mutations is specific for the 
"Coloured" population, or whether it is common to other race groups in South Africa. 
2) 	 It would be necessary to investigate different population groups from various 
geographical locations to determine the nature and frequency of p53 mutations in 
these people, as different populations may be exposed to different 
environmental/chemical mutagens and carcinogens which may result in a specific 
type of mutation. 
3) 	Further studies could be done on the three new mutations identified in this study to 
determine their effect on p53 responsive genes, such as p21 eIFl, and to elucidate the 











4) 	 The effect of various chemotherapeutic agents on stably transfected cells could be 
determined to see whether any of the mutants are able to impart some sort of drug 
resistance to the cells, This may also aid in determining the kind of agent that would 











CHAPTER 6: MATERIALS AND METHODS 
6.1 ISOLATION OF DNA 
6.1.1 Isolation of DNA from Fresh Tissue 
Tissue samples were frozen in liquid nitrogen in the operating theatre immediately 
after excision, and stored at -70°C until required. The tissue samples were 
homogenised in 2 volumes of digestion buffer (section 6.14) using an Ultra-Turrex 
homogeniser and incubated overnight at 50°C. The next day, 2ul of RNase A 
(lOmglml) was added and the samples were incubated at 50°C for another 30min. An 
equal volume ofphenol:chloroform:isoamyl alcohol (25:24:1) was added, the samples 
were shaken vigorously and centrifuged at 5000rpm for 10min in a Beckman J-21C 
centrifuge. After centrifugation, the aqueous phase was mixed with an equal volume 
of chloroform:isoamyl alcohol (24: 1) and centrifuged as above. The DNA, was 
precipitated by the addition of 2 volumes of 96% ethanol (-20°C) to the aqueous 
phase, washed in 70% ethanol and dried under vacuum in a Savant SVC 1 00 
Speedvac. Finally the DNA was resuspended in a suitable volume of IX TE buffer 
and stored at -20°C until required. 
6.1.2 Isolation of DNA from Cell Lines 
Confluent 150mm dishes of cells were rinsed with PBS followed by the addition of 
6ml of 0.05% trypsin in PBS containing 10mM EDTA and incubation at 37°C until 
the cells lifted from the dish (approximately 3min). The cells were pelleted by brief 
centrifugation in a Spinette benchtop centrifuge (Damon/IEC Division), resuspend in 
1 volume digestion buffer (section 6.14) and incubated overnight at 55°C with gentle 
agitation. The samples were then treated as described in section 6.1.1. 
6.1.3 Isolation of DNA from Paraffin-Embedded Tissue Sections 
5!J.,M thin tissue sections were cut from Wax blocks, placed into eppendorf tubes and 
stored at 4°C until required. The sections were dewaxed by the addition of Iml xylene 
and vigorous shaking for 30min at room temperature. The tissue was pelleted by 











xylene was added to the tissue pellet and the above procedure was repeated. After 
removal of the xylene, the sections were dehydrated by the addition ofO.5ml of96% 
ethanol and mixed by sev.eral inversions. The tissue was pelleted as described above, 
fresh ethanol was added, the contents were again mixed by inverting the tubes 
followed by centrifugation and removal of the ethanol. The samples were dried under 
vacuum (as described in section 6.l.1) followed by the addition of 200).!1 of digestion 
buffer (containing 200).!glml Proteinase K) was and incubated overnight at 55°C. The 
samples were incubated at 95°C for 8min to inactivate the protease and stored at ­
20°C until required. 
6.2 PROPAGATION OF CELL LINES 

The cell lines used were: 

. (1) WI-38: a human embryonic lung fibroblast cell line, obtained from the American 
Type Culture Collection (ATCC # CCL-75). 
(2) MCF-7: an epithelial breast tumour cel11ine obtained from ATCC (ATCC # HTB­
22). 
(3) T-47D: an epithelial breast tumour cell line obtained from ATCC (ATCC # HTB­
133). 
(4) MDA-MB-231: an epithelial breast tumour cell line obtained from ATCC (ATCC 
#HTB-26). 
(5) ZR-75-2: 	an epithelial breast tumour cell line obtained from ATCC (ATCC # 
CRL-1500). 
WI-38 cells were grown and maintained in Dulbecco's Modified Eagle's Medium 
(DMEM) containing 10% heat-inactivated foetal bovine serum, 100 units penicillin 
and 100Jlg/ml streptomycin. The 4 breast tumour cell lines were cultured in DMEM 
supplemented with 5% heat-inactivated foetal bovine serum, 100 units penicil1in and 
100Jlglml streptomycin. All the cell lines were incubated at 37°C with 5% CO2 
humidity. On reaching confluency, the cells were rinsed with PBS and harvested by 
incubation with 9.05% trypsin in PBS containing 10mM EDTA at 37°C for 3-5min. 
The cells were pelleted by brief centrifugation (as described in section 6.1.2), 
resuspended in DMEM and split at a ratio of 1:2 (WI-38 cells) or 1:3 (MCF-7, T47-D, 











6.3 POLYMERASE CHAIN REACTION (PCR) - SINGLE STRAND 
CONFORMATION POLYMORPHISM (SSCP) ANALYSIS 
6.3.1 Polymerase Chain Reaction (PCR) 
Exons 2, 4-9 and 11 of the p53 gene and exons 1 and 2 of the Ha-ras gene were 
individually amplified using the primer pairs and annealing temperatures indicated in 
tables 2.1 and 6.1. PCR was performed using 100ng of template DNA (isolated in 
section 6.1) in 1 X PCR buffer (section 6.14) containing 30pmol of each primer, the 
four deoxynucleotide phosphates (dNTP's; dGTP, dATP, dTTP and dCTP) at a final 
concentration of O.2mM each and 2 units of Taq DNA Polymerase (Roche 
Biochemicals) in an Omnigene thermocycler (Hybaid). PCR reactions were carried 
out in a final volume of 50111 for 35 cycles of Imin denaturation (94°C), Imin 
annealing (see temperature in tables 2.1 and 6.1) and 2min extension (72°C). After 
amplification, the PCR products were stored at 4°C until required. 
Table 6.1: PCR primers and annealing temperatur s. 

Primers were synthesised in a Beckman 1000A DNA synthesiser. The annealing 

Temperature for each primer pair is indicated (Tm). 

Gene Exon Primer Pair Tm Fragment Size 
p53 5 p53-5A: 5' - TGTICACTTGTGCCCTGACT - 3' 
p53-5B: 5'- AGCAATCAGTGAGGAATCAG - 3' 
61°C 310bp 
p53 6 p53-6A: 5' - TGGTIGCCCAGGGTCCCCAG - 3' 
p53-6B: 5' - TIAACCCCTCCTCCCAGAGA - 3' 
58°C 20lbp 
p53 7 p53-7A: 5' - CTIGCCACAGGTCTCCCCAA - 3' 
p53-7B: 5' - AGGGGTCAGCGGCAAGCAGA - 3' 
60°C 237bp 
p53 8+9 p53-89A: 5' - TIGGGAGTAGATGGAGCCTG - 3' 
p53-89B: 5' - AGTGTTAGACTGGAAACTIT - 3' 
58°C 445bp 
p53 11 p53-1IA: 5' - AGACCCTCTCACTCATGTGA - 3' 
p53-11B: 5' - TGACGCACACCTATIGCAAG - 3' 
58°C 245bp 
Ha-ras I Hl2/I: 5'· GGGCCCTCCTIGGCAGGTGG - 3' 
HI212: 5' - CACCTGGACGGCGGCGCTAG· 3' 
65°C 206bp 
Ha-ras 2 H61/A: 5' - GGAGAGGCTGGCTGTGTGAA - 3' 
H611B: 5' - AAAAGACTTGGTGTIGTIGA - 3' 
56°C 230bp 
6.3.2 Single Strand Conformation Polymorphism (SSCP) Analysis 











and ex on 11 of the p53 gene and exons 1 and 2 of the Ha-ras gene were individually 
amplified, and exons 8 and 9 of the p53 gene were amplified as one fragment as 
described in section 6.3. L PCR reactions were performed in the presence of 1!-lCi 
ae2p]dCTP (3000Cilmmol) (lCN). After amplification of exons 8 and 9, the PCR 
product was incubated at 37°C overnight with the restriction endonuclease Styl to 
yield digestion products of 262bp (incorporating exon 8) and 183bp (incorporating 
exon 9). 
3!-l1 of the labelled PCR products (or digestion products in the case of exons 8 and 9) 
were mixed with 3!-l1 offormamide loading buffer (section 6.14), denatured by heating 
at 95°C for 5min and loaded immediately on a non-denaturing 6% polyacrylamide gel 
(42cm long, 0.2mm thick) in the presence or absence of 5% (v/v) glycerol. 
Electrophoresis was performed in 1 X TBE running buffer (section 6.14), at either 
room temperature (using a fan to cool the gel to prevent excessive heating) or at 4°C. 
The samples were electrophoresed through the gels for 5-6 hours at 30W, after which 
the gels were dried under vacuum and exposed to x-ray film (Cronex) at -70°C for 16­
48 hours. 
6.4 CLONING OF PCR PRODUCTS 
6.4.1 Preparation of Competent Cells 
5ml of Luria broth (section 6.14) was inoculated with 50!-l1 of a glycerol stock of 
E.coli DK-1 cells and incubated at 37°C with vigourous shaking for 16 hours. 300ml 
of Luria broth was inoculated with 300!-l1 of the overnight culture and incubated at 
37°C with vigorous shaking until the OD650 of the culture was between 0.2 and 0.4. 
The cells were pelleted by centrifugation for lOmin in a JA-lO rotor at 5000rpm at 
4°C. The cell pellet was gently resuspended in 40ml of cold 60mM Cacb, lOmM 
Pipes, pH 7.2 and incubated on ice for 20min. The solution was transferred to 30ml 
Corex™ tubes and the cells were pelleted by centrifugation at 5000rpm in a JA-20 
rotor at 4°C. The cells were then resuspended in 4ml of cold 60mM CaCh, 10mM 












6.4.2 - Preparation of pUC-19 Vector 
10llg of pUC-19 was incubated for 16 hours at room temperature with 20 units of 
restriction endonuclease SmaI, in the appropriate digestion buffer (section 6.14). The 
5' ends of the digested vector were then dephosphorylated by incubation for 1 hour at 
50°C with calf intestinal phosphatase (Roche Biochemicals) at a final concentration of 
1unit/pmol DNA ends in 1 X ClP buffer (section 6.14). The phosphatase was heat 
inactivated at 65°C for 10min and the prepared vector stored at 4°C until required. 
6.4.3 Preparation of PCR Products 
6.4.3.1 Purification of PCR Products 
The peR products (section 6.3) to be cloned were combined with 1/10 vol of DNA 
stop buffer (section 6.14) and electrophoresed on a 1 % low-melting agarose gel at 
25mA in 1 X TAB buffer for 2-3 hours. The bands were visualised by staining the gel 
with ethidium bromide (EtBr) at a final concentration of 0.2511glml. The bands of 
interest were excised from the gel, placed in microfuge tubes and the DNA isolated 
using Qiaex beads (Qiagen) as per the manufacturer's instructions. Briefly, 300111 of 
solution QX1 and lO~tl Qiaex beads were added to the agarose which was then 
solubilised at 50°C for 10min with brief vortexing every 2min. The beads were 
pelleted by centrifugation in a microfuge for 1min, washed twice with solution QX2 
and twice with solution QX3. After the last wash the beads were dried under a 
vacuum for 5 min, resuspended in 20111 of sterile H20 and incubated at room 
temperature for 5min. The beads were pelleted by centrifugation for 1min in a 
microfuge and the supernatant containing the DNA was transferred to a fresh 
microfuge tube. This final step was repeated with another 20111 of sterile H20. The 
resulting 40111 of DNA was dried down in a speed-vac and resuspended in l0111 of 
sterile H20. 
6.4.3.2 Phosphorylation of PCR Products 
The purified PCR products from section 6.4.3.1 were phosphorylated at the 5' end by 
. incubation with 3 units ofT4 polynucleotide kinase (Amersham) for 1 hour at 37°C in 












6.4.3.3 Blunt-ending of Kinased PCR Products 
The kinased PCR products (section 6.4.3.2) we~e blunt-ended usmg the Klenow 
fragment of DNA polymerase I (Amersham) as described by Sambrook et aI., 1989. 
PCR products were incubated at room temperature for 30min with Sunits of Klenow 
DNA polymerase in the presence of 0.2SmM of each dNTP in 1 X Klenow buffer 
(section 6.14). The enzyme was then heat-inactivated at 6SOC for 10min. 
6.4.4 In-gel Ligation ofPCR Products to pUC-19 
The prepared pUC-19 vector (section 6.4.1) and the ki1J.ased and blunt-ended PCR 
products (section 6.3) were combined with 1110 vol of DNA stop buffer and 
electrophoresed on a 1 % low-melting agarose gel in 1 X T AE running buffer. The gel 
was stained with ethidium bromide (0.2Sllglml) and the DNA visualised under UV 
light. The bands of interest were excised from the gel and placed in microfuge tubes. 
The gel slices were melted at 70°C for 10min, followed by incubation at 37°C for 
Smin. Vector and insert DNA were combined at ratios of 1:8, 2:7 and 3:6 with 1 unit 
of T4 DNA ligase (Amersham) in 1 X T4 DNA ligase buffer (section 6.14) and 
incubated at room temperature for 16 hours in a final volume of20~.d. 
6.4.5 Transformation of Competent Cells 
Competent E-coli DK-1 cells (section 6.4.1) were thawed on ice. The ligation 
reactions (section 6.4.4) we e heated at 70°C for lOmin then incubated at 37°C for 
Smin, and S)11 of the ligation reaction was added to 100)11 of competent cells. The 
cellslDNA mixture was· incubated on ice for 30min and heat-shocked at 42°C for 
2min. 1ml of Luria broth (pre-warmed to 37°C) was added to the cells which were 
then incubated for 1 hour at 37°C. AHquots of the transformation mix were plated on 
Luria-agar plates (section 6.14) containing O.OSmglml ampicillin and incubated for 16 
hours at 37°C. 
6.4.6 Screening ofBacterial Colonies 
6.4.6.1 Screening using Plasmid Minipreps 
An alkaline lysis method of plasmid isolation was used to rapidly screen recombinant 
clones as described (Birnboim and Doly, 1979; Birnboim, 1983). 10ml Luria broth 











incubated for 16 hours at 37°C with vigotlrous shaking. 5001J,1 of the overnight culture 
was mixed with 5001J,1 glycerol to make a glycerol stock. The glycerol stock was 
incubated at room temperature for 4 hours and then stored at -70°C. 
The remainder of the overnight culture was centrifuged at 3000rpm in a Beckman TJ­
6 benchtop centrifuge for lOmin at 4°C. The cell pellet was resuspended in 2001J,1 
"RAPS" solution 1 (section 6.14), transferred to 1.5mI microfuge tubes and incubated 
at room temperature for 5min. The cells were then lysed by the addition of 4001J,1 
"RAPS" solution 2 (section 6.14) and kept on ice for 5min. 3001J,1 of "RAPS" solution 
3 (section 6.14) was added and the cells were incubated on ice for a further 10min. 
The samples were centrifuged at 4°C for 5min at maximum speed in a microfuge. The 
supernatant was transferred to a fresh 1.5ml microfuge tube and the samples were 
centrifuged again for 5min at 4°C. The supernatant was transferred to a fresh 1.5ml 
microfuge tube and the plasmid DNA was precipitated by the addition of 6001J,1 
isopropanol and kept at -20°C for 1 hour. The DNA was pelleted by centrifugation at 
room temperature for 10min in a microfuge, washed twice with 70% ethanol, dried 
under a vacuum and resuspended in a 801J,1 of 1 X TE. 
251J,1 of the plasmid DNA was digested with the restriction endonucleases EcoRI and 
HindIII at 37°C for 16 hours and checked for the presence of an insert by agarose gel 
electrophoresis. 
6.4.6.2 Screening using peR 
5ml of Luria broth was inoculated with a single bacterial colony and incubated at 

37°C with vigorous shaking for 16 hours. 21J,1 of the overnight culture was heated at 

95°C for 5min and used directly as a template in a PCR reaction. The lysate was 

. incubated in 1 X PCR buffer (section 6.14) in the presence of the 4 dNTP's at a final 

concentration of O.2mM, 2units of Taq DNA polymerase (Roche Biochemicals) and 
30pmol of the following primers (USB Sequenase PCR Product Sequencing Kit): 
Forward Primer: 5' - GTTTTCCCAGTCACGACGTTGTA - 3' 
Reverse Primer: 5'-TTGTGAGCGGATAACAATTTC - 3' 











step of2min at 95°C, followed by 35 cycles of denaturation at 95°C (lmin); annealing 
at 60°C (lmin) and extension at 72°C (lmin). lO!J.I of the PCR reaction was mixed 
with 2!J.I of DNA stop buffer (section 6.14) and electrophoresed on an 1.5% agarose 
gel in 1 X TBE. The gel was stained with ethidium bromide (O.25!J.g/ml) and the 
bands visualised under a UV light. 
6.5 LARGE-SCALE PLASMID PREPARATION 
6.5.1 Qiagen Columns 
Qiagen columns (Qiagen) were used to prepare plasmid DNA from 200ml overnight 
cultures as described by the manufacturers. Briefly, overnight bacterial cultures were 
lysed essentially as described in section 6.4.6.1 and the cleared lysate was passed over 
an ion exchange column to purify the plasmid DNA. Generally O.2-0.5mg plasmid 
was obtained from a 200ml overnight culture, and the DNA was sufficiently pure to 
be used for transfections. 
6.5.2 Cs-CllEthidium Bromide Equilibrium Centrifugation 
Plasmid DNA was isolated using CsCl/ethidium bromide centrifugation based on the 
method by Radloff et aI., 1967. Five hundred ml of overnight bacterial cultures were 
harvested by centrifugation at 5000rpm in a Beckman JA-lO rotor at 4°C for 10min. 
The bacterial pellet was resuspended in 10ml of "RAPS" solution 1 (section 6.14) 
after which 5 ml of "RAPS" solution 1 containing lysozyme (final concentration of 
13.3mg/ml) was added. The samples were mixed well by pipetting and incubated at 
room temperature for 30min. The cells were lysed by the addition of 30ml "RAPS" 
solution 2 (section 6.14) on ice for 30min. Fifteen ml of "RAPS" solution 3 (section 
6.14) was added, the solution was mixed by gentle swirling and incubated on ice for 
20min. The cell lysate was cleared by centrifugation at 8000rpm in a Beckman J A-I 0 
rotor at 4°C for lOmin. The supernatant was transferred to a clean 250ml plastic bottle 
and the plasmid DNA was precipitated by the addition of 40ml of isopropanol. The 
DNA waspelleted by centrifugation at 8000rpm in a Beckman JA-lO rotor for 10min 
at 4°C, the pellet was air-dried and resuspended in 4.2ml of 1 X TE (section 6.14). 
After the pellet was completely resuspended, the solution was transferred to 10ml a 
sterile Falcon tube and 4.6g CsCl was added. The CsCI was dissolved completely by 











by inverting the tubes followed by incubation on ice for 10min. The samples were 
centrifuged at 10000rpm in a Beckman JA-20 rotor at 4°C for 10min, after which the 
supernatant was transferred to Sml Quick-Seal ultracentrifuge ,tubes (Beckman) and 
centrifuged at 50 OOOrpm for 20 hours at 20°C in a Beckman NVT -90 rotor. 
The plasmid band was collected by inserting an 18-G needle into the top of the tube, 
and then inserting a 20-Gneedle connected to a 2ml syringe below the plasmid band 
and gently aspirating the band. The solution was transferred to a second Quick-Seal 
tube, which was filled with 0.8g1m! of CsCI, and centrifuged in a Beckman NVT-90 
rotor at 64 OOOrpm for 4-6 hours. The plasmid band was removed as described above 
and transferred into a sterile 10m! Falcon tube. 
EtBr was removed by adding 10ml of H20-saturated I-butanol, mixing and 
centrifugation at room temperature in a Sigam-302K benchtop centrifuge. The butanol 
layer containing the EtBr was aspirated and the butanol extraction of the aqueous 
layer repeated until the EtBr was completely removed. The plasmid DNA was 
precipitated by the addition of an equal volume of isopropanol and incubation on ice 
for 1 hour. The DNA was pelleted by centrifugation at 10 OOOrpm in a JA-20 rotor for 
15min at 4°C, the pellet air-dried and resuspended in a suitable volume of sterile H20 
6.6 DNA SEQUENCE ANALYSIS 
6.6.1 Direct Sequencing ofPCR Products 
Sequencing reactions were based on the Sanger dideoxy chain-termination method of 
sequencing (Sanger et aI., 1977). PCR products were sequenced directly using the 
USB Sequenase PCR Product Sequencing Kit (Amersham) as per the manufacturer's 
instructions. Briefly, Sill of the PCR product to be sequenced was treated with 
exonuclease I and shrimp alkaline phosphatase at 37°C for lSmin and then subjected 
to sequence analysis. The resulting sequencing reactions were separated on a 6% 
polyacrylamide gel containing 7M urea in 1 X TBE. The gel was dried under vacuum 
and exposed to x-ray film (Cronex) for 16-48 hours at -70°C. 
6.6.2 Sequencing of Cloned PCR Products 











(Sanger et aI., 1977) with the T7Sequencing™ Kit (Pharmacia Biotech) as 
recommended by the manufacturer. Sequence reactions were separated on a 6% 
polyacrylamide gel containing 7M urea as described above. 
6.7 ISOLATION OF RNA FROM CELL LINES 
RNA was isolated based on the method described by Chomczynski and Sacchi, 1987. 
Confluent dishes of cells were rinsed once in PBS before the addition of 2ml solution 
D (section 6.14) at 4°C. The cells were transferred to lOmI Falcon tubes and 200j.l1 
2M Na Acetate, pH 4.0; 2ml H20-saturated phenol and 400j.l1 C:lAA (49: 1) (section 
6.14) was added. The solution was mixed well by vortexing and then allowed to 
incubate on ice for· 15min. The samples were then centrifuged at 10 OOOrpm in a 
Beckman JA-20 rotor at 4°C for 20min after which the aqueous phase was transferred 
to a fresh Falcon tube. The RNA was precipitated by the addition of an equal volume 
of isopropanol and left overnight at -20°C. RNA was pelleted by centrifugation at 10 
OOOrpm in a Beckman JA-20 rotor at 4°C for 20m in, washed twice in 70% ethanol, 
dried under a vacuum and resuspended in a suitable volume of DEPC-treated H20. 
The samples were stored at -70°C until required. 
The concentration of the RNA was determined spectrophotometrically usmg a 
Beckman DU 650 spectrophotometer. 
6.8 NORTHERN BLOT ANALYSIS 
6.8.1 Transfer of RNA onto Hybond-N Membranes 
5-10j.lg of total RNA was mixed with 16.5j.l1 RNA loading buffer (section 6.14), 
heated at 65°C for 5min and loaded onto a 1 % agarose gel containing 8% 
formaldehyde. The gel was electrophoresed at 30mA in 1 X RNA running buffer 
(section 6.14) for 2-3 hours. After electrophoresis, the gel was placed upside down on 
3 pieces ofWhat man 3MM paper, cut to the same size as the gel and pre-soaked in 10 
X SSC (section 6.14). A piece of Hybond-N nylon membrane (Amersham), also pre­
soaked in 10 X SSC and cut to the same size as the gel, was placed on top of the gel, 
and finally another piece of Whatman 3MM paper, cut to the size of the gel and pre­
soaked in lOX SSC, was placed on top of the nylon membrane. A wad of tissues was 











was allowed to transfer to the membrane by capillary action at room temperature 
overnight. 
The next day, the blot was disassembled and the membrane rinsed briefly in 6 X SSC, 
air-dried and UV -crosslinked in a Spectrolinker XL-IOOO UV Crosslinker 
(Spectronics Corporation). 
6.8.2 Preparation of&'ldiolabelled Probe 
25ng of linear DNA was used as a template to synthesise radioactive probes for 
northern analysis. Prior to labelling, the double-stranded DNA was separated into 
single strands by heating at 95°C for 5min. Radioactive probes were generated using 
the Multiprime DNA Labelling System (Amersham) as recommended by the 
manufacturer. Briefly, the single-stranded DNA template was incubated with random 
primers and Klenow enzyme in the presence of 50J-lCi a 32P_dCTP for I hour at 37°C. 
The reaction mix was passed over a Sephadex G-50 column and fractions containing 
the radiolabelled probe were pooled. An aliqout of this was counted on a Packard Tri­
carb 4640 scintillation counter to calculate the specific activity of the probe. 
6.8.3 Hybridisation of Probe to Nylon Membrane 
Membranes were pre-hybridised for 4 hours at 42°C in a Hybaid Dual Hybridisation 
Oven in 10 ml of pre-hybridisation solution (section 6.14). Radiolabelled probe was 
then added at a final concentration of 2 X 106 cprnlml and the membranes were 
incubated at 42°C for 16 hours. 
The next day the membranes were washed twice at room temperature with wash 
solution 1 (section 6.14) for 15min each, and twice at 65°C with wash solution 2 
(section 6.14) for 15min each. Membranes were then exposed to X-ray film for 16-48 
hours at -70°C. 
6.9 SITE-DIRECTED MUTAGENESIS 
6.9.1 Sub-cloning of wild-type p53 eDNA 
6.9.1.1 Preparation of Insert 













1990), was obtained as a gift from Dr B. Vogelstein. The 1.8kb wild-type p53 insert 
was released from the vector by digestion with the restriction endonuclease BamID (2 
units/llg DNA) at 37°C for 1 hour in the appropriate reaction buffer. 
6.9.1.2 Preparation of pUC-19 Vector 
pUC-19 was digested with the restriction endonuclease BamID (2 units/llg DNA) at 
37°C in the appropriate reaction buffer for 1 hour. The 5' ends were dephosphorylated 
with calf intestinal phosphatase (CIP) (0.01 units/pmol DNA ends) at 37°C for 1 hour. 
The enzyme was inactivated at by heating at 65°C for 10min. 
6.9.1.3 In-gel Ligation of Vector and Insert 
Ligation reactions were performed as described in section 6.4.4, except the reactions 
were incubated for 16 hours at 15°C. 
Ligation reactions were transformed into competent E-coli DK-1 cells, and bacterial 
colonies were screened for inserts by PCR, as described in section 6.4. Those clones 
containing inserts were sequenced as described in section 6.6.2 using the pUC primers 
(section 6.4.6.2) to check their orientation and to confirm the sequence. 
6.9.2 Mutagenesis 
A PCR based method of mutagenesis based on a modification of the methods by 
McCracken et aI., 1988 and Kohli, 1998 was used to incorporate the desired mutations 
into the wild-type sequence using the primers outlined in table 6.2. 
Silent mutations that generated restriction endonuclease sites were incorporated in the 
primers together with the required mutations. The restriction sites generated by the 
silent mutations were a KpnI site for the ~A mutation and an Asp700 site for both the 
S269R and +15bp mutations. 
The wild-type p53 cDNA in pUC-19 was PCR amplified in separate reactions using 
the mutA primers (table 6.2) and the pUC-reverse primer (section 6.4.6.2), or the 
mutB primers (table 6.2) and the pUC-forward primer (section 6.4.6.2). Amplification 











(section 6.14) in the presence of O.2mM dNTP's and 60pmol of each primer, using 1 
unit of Deep Vent DNA Polymerase (New England Biolabs) with an initial 
denaturation step of 94°C for 2min, followed by 35 cycles of denaturation (94°C, 
1 min); annealing (60°C, Imin) and extension (72°C, Imin) for all the primers except 
p53-mutlB. The reaction conditions for p53-mutlB were exactly the same as for the 
other primers, except the annealing temperature was 55°C. 
Table 6.2: Primers used for site-directed mutagenesis. Primers were synthesised on 
A Beckman lOOOA DNA synthesiser. Silent mutations generating restriction 
endonuclease sites are underlined. 













6.9.3 Cloning of Mutated PCRProducts into pUC-19 
6.9.3.1 Preparation of Vector 
pUC-19 was incubated with the restriction endonucleases EcoRI and HindIII for 1 
hour at 37°C in the appropriate reaction buffer. The 5' ends of the digested vector 
were then dephosphorylated as described in section 6.9.1.2. 
6.9.3.2 Preparation of PCR Products 
PCR products were purified from unincorporated dNTP's and free primers with the 
High Pure PCR Product Purification Kit (Roche Biochemicals). The purified PCR 
products were then digested with either HindIII and the created restriction 
endonuclease site (KpnI or Asp700 as described in section 6.9.2) or EcoRI and the 
created restriction endonuclease site. HindIII was used when the pUC-reverse primer 
was used in the PCR reaction, and EcoRI was used when the PCR was done using the 
pUC-forward primer. All digestion reactions were carried out for 1 hour at 37°C in 











6.9.3.3 In-gel Ligation of Digested PCR Products and Vector 
The digested PCR products were ligated to the prepared pUC-19 vector by a triple 
ligation reaction. The 2 PCR products making up the full length cDNA were added to 
the vector and ligated at 15°C for 16 hours as described in section 6.9.1.3. 
Ligation reactions were transformed into competent E-coli DK-1 cells and bacterial 
colonies were screened for inserts using PCR as described in section 6.4. 
Clones containing inserts were sequenced (as described in section 6.3.2) to confirm 
that the mutation had been inserted correctly, as well as to ensure that no other 
mutations were erroneously incorporated into the cDNA 
6.9.4 SubcIoning of Mutated cDNA into pcDNA-3 Expression Vector 
6.9.4.1 Preparation of Vector 
The pcDNA-3 vector was digested with Bamfll and EcoRV (2 units/lJ.g DNA) at 
37°C for 1 hour in the approriate buffer. The 5' ends of the digested vector were 
dephosphorylated as described in section 6.9.1.2. 
6.9.4.2 Preparation and Ligation of Inserts with Expression Vector 
The mutated p53 cDNA was released from pUC-19 by incubating the clones with 
Barnfll and SmaI at 37°C for 1 hour in the appropriate reaction buffer. The inserts 
were ligated to pcDNA-3 as described in section 6.9.1.3 and transformed into 
competent E.coli DK-l cells as described in section 6.4. 
6.10 TRANSFECTION OF PLASMID DNA 
6.10.1 Preparation of Cells 
NllI-3T3 cells were grown to confluency in Dulbecco's Modified Eagles medium 
(DMEM) supplemented with 10% heat-inactivated foetal bovine serum, 100 units 
penicillin and 100llglmi streptomycin in 100mm petri dishes. The day prior to the 
transfection, the cells were split 1: 12 in DMEM and incubated overnight at 37°C. 2-4 
hours prior to the transfection, the medium was removed and replaced with 9ml of 











6.10.2 Preparation of DNA 
Cells were transfected as described (Chen and Okayama, 1988). The plasmid DNA to 
be transfected was isolated from overnight cultures of DK-l cells using Qiagen 
columns as described in section 6.S, except that the DNA was suspended in sterile 
H20 instead of 1 X TE buffer. 10-20!-lg of plasmid DNA in a final volume of 4S0!-l1 
sterile H20 was mixed with SO!-ll of 2.5M CaCho The DNNCaCh mixture was then 
added dropwise to SOO!-ll of 2 X Hepes buffered saline (HeBS), pH 7.0S (section 
6.14), while bubbling air through the HeBS. The solution was then left at room 
temperature for ISmin, then added dropwise to the cells which were then returned to 
37°C and incubated for 16 hours. 
6.10.3 Selection of Stable Clones 
After the overnight incubation in the presence of the calcium phosphatelDNA 
precipitate, the medium was removed and the cells were washed 3 times with PBS 
(section 6.14) and fresh medium was added. The cells were returned to 37°C for two 
days before the addition of selective medium containing 400j.lg/ml G418 (Gibco). The 
medium was changed every 4 days and replaced with fresh selective medium until 
discreet colonies were visible on the plates. 
6.10.3.1 Propagation of stable clones 
Once the clones had grown sufficiently such that they were visible to the naked eye, 
individual clones were picked using sterile cotton-wool swabs dipped in O.OS% 
trypsin and transferred into 24-well plates. Once the cells had become confluent in the 
24-well plates they were transferred to 60mm petri dishes until confluent, from where 
they were transferred to IOOmm petri dishes and again grown to confluency. Cells 
were trypsinised and frozen in 1ml aliqouts in the presence of 10% dimethyl 
sulphoxide (DMSO). The cells were initially frozen at -70°C for 16 hours and then 
transferred to liquid nitrogen. 
6.11 IMMUNOHISTOCHEMISTRY 
6.11.1 Immunohistochemistry using Cell Lines 
Cells were grown overnight on glass slides at 37°C in DMEM. The cells were fixed in 











They were then blocked with goat non-immune serum diluted, 1 :20 in PBS, for 10min 
at room temperature. The serum was drained off and the anti-p53 primary antibody, 
clone DO-7 (Dako), was diluted 1: 100 in PBS and added to the cells. The cells were 
incubated for 30min at room temperature with the primary antibody, after which they 
were washed very well with PBS and drained. The Envision detection system (Dako) 
was used to detect the primary antibody as per the manufacturer's instructions, and the 
chromagen used was 3'-3'-Diaminobenzidine (DAB) which was also obtained from 
Dako. After the colour had developed, the slides were washed and the DAB signal 
was enhanced by incubating the slides in a 1 % copper sulphate solution. The slides 
were washed again and then lightly counterstained with Haematoxylin. They were 
then "blued" in Scotts tap water substitute and dehydrated through graded alcohols, 
eventually to xylol, and mounted in Entelan. 
6.11.2 Immunohistochemistry Using Tissue Sections 
511m thin tissue sections were cut onto glass slides and treated essentially as described 
for the cell lines (section 6.11.1) except that prior to blocking, an antigen retrieval step 
was carried out. The sections were heated in a pressure cooker at full pressure for 
2min in O.IM citrate buffer (pH 6.0). All subsequent steps were as described in 
section 6.11.1. Each section was scored for the intensity of p53 staining from 0 
(negative) to 3+, and the percentage of p53 positive cells for each section was 
determined. 
6.12 	 ANCHORAGE-INDEPENDENT GROWTH STUDIES 
Colony formation in soft agar was carried out as described previously (Rhim et al., 
1997; Tavoloni and Inoue, 1997). Briefly, a suspension of either 1 X 105 or 3 X 103 
cells in 5ml of 0.35% agar-select (Sigma) made up in normal growth medium 
(DMEM) was overlaid onto a base of 0.6 % agar-select in a 60mm dish. The cells 
were incubated at 37°C in a humidified incubator and the plates examined for colony 
formation 21 days later. 
6.13 	 CELL CYCLE ANALYSIS AFTER EXPOSURE TO IONISING 
RADIATION 











DMEM (NllI-3T3) or DMEM containing 800Ilg/ml G418 (NllI-3T3 transfectants) at 
37°C in a humidified incubator. Prior to irradiatio~ the medium was removed and 
fresh DMEM was added to all the cells. The cells were irradiated with 7Gy of 60CO 
and incubated at 37°C until ready for harvesting. At various time points after exposure 
to the radiatio~ the cells were harvested by removing the medium and rinsing them 
with PBS. They were trypsinised and the cells pelleted by brief centrifugation in a 
bench top centrifuge and resuspended in 200).11 1 X PBS. 2ml of ice-cold (-20°C) 70% 
ethanol was added to the cells, which were then incubated at -20°C until required (a 
minimum of30min). 
When ready for analysis, the cells were pelleted at 2000rpm for 10min in a bench top 
centrifuge and the ethanol removed. The cell pellet was briefly vortexed and 
resuspended in 100111 RNAse A (lmg/ml); 10).11 propidium iodide (lmg/ml) in a final 
volume of 1ml PBS. The solution was passed 2-3 times through a 25 gauge needle 
and incubated in the dark for 30min at 37°C. The reaction was stopped by transferring 
the samples to 4°C. The samples were sorted on a Becton Dickinson Facscan to 
determine the fraction ofcells in the various stages of the cell cycle. 
6.14 BUFFERS AND SOLITTIONS 
40% ACRYLAMIDE STOCK SOLUTION (38:2) 
38% Acrylamide 
2%Bis 
2% Ion exchanger V 
The solution was mixed on a roller at 4°C for 16 hours, filtered and then stored at 
4°C. 
Chlorophorm:Isoamyl Alcohol (CIAA) (49:1) 
49ml chloroform 
Iml isoamyl alcohol 
10 X CIP DEPHOSPHORYLATION BUFFER 
10mMZnCh 
10mMMgCh 











100 X DENHARDT SOLUTION 
109 Ficoll 400 
109 Polyvinylpyrrolidone 
109 Bovine Serum Albumin (Fraction V) 








lOmM Tris-Cl, pH 8.0 
2SmM EDTA, pH 8.0 
O.lmg/ml Proteinase K (added fresh with each use) 
DIGESTION BUFFER (PARAFFIN SECTIONS) 
SOmM Tris, pH 8.S 
1mMEDTA 
O.S% Tween 20 
10 X DNA STOP BUFFER 
20% Ficoll 400 
O.lM EDTA, pH 8.0 
1% SDS 
O.2S% Bromophenol blue 
O.2S% Xylene cyano! 
ETHIDIUM BROMIDE (10mg/ml) 
10 mg ethidium bromide 
1ml sterile H20 












0.25% Bromophenol blue 
0.25% Xylene cyanol 
50% Glycerol 
FORMAMIDE LOADING BUFFER 
95% Formamide 
IOmMEDTA 
0.05% Bromophenol blue 
0.05% Xylene cyanol 




Titrate to pH 7.05 with 5M NaOH 
Filter sterilise and store in lOml aliquots at -20°C 
10 X KLENOW BUFFER. 























1 X peR BUFFER 
10mM Tris-Ct, pH 8.3 
50mMKCI 
1.5mMMgCh 
PHOSPHATE BUFFERED SALINE 
137mMNaCI 
2.7mMKCI 
4.3mMNa2HP04.7H20 (pH 7.4) 
1.4mM KH2P04 
PRE-HYBRIDISATION SOLUTION (NORTHERN ANALYSIS) 
5XSSC 
10% Dextran Sulphate 
50mM Sodium Pyrophosphate, pH 6.5 
50% Formamide 
5 X Denhardt's solution 
O.lmglml Sonicated Herring Sperm DNA 
0.1% SDS 
"RAPS" SOLUTION 1 
25mM Tris-CI, pH 8.0 
1 OmM.EDTA 
50mM Glucose 
"RAPS" SOLUTION 2 
200mMNaOH 
1% SDS 
"RAPS" SOLUTION 3 
3M Potassium Acetate, pH 4.8 
RNA LOADING BUFFER 











4S% deionised formamide 
6% formaldehyde 
1 X Formaldehyde loading buffer 
10 X RNA RUNNING BUFFER 
41.8g 3-[N-morpholino ]propanesulfonic acid (MOPS) to 800mi DEPC-treated H20 
Adjust to pH 7.0 with NaOH 
16.6ml 3M Na Acetate, pH S.S 
20ml O.SM EDTA, pH 8.0 
Make up to 1 litre with DEPC-treated H20 
SOLUTIOND 
4.2M Guanidine thiocyanate salt (GITC) 
300mM Na Citrate, pH 7.0 
O.S% Sarcosyl 
Add 360!J,1 2-mercaptoethanol to SOml solution D prior to use. 
20 X SSC 
3M NaCI 
0.3M Na3 citrate 
10 X T4 DNA LIGASE BUFFER 




10 X T4 POLYNUCLEOTIDE KINASE BUFFER 


















pH to 7. 8 with acetic acid 

10 X TBEBUFFER 
890mM Tris 
890mM Boric acid 
25mMEDTA 
pH 8.3 
1 X TE (TrisIEDTA) BUFFER 
lOmM Tris-Cl, pH 8.0 
ImMEDTA, pH 8.0 





0.1% Triton X-IOO 
pH 8.8 
WASH SOLUTION 1 (NORTHERN ANALYSIS) 
2 XSSC 
0.1% SDS 
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